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ABSTRACT:
The incidences of Johne’s disease (JD) in farms worldwide have increased significantly over
the last 80 years. The increase in JD is owing to the lack of diagnostic tests available and the
long incubation period of the disease causing pathogen, Mycobacterium avium
paratuberculosis (MAP). In addition, treatment of JD with antibiotics has proven difficult
due to the emergence of antibiotic resistance MAP strains and the presence of the thick lipid
rich mycobacterial cell wall. An alternative diagnostic and treatment method for JD involves
the use of mycobacteriophages. As part of this research, individual mycobacteriophages
(TM4) and a mycobacteriophage cocktail (LE1 to LE6) were utilised to develop a
mycobacteriophage based diagnostic and viability assay for MAP. The first part of the study
was to develop a preliminary optimisation assay utilising the fast growing mycobacterial
strain; M.smegmatis mc2 155. The premise of the assay was; (a) if the drug is not effective
against killing mycobacteria, mycobacterial cells would remain viable and
mycobacteriophage would infect these cells causing an increase in plaque forming units over
a four hour time period and (b) If the drug is effective against mycobacteria, then the
mycobacterial cells would no longer be viable, therefore the mycobacteriophage have no cells
to infect and plaque forming units will remain equivalent over time. The use of the
mycobacteriophage TM4 proved to be effective in determining drug susceptibilities as
M.smegmatis mc2 155 was determined to be sensitive to Isonazid, Rifampicin, Pyranzaimide
and Ethambutol (plaque numbers increased) and resistant to Ampicillin, Erythromycin,
Amoxicillin, Streptomycin as plaque numbers remained static. The second part of the study
was aimed to utilise the optimisation conditions devised from the first part and implement
them against six Irish MAP field isolates in order to assess their drug susceptibility profiles.
The six MAP strains all yielded resistance to Ampicillin, Streptomycin, Erythromycin and
Amakacin as plaque numbers increased over 4 hours. The six MAP strains also yielded
resistance to Rifampicin, Isoniazid and Clindamycin as plaque numbers remained static over
4 hours. Resistance levels for three MAP strains against Vancomycin, Ciproflaxin,
Clofazimine and Cefdinir were moderate and for the remaining MAP strains drug sensitivity
was high against Trimethoprim, Tetracycline and Doxycycline. A mycobacteriophage
cocktail was applied for comparison against an individual mycobacteriophage to ensure that
the addition of extra phage didn’t interfere with the fidelity of the assay. Drug susceptibility
profiles were identical to the profiles obtained in utilising one mycobacteriophage type
(TM4).
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CHAPTER 1: LITERATURE REVIEW

PATHOGENIC PROPERTIES OF MYCOBACTERIUM AVIUM SUBSPECIES
PARATUBERCULOSIS:

Biological Properties and Taxonomy
The etiological agent of many animal based diseases, in particular Johne’s disease is the
pathogen Mycobacterium avium paratuberculosis (MAP). This bacterium is extremely
problematic as a result of its slow growth rate, acid fast nature and thick-waxy, Gram-positive
cell wall (Harris & Barletta, 2001). MAP typically resides in the environment and has the
ability to survive pasteurisation of milk and certain dairy processing steps (Gerrard et al.,
2018). Human populations are therefore widely exposed to MAP. Multiple reviews have
suggested that MAP is also pathogenic to humans (Pierce, 2010), particularly in its
association with Crohns disease, an inflammatory condition of the gastrointestinal tract,
similar to that observed in animals affected with Johne’s disease (Tasara & Stephan, 2005).

Mycobacterium avium paratuberculosis (MAP) belongs to the M.avium complex (MAC),
however various phenotypic differences exist between the other M.avium subspecies (Naser,
Ghobrial, Romero, & Valentine, 2004). Slowing growing mycobacterial species are
characteristic of the MAC complex which are ubiquitous in the environment (soil and water),
and have the ability to cause a wide range of disease in domestic and wild animal’s aswell as
humans.

MAP has portrayed pathogenicity in ruminants and primates who are nonimmunocompromised, however, the M.avium complex only affects an immunocompromised
host (Pierce, 2010). This would suggest that if MAP has the ability to cause Crohn’s disease
and infect immunocompromised patients, and then there should be sufficient levels of MAP
found in the blood and tissues of patients; however no studies have found sufficient levels of
MAP to date.

The main distinguishing features between MAP and other mycobacterial species includes its
slow growth rate, its inability to produce mycobactin, the presence of the insertion sequence
IS900 and its extremely lipid rich cell wall (Castellanos, Juan, Domínguez, & Aranaz, 2012).
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The slow growth rate of MAP is mainly attributed to the presence of its cell wall, which is
made up of approximately 60% covalently attached lipids. Destruction of MAP by chemicals
and heat is difficult as a result, thereby rendering MAP one of the most persistent pathogens
of the Mycobacterium avium complex (MAC). Certain antibiotic regimens have proven
successful in treating MAP, however due to the rise in antibiotic resistance; the number of
effective antibiotics against MAP has started to decrease.

IS900 which is unique to MAP was the first insertion sequence element to be identified in
mycobacteria. Based on a study in 2001, Southern blot analysis estimated that MAP contains
roughly 18 copies of IS900 integrated in its genome (Harris & Barletta, 2001).
The IS900 insertion sequence is a member of the IS116 family with each member sharing 60
to 80% identity. There has been speculation that IS900 plays a role in genomic plasticity but
the source is unknown. A variety of other insertion elements are thought to migrate between
genomes. An example of such an insertion element is IS110 (Green et al., 1989).

The process of invasion in MAP based infections
Mycobacterium avium paratuberculosis (MAP) upon infection has the ability to invade tight
junctions and evade antimicrobial peptides present in the intestinal epithelium thereby
causing a chronic infection in the host (Koets, Eda, & Sreevatsan, 2015). In entering the
gastrointestinal tract, MAP reaches the mucosa which lines the small intestine where it can
proceed into two cell types (microfold cells and enterocytes). A particular study indicates that
the uptake of MAP in calves by microfold cells is larger than enterocytes when they enter a
calves intestine (Ponnusamy, Periasamy, Tripathi, & Pal, 2013). The larger number of Mcells compared to enterocytes is associated with the early life of calves, in which MAP
susceptibility is high due to the presence of large numbers of M-cells, which are the major
portal of entry for MAP combined with the developing immune system.

MAP mainly affects the Peyers patches, particularly M cells of the small intestine, due to the
presence of antigen sampling cells, which is also undertaken by other invasive pathogens
such as Escherichia coli and Vibrio cholera, as well as Salmonella and Shigella species
(Momotani, Whipple, Thiermann, & Cheville, 1988). A potential reasoning is that M cells
display β1 integrins containing a fibronectin bridge which serve to target MAP to M cells
(Secott, Lin, & Wu, 2004). This has been demonstrated through the use of electron
microscopy.
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The entry of MAP into M cells however does not appear to be the only method for evading
the host response. The under-development of the Peyers patches and M-cells in a neonatal
calf due to antigen exposure is thought to be another reason (Neutra, Mantis, & Kraehenbuhl,
2001). In one study is has been demonstrated that when M-cells are absent, MAP still has the
ability to invade enterocytes (Bermudez, Petrofsky, Sommer, & Barletta, 2010). In addition,
the uptake of MAP has also been effected by goblet cells of the small intestine
(Sigurdardóttir, Bakke-McKellep, Djønne, & Evensen, 2005). The ability of MAP to grow in
diverse hosts has been said to be affected by the choice of cell type. As MAP does not grow
once outside a host (it only persists in the environment), this diversity is crucial to its
survival.
The diverse host range of MAP infection
Mycobacterium avium paratuberculosis (MAP) primarily affects ruminants such as cows,
sheep and goats but in recent years the organism has infected a much larger host range
including monogastric species (Morand, McIntyre, & Baylis, 2014). The existence of wildlife
reservoirs has also provided evidence that they play a role in the epidemiology of the disease,
for example rabbits infected with MAP in Scotland have been shown to cause problems in the
spread of the disease, however this data still has to be clarified (Carta, álvarez, Pérez de la
Lastra, & Gortázar, 2013). Clinical incidences of MAP in non-domesticated animals are
extremely variable in their prevalence and timing but are comparable to those of
domesticated origin. It has been noted that little research has been specifically published in
relation to MAP infection in non-ruminant wildlife.

MAP has been reported in every continent of the world in domesticated animals, although no
systematic survey has been completed. Numerous MAP prevalence studies have been
undertaken on domesticated animals in various countries (Claudia, Lurdes Pinto, Matos,
Matos, & Anjos Pires, 2013). Differences in sampling strategies make evaluation of the
studies difficult; nonetheless they imply significant variation in the numbers of infected herds
within different countries, geographical areas and within affected herds.
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The environmental distribution of Mycobacterium avium paratuberculosis (MAP)
Mycobacterium avium paratuberculosis (MAP) is an environmental pathogen that is
commonly found in soil and water which are associated with low pH conditions and high iron
content (Norby, Fosgate, Manning, Collins, & Roussel, 2007). MAP can persist in the
environment for extended periods of time and remain dormant outside the host until
transmission to a host occurs via the environment (Emery & Whittington, 2004). The survival
of MAP does however decrease over time and is finite. Plants or grass that grow in infected
soil eventually become contaminated and have the ability to infect grazing animals (Pribylova
et al., 2011).
Once a ruminant ingests MAP from the environment and infection occurs, shedding
eventually follows and the infection cycle commences again. MAP is shed in several ways
from animals, but faecal shedding followed by oral ingestion is a primary means of
transmission.

A variety of physical, chemical and biological factors of the soil may have an impact on the
movement of MAP through soil, as was established for other bacteria. However the ability of
MAP to survive in soil has been attributed to many factors such as soil substrates and
surfaces, temperature of the soil and pH (Pavlik & Falkinham, 2009). In a study conducted in
2011, the survival of MAP in soil environments was evaluated (Salgado et al., 2015). From
this study, the presence and survival of MAP in soil has been associated with moisture,
organic material and clay, temperature, pH with warmer soils reducing the rate of survival.
The study also demonstrated the ability of MAP to survive in a shaded environment for up to
48 weeks. However, it should be noted that this was an artificial laboratory study and
moisture levels made no difference in other relevant field trials.
The survival of MAP in tap, pond and sealed water bottles is estimated to be 6 to 18 months
(Amin et al., 2015). In a neutral pH, MAP survives optimally (17 months); however an
increase or decrease in pH from neutral allows MAP to survive for 14 months. Other studies
have demonstrated that in lake water environments MAP remains culturable for up to 841
days (Pickup et al., 2005) . The survival of MAP in water is based on the presence of fatty
acids, lipids and waxes in its cell wall which creates hydrophobicity. The presence of the cell
wall in MAP promotes its absorption to surfaces, and allows phagocytosis by macrophages
and protozoa (Bolster, Cook, Haznedaroglu, & Walker, 2009) (Strahl, Gillaspy, &
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Falkinham, 2001). Consequently, as MAP has the ability to survive in water, this creates
potential for disease transmission.

Antibiotic regimens for the treatment of MAP based infections
For reasons covered earlier, the treatment of MAP with standard antibiotics is difficult.
Additionally, the overuse of antibiotics in agricultural settings has also contributed to the
increase in MAP resistance (Garvey, 2018). Antibiotic therapy is a regime which has been
utilised continuously for the treatment of MAP infection. Antimicrobial therapies such as the
use of macrolides, rifamycins, clofazimine and ethambutol have been recommended for
potential MAP infections although each drug has limited potency against MAP (Kuenstner et
al., 2017).
To date, there are no antibiotics specifically designed for the treatment of MAP infections,
instead drugs are utilised on a “trial and error” basis. Alternative mycobacterial diseases such
as TB, leprosy and M.avium are treated with multi drug therapy with different types of
antibiotics; thereby this may be necessary in treating MAP based infections and help avoid
the development of MAP resistance. The general type of antibiotics used in combination for
MAP treatment are macrolide protein synthesis inhibitors such as clarithromycin and
azithromycin which are typically combined with ethambutol and rifamycin which together
inhibit cell metabolism and RNA synthesis (Savarino et al., 2019). Anti-inflammatory agents
such as monoclonal antibodies may also have the ability to directly affect MAP based
infections by inhibiting the immune response (Bannantine et al., 2007).

In the infection of humans with MAP, the cell wall is absent thereby attempts to treat the
bacterial cell wall with an antibiotic is ineffective. Efforts which involve targeting
peptidoglycan biosynthesis (penicillin’s, cephalosporin’s and vancomycin) are also
ineffective against MAP (Beran, Havelkova, Kaustova, Dvorska, & Pavlik, 2006). In fact, the
utilisation of such antibiotics may lead to the development of multi-drug resistant bacteria. As
mentioned previously the slow growth rate of the microorganism and an inactive dormant
stage outside of the host may make the treatment of MAP with antimicrobials difficult. At
present, there is no long term in vitro infection model for testing the efficacy of
antimicrobials against MAP infections.
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Due to lack of effective diagnostic assays and the increase in antibiotic resistance in MAP,
the development of effective diagnostic assays, which have the ability to incorporate both
MAP viability and drug susceptibilities, would be highly beneficial to this field of research.
THE RELATIONSHIP BETWEEN JOHNE’S DISEASE AND MYCOBACTERIUM
AVIUM PARATUBERCULOSISS (MAP)
The history and financial impact of Johne’s disease caused by Mycobacterium avium
paratuberculosis (MAP):
Approximately 120 years ago, the agricultural industry was introduced to a problematic
disease referred to as Johne’s disease (Bastida & Juste, 2011). Chronic granulomatous
enteritis of ruminants is the most characteristic feature of Johne’s disease followed typically
by persistent diarrhoea, weight loss and eventually death.
The causative agent of Johne’s disease is the pathogen Mycobacterium avium subspecies
paratuberculosis (MAP) as mentioned previously. The identity of Mycobacterium avium
subspecies paratuberculosis was firstly confirmed in 1910 as an extremely slow growing
pathogen of the Mycobacterium genus. This pathogen mainly affects many species of animals
but as MAP is typically spread through contaminated environments, in particular on farms
(i.e. environmental pathogen), it mainly affects ruminant livestock such as cattle, sheep, goats
and deer (Espejo, Godden, Hartmann, & Wells, 2012). Transmission of the pathogen is most
commonly caused by contaminated milk passing from mothers to offspring, through the
environment or through contaminated faeces in farm environments.
The most important step to prevent and control the spread of Johne’s is to monitor animals
and prevent the spread of contamination. To monitor animals, a classification system is in
place based on the bacterial level detected in their faeces, using the following scoring system,
low (<10 CFU/tube), moderate (10 to 50 CFU/tube) or high (>50 CFU/tube) faecal shedders
(Koets et al., 2015). Farmers typically lack the knowledge in Johne’s disease research to
identify clinical symptoms before treatment is too late.
There are four stages of MAP infection based on the severity of clinical symptoms. Diagnosis
of a cow with Johne’s disease is very difficult at Stages 1 and 2 as animals are asymptomatic.
Common blood tests and shedding detect no traces of MAP. Detection of MAP typically
occurs at Stages 3 and 4 as clinical symptoms begin to develop, in which treatment is not
effective.
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Table 1: The clinical stages of Johne’s disease in cattle caused by MAP determined by
blood tests and faecal shedding:
Stage

Stage 1: Silent/

Clinical signs

None

Positive with

Shedding in

blood tests

faeces

No

No

References

Early infection
Stage 2:

(Jesse et al.,
None

Yes/No

Subclinical

2016)

Yes (low
numbers)

infection
(R. J.
Stage 3: Clinical

Decreased

infection

appetite, weight

Yes

Yes (high

Whittington et

numbers)

al., 2017)

loss, persistent
or intermittent
diarrhoea
Stage 4:

Weakness,

Advanced

anaemia,

infection

dehydration

Yes

Yes (extremely
high numbers)

The prevalence and impact of Johnes disease on dairy industries globally:
One of the largest profitability losses in the dairy industry is caused by Johne’s disease,
which in turn has a direct impact on the global economy. Many studies have documented the
impact of profitability on the U.S dairy industry. From a period of 2004 to 2005 in the U.S,
the number of cattle with Johne’s disease increased from 7,879 to 10,280 (Garcia & Shalloo,
2015). In the U.S from 2009 to 2010, Johne’s disease had caused losses of $200 million to
1.5 billion due to infection (Pillars, Grooms, Wolf, & Kaneene, 2009)(Johnston, Coffey,
Mahony, & Sleator, 2010). Increased culling and decreased milk production have also been
associated with these costs. Assessing profitability and productivity is difficult when basing
both at the herd level; therefore it is difficult to estimate the financial impact of Johne’s
disease worldwide.
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From a period of 1999 to 2018, the total annual economic losses per cow in infected US dairy
herds were estimated at US$21 to US$79 while dairy herds in Canada had losses of CDN$49,
French herds with losses of €234 and UK herds with losses of £27 (Ott, Wells, & Wagner,
1999)(Verteramo Chiu et al., 2018).
The U.S had the highest number of JD in ruminants from a period of 1999 to 2018, and
Norway and Sweden had the lowest levels, clearly illustrating that levels of JD differ between
each country and region (R. Whittington et al., 2019).
Agriculture in Ireland has contributed significantly to the Irish economy. The presence of
Johne’s disease in particular within dairy herds in Ireland has resulted in substantial
economic losses. Clinical cases of MAP from 1992 to 2002 had increased from 92 to 232 per
year (Cashman et al., 2008). The importation of animals from Europe between 1992 and 2004
was suggested as an increase to the levels of JD during this period (Good et al., 2009).
In 2009, 376 clinical cases of bovine Johne’s disease was detected in Ireland according to the
animal disease surveillance report in 2010. No data has yet been released about the number of
cases of bovine Johne’s disease in Ireland from the period of 2011 to 2018. From Table 2 it
can be observed that the number of cases of bovine Johne’s disease has dramatically
increased from the period of 1932 to 2009 indicating that a biocontrol mechanism needs to be
developed.
Table 2: The number of clinical cases of bovine Johne’s disease reported in Ireland
during specified time periods (Cashman et al., 2008) (Good, M. et al, 2009)
Year

Number of cases of bovine Johnes disease reported in
Ireland

1932 to 1992

92

1993 to 2002

232

2009

376

2011 to 2018

Unknown but expected to increase
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Control strategies and programs to prevent the spread of Johne’s disease:
The spread of MAP into herds is often recognised before treatment is ineffective. Diagnosis
and treatment of Johne’s disease can be extremely subjective; therefore the most effective
way to prevent the spread of Johne’s disease is using proper control strategies. Much of the
pioneering work on Johne’s disease control programmes can be attributed to Mike Collins
with subsequent authors developing his research on farm practices (Collins, 1996) (Krishnan,
Manning, & Collins, 2009b) (Shin et al., 2010). From the literature is it evident that proper
control programs are present in only 22 worldwide countries, including Ireland (R.
Whittington et al., 2019). These are more developed countries with advanced veterinary
facilities. Countries which lacked a formal control program were more apparent in South
America and Asia (76%) whilst the remainder were in Europe (20%) (R. Whittington et al.,
2019). Reducing the prevalence of Johne’s disease is the most important consideration in
most countries; however Norway and Sweden are concerned with surveillance in order to
eradicate the disease entirely.
The majority of European countries are concerned with proper manure disposal on their
farms as cross contamination may occur (Over, Crandall, O’Bryan, & Ricke, 2011). Removal
of young calves from herds after birth if diagnosis of Johne’s disease occurs is another major
control strategy. Segregating infected ruminants from non-infected ruminants and the manure
of each is another major consideration in preventing the spread of infection. In reading
various control programs particularly in Ireland, cleaning of water tanks, milking parlours,
and cow sheds is the most extensive measure in controlling the disease (Garcia & Shalloo,
2015). The main advice for farmers with Johne’s disease on their farms is to follow the exact
procedures listed above, although certain countries have different levels of standards. Control
programs were reported to be successful in 16 (73%) of the 22 countries (R. J. Whittington et
al., 2017).
UNDERSTANDING THE VIRAL ENTITIES TERMED “BACTERIOPHAGES”
The discovery of bacteriophages and their implication in phage therapy:
Bacteriophages are viruses which infect and lyses bacterial hosts and have been described as
“the most abundant organisms on earth, playing a significant role in maintaining the
microbial balance throughout the planet” (Wittebole, X., et al, 2013).
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The number of total phages discovered to date currently stands at 15,538 according to the
PhagesDB.org. From this database it is evident that all phage genomes are double stranded
and range in size from approximately 3.4kb to 500kb (Golkar, Bagasra, & Gene Pace, 2014).
The mode of phage infection differs based on their life cycle. Temperate (lysogenic) and
virulent (lytic) are the most common phage life cycles (Lin, Koskella, & Lin, 2017).
Virulent phages lyse the host cell with their lytic machinery. Phage encoded genes are
produced once the phage enters the cell which regulates bacterial function (Fortier &
Sekulovic, 2013). Temperate phages (commonly referred to as lysogenic phages) incorporate
their genetic material into the host cell as an endogenous prophage (Olszak, Latka,
Roszniowski, Valvano, & Drulis-Kawa, 2017). In order to treat bacterial infections utilising
phage therapy, the composition and life cycle of bacteriophages must be well understood.
Modern society has given considerable thought to the utilisation of phage therapy compared
to the past. A common reason for utilising phage therapy is the specificity of the virus in
targeting the host cell. Phage therapy utilises bacteriophages specific to the bacterial host for
execution by infecting the host with their genetic machinery (Furfaro, Payne, & Chang,
2018). There is a move from utilising whole phage preparations which were used extensively
from 1920 to 1940 to employing bioengineered phages and purified phage lytic proteins to
improve biotechnological advances. These components have proven effective in treating
multi-drug resistant infections as outlined in various studies (Lin et al., 2017), (Górski et al.,
2016) and (Weber-Dabrowska et al., 2016). These studies have illustrated the potential
advantages and disadvantages of phage therapy as listed in Table 3.
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Table 3: Advantages and disadvantages of phage therapy (Lin, Koskella and Lin, 2017),
(Górski et al., 2016) and (Weber-Dąbrowska et al., 2016) (Drulis-Kawa, Z., et al, 2015)
(Sulakvelidze, A., et al, 2001)
Advantages of Phage Therapy
-

Disadvantages of Phage Therapy

Highly specific for target bacteria

Antibody mediated response in vivo

Replication occurs at site of infection

Narrow host range

-

Little or no side effects

Ability to overcome bacterial
resistance

-

Safety profile not fully established

Pharmacodynamics not fully understood

Selecting new phages is a rapid
process that can be accomplished in
days or weeks

Random case studies (such as phages used in treating colibacteriosis in poultry and treating
Salmonella infections in humans with gastroenteritis) have been employed frequently in
phage treatment of humans and animals in lieu of blinded experiments (Moelling, Broecker,
& Willy, 2018). Since the post antibiotic era, phages have become better understood in the
treatment of bacterial infections and phages have been accepted as advanced pharmacological
entities (Górski et al., 2018).
INSIGHTS INTO THE MYCOBACTERIOPHAGE GENOME:
Mycobacteriophages are useful tools for gaining understanding into viral evolutions and
diversity as well as the genetic manipulation of mycobacterial species. In comparing genomes
of mycobacteriophages it allows us to gain insight into the genes involved in the upregulation
of the immune response caused by mycobacterial infections, mycobacterial latency and the
development of detection methods for mycobacteria. Areas of research such as
mycobacteriophage organisation, diversity, cluster arrangement, mosaicism and knowledge
of pathogenesis genes have been greatly studied and will be discussed in more detail below.
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Genome Organisation:
In comparing mycobacteriophage genomes it is perceived that they are several features
present in their organisation and architecture although each mycobacteriophage differs
greatly in their sequence diversity. Structural genes are typically shared between each
mycobacteriophage type including the terminase (small and large subunit genes), portal,
scaffold, tail assembly chaperones, capsid maturation protease, tape measure protein and
minor tail proteins. Interestingly, in mycobacteriophages whose genomes are short, the
assembly genes comprise 50% of the entire genome. An example of such a genome is the
mycobacteriophage Taheera, whose terminase small subunit gene is located nearby the end of
the genome (Pope et al., 2013). Mycobacteriophages such as Omega display conserved
genes; however the virion structure and assembly genes are dispersed with non-structural
genes.

Interestingly most mycobacteriophages contain a lysis system which consists of a holin, an
endolysin (Lysin A) and Lysin B. It has been demonstrated in various bioinformatic studies
that the holin gene, presents difficulty in being assigned due to the presence of
transmembrane domains located near the Lysin A gene which may have a role in lysis
regulation (Hatfult & Sarkis, 1993) (Dedrick, Mavrich, Ng, & Hatfull, 2017a). Endolysins
which cleave the host cell wall are formulated modularly (K. M. Payne & Hatfull, 2012).
Lysin B which has been studied extensively as a target to cleave the mycolic acids in the cell
wall of MAP, codes for esterases (K. Payne, Sun, Sacchettini, & Hatfull, 2009). Surprisingly
a minority of mycobacteriophages lack the Lysin B gene completely (such as Rosebush). It is
unknown if the absence of this gene is substituted by other genes.

Mycobacteriophages can be grouped into 26 clusters based on genomic analysis.
Eighteen of these mycobacteriophage clusters when analysed present themselves as temperate
with an integration cassette (e.g. Clusters A, E, F, G, I, J, K, L, M, N, O, P, Q, T, X, Y, Z;
Singletons). Serine integrases (part of the integrase family) are only found in the genomes of
Clusters A and K. Prophage integration is present in all mycobacteriophages apart from
Cluster A genomes which allows these phages to replicate extrachromosomally (Graham F
Hatfull, 2012) (Dedrick et al., 2016).

The overall genome size influences genes that are involved in virion structure, integration
lysis and assembly. The smallest mycobacteriophage clusters may only contain 25-30
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supplementary genes whereas mycobacteriophages with larger genomes may contain 150
additional genes. The majority of these genes are of unknown function and have yet to be
researched, but few of these genes have a role in replication and recombination in DNA
metabolism. Many mycobacteriophages contain predicted DNA replication functions such as
Pol I type genes and Pol III alpha genes, but limited information is known about the function
of these genes.
DNA Polymerase is not encoded by many mycobateriophages, so this raises the question as
to why a minority of mycobacteriophages require DNA polymerase? Is it due to the
inactivation of host polymerases or to be able to make genomes with altered chemistry? This
has yet to be researched.
The diversity associated with mycobacteriophage genomes:
Mycobacteriophage genome sequences are abundant and widely diverse showing them to be
highly varied to other bacteriophage species. This diversity offers insights into bacteriophage
evolutionary mechanisms (Hatfull, 2010). As mycobacteriophages only infect mycobacterial
species, their specificity can lead to the creation of novel technologies for the control and
treatment of various mycobacterial infections (Hatfull, 2012).
Mycobacteriophages are typically found in the environment, utilising the most common
mycobacterial host which is Mycobacterium smegmatis mc2 155. It is possible that phages
discovered against M.smegmatis mc2 155 may be able to infect other mycobacterial strains in
particular Mycobacterium avium subspecies paratuberculosis (MAP) strains, as proven from
a small minority of studies (Swift, Gerrard, Huxley, & Rees, 2014) (Arutyunov et al., 2014).
There are 25 mycobacteriophages discovered which were effective against seven other
mycobacterial hosts (phagesdb.org). This is significant considering there are currently 180
mycobacterial species discovered since 2018 (Seth-Smith et al., 2019).
As mentioned previously, mycobacteriophages are extremely diverse with very high host
specificity. Despite this specificity, mycobacteriophages do not share genetic sequence
similarity (Pope et al., 2015; Brüssow & Hendrix, 2002). Mycobacteriophages are grouped
into clusters based on their sequence similarity based on 50% of their genome lengths
(Hatfull et al., 2006) (Pope et al., 2015; Grose & Casjens, 2014). It is quite rare to observe
nucleotide sequence similarity between the 24 distinct mycobacteriophage clusters that exist.
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Each cluster designation doesn’t provide sufficient diversity for all phages discovered to date,
therefore the clusters are divided into subclusters, in which 42 different subclusters exist.
Some phages, however, have no close relatives such as Corndog and Marvin, and these are
designated as singletons (Mageeney et al., 2012). Substantial levels of genomic mosaicism
have been observed in phages between different clusters (Rybniker et al., 2006).
Figure 1 demonstrates diversity associated with mycobacteriophage genomes for
mycobacteriophages LE1 to LE6 discovered previously (Endersen et al., 2013).
Regions of sequence similarity are connected by the shaded area, using a grey scale; genome
maps consisting of orange arrows indicating the location of ORFs along the phage genomes.
It is quite evident that each mycobacteriophage demonstrates significant diversity based on
sequence similarty. Mycobacteriophage LE2 and LE3 have little sequence similarty whereas
mycobacteriophage LE1 and LE2 demonstrate improved similarty. Mycobacteriophage LE4
and LE6 share almost identical similarty based on ORF’s. Mycobacteriophages LE1, LE2,
LE3 and LE5 appear to be the most diverse in comparison to mycobacteriophages LE4 and
LE6.
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LE1

LE2

LE3

LE4

LE5

LE6

Figure 1: Genome comparison of mycobacteriophages LE1, LE2, LE3, LE4, LE5 and
LE6 discovered previously (Endersen et al., 2013), using currently available annotations
employing BLASTN and visualized with Easyfig.

The importance of comparative analysis of mycobacteriophage genomes:
Mycobacteriophage clusters have been studied extensively, in particular by Graham Hatfull.
From the literature it has been noted that two factors which differ between each cluster
includes the size and as previously discussed the diversity. The largest cluster to exist is
Cluster A which contains 60 genomes and contains at least nine subclusters. The smallest
cluster to exist excluding the eight singletons are Clusters M, N and O, each containing two
genomes (Mavrich & Hatfull, 2017).
One cluster group contains genomes which are extremely similar; these are the Cluster G
phages. Their gene content is similar but the number of nucleotide substitutions between each
phage differs slightly. For example, Angel and BPs which are part of the Cluster G phages
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differ by a small mobile element MPME1 in BPs, and 138 nucleotide substitutions) (Sampson
et al., 2009).
The majority of the mycobacteriophage clusters display diversity and hence can be divided
into subclusters. The rationale of utilising subclusters appears to be based on the correct
arrangement of similar gene contents and genome organisation with varying degrees of
nucleotide similarity (Suarez, Franceschelli, & Morbidoni, 2019). In 2012, it was determined
that the total number of non-divided clusters, subsclusters and singletons was 44 (Hatfull,
2012a). Additionally, from the literature is has been noted that a large majority of
mycobacteriophage clusters are temperate whereas the remainder of the mycobacteriophage
clusters are lytic (Hatfull, 2018).

Figure 2: Mycobacteriophage clusters and subclsters of 471 analysed
mycobacteriophage genomes as studied by (Graham F. Hatfull, 2014)
Mosaicism of mycobacteriophage genomes plays an important role in the assembly of single
mycobacteriophage genes which are placed in unison in a specific combination. (Hatfull,
2010, Pedulla et al., 2003) but mosaicism also has the potential to display evolutionary
relationships, which have been developed by illegitimate recombination over an extended
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period of time. This mosaicism can be particularly observed in comparing amino acid
sequences (Hatfull, 2010, Hendrix et al., 1999).
Is there a correlation between mycobacteriophage genomes and morphology?
From the current literature it is understood that three distinct bacteriophage morphologies
exist; Siphoviridae, Mycoviridae and Podoviridae. All morphotypes have isometric heads
although a minority have elongated heads. The most important distinguishing feature between
each morphology type appears to be the nature of the phage tail (Hatfull, 2018). Siphoviridae
which are the most common morphology to exist in the literature of phage genomes, have
long flexible non-contractile tails, which have been evident in documented Electron
microscopy images from various studies (Endersen et al., 2013) (Pham, Jacobs-Sera, Pedulla,
Hendrix, & Hatfull, 2007). The other most common mycobacteriophage type is Myoviridae
in which the phages have contractile tails. From the current literature it has been noted that
there are no mycobacteriophages that have been assigned to the Podoviridae type and all
appear to be either of the myoviridae or siphoviridae type.
There is speculation that the reasoning for the absence for the Podoviridae morphotype in
mycobacteriophage is due to their short stubby short tails which are unable to penetrate the
thick lipid rich mycobacterial cell wall and cell membrane.
An insight into mycobacteriophage genes involved in bacterial infections and
human/animal diseases:
The development of novel mycobacteriophage therapies based on the manipulation of their
genomes would be of benefit in treating human and animal diseases. One particular
advantage of utilising mycobacteriophages involves their unusual system of immunity
regulation associated with certain mycobacteriophage clusters. A study undertaken in 2000
and 2017 provides an example of this in which the phage repressor L5 gp71 was shown to
have the ability to bind to an operator site and to a large number of related sites throughout
the phage genome which results in downregulation of the reporter gene (Dedrick et al.,
2017a) (Jain & Hatfull, 2000).
The application of mycobacteriophages in the treatment of human and animal diseases would
also be highly beneficial due to their specificity for their host, cheap cost of propagation and
their fast generation time. Interestingly, there are disadvantages associated with the
application of mycobacteriophage in human and animal diseases. Toxin genes present in
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other phage types have been discovered to generate a selective advantage for their bacterial
host (Wagner and Waldor, 2002).
To date, no toxin genes have been found in newly sequenced mycobacterial genes or
mycobacterial virulence. As already mentioned, bacteriophages are highly specific and only
infect their host, therefore bacteriophages develop independently of phages of other hosts.
Toxin genes however, may have the potential to reside in phage genomes of other hosts. The
ubiquity of these genes could in fact be transitory and they may not confer a selective
advantage alone therefore other selective forces could exist. These genes are interesting as
they may play a crucial role in the pathogenesis of human and animal diseases.
From the literature one example of these genes would include genes 39 and 61 present in the
mycobacteriophages Cjw1 and Omega which stimulate humoral and immune responses from
the Lsr2 antigen present in leprosy and tuberculosis (Laal et al., 1991; Oftung et al., 2000).
This may suggest a possible role for mycobacteriophages in mycobacterial virulence. The
potential function of the Lsr2 protein could influence immune responses of their hosts by
introducing this gene but its role has never fully been confirmed in the literature.
The mycobacteriophage phenomenon:
Mycobacteriophages are viruses that infect mycobacterial hosts, such as Mycobacterium
tuberculosis and Mycobacterium smegmatis. Numerous studies on mycobacteriophages were
published over the last 62 years. The first publication to document mycobacteriophages was
published in 1957.
Thousands of mycobacteriophages have been isolated using the fast-growing mycobacterial
strain M. smegmatis mc2155 through educational platforms and programs for undergraduate
students, with 1795 mycobacteriophage genomes sequenced to date according to
phagesdb.org (https://phagesdb.org/hosts/genera/1/).
Understanding transfection, morphology, biochemical characteristics and transduction
mechanisms were areas that researchers were focused on in the 1950’s. These studies
provided a platform for mycobacteriophage research particularly with notable pathogens such
as Mycobacterium tuberculosis and Mycobacterium avium subspecies paratuberculosis.
Utilising M.smegmatis mc2 155 as a surrogate strain, a vast majority of mycobacteriophages
have been isolated from the environment in sources such as soil and water (Graham F Hatfull,
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2012). Interestingly, mycobacteriophages have been isolated from stool samples in patients
with Crohn’s disease and Tuberculosis many years ago, although it is very uncommon
(Parent & Wilson, 1971). These mycobacteriophages represent a small fraction of the overall
bacteriophage population as discussed previously. A large proportion of mycobacteriophages
have been isolated from Pittsburgh, Pennsylvania and other locations in the United States. No
apparent differences were noted in the different mycobacteriophage genomes from different
global locations.
In discovering novel mycobacteriophages and performing genomic analysis, well known
mycobacteriophage genomes exist for comparison. These mycobacteriophages are L5, TM4
and D29. These are the first mycobacteriophages to be discovered and they have a complete
genomic sequence assigned to them (Fu, Ding, Zhang, & Li, 2015a). According to Hatfull et
al., (1994), the mycobacteriophage L5 is the best mycobacteriophage to be characterised.
Large quantities of genomic/bioinformatic analysis, molecular and gene expression studies
have been undertaken utilising the mycobacteriophage L5.
Mycobacteriophage D29, which has also been characterised extensively, was first isolated
from soil with a lytic nature and has proven to be effective against the slow growing pathogen
MAP. The D29 mycobacteriophage has a genome size of 49,136bp in length (GenBank
accession no. AF022214) (Dedrick, Mavrich, Ng, & Hatfull, 2017b).
TM4 is a mycobacteriophage capable of infecting Mycobacterium smegmatis mc2 155 but
also other slow growing strains of mycobacteria. TM4 displays a morphology which is
common in several thousand other mycobacteriophages. The sequence of TM4 has similarity
to mycobacteriophage D29 and L5 (Ford, Stenstrom, Hendrix, & Hatfull, 1998).
The future of mycobacteriophages in Johne’s disease detection and treatment
Currently research has been focused on the discovery of novel treatment and control
strategies for Johne’s disease caused by Mycobacterium avium paratuberculosis (“Diagnosis
Control Johne’s Dis.,” 2015). The discovery of novel mycobacteriophages and sequencing of
their genomes are fundamental steps in the development of a novel phage-based detection
method.
Established protocols have been developed for high throughput screening methods which
assess the effect of mycobacteriophages against MAP (Yang & Nolan, 2007). As MAP is
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such a difficult pathogen to cultivate, little research has been employed to establish such a
screening method for inhibiting its growth.
Various mycobacteriophages have been isolated from previous studies and have been tested
against the pathogen MAP (Anany et al., 2014), (Swift, Denton, Mahendran, Huxley, &
Rees, 2013), a minority of which appear to be effective. Utilising mycobacteriophages such
as TM4 and D29, cell culture models have yet to be researched to examine the effect of
these mycobacteriophages against MAP in the gastrointestinal system. Analysing the
bacteriophage effect against other bacterial hosts such as Clostridium difficile,
Campylobacter jejuni and Salmonella typhimurium has been explored in cell culture models
and have proven successful in treating certain infections (Mirzaei et al., 2016) (Vo et al.,
2007) (Shan et al., 2018) (Cairns, Timms, Jansen, Connerton, & Payne, 2009) (Lee,
Biswas, & Ahn, 2015). The application of similar methods to MAP would greatly benefit
the mycobacterial field of research.
The use of mycobacteriophage cocktails may have the potential to increase detection and
treatment by providing a broad host range. Mycobacteriophage cocktails have been
assessed in previous assays using sources such as milk to adequately kill MAP (Endersen et
al., 2013). Introducing mycobacteriophage or cocktails of mycobacteriophages into other
MAP based detection methods may aid in the development of advanced novel detection or
diagnostic methods.
EXPLORATION OF MYCOBACTERIOPHAGE BASED DIAGNOSTIC ASSAYS
FOR JOHNE’S DISEASE
Detection methods for Mycobacterium avium paratuberculosis in the control of Johne’s
disease:
Proper management of the spread and control of disease is directly correlated with rapid
diagnosis. Current methods of disease diagnosis for Johne’s disease caused by
Mycobacterium avium paratuberculosis (MAP) are slow and subject to bias. As Johne’s
disease is extremely difficult to detect at the early stages of disease, the development of a
novel detection method for MAP would be highly desirable to prevent further economic
losses.
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The diagnosis and detection of Mycobacterium avium paratuberculosis (MAP) from various
sources through traditional methods (culturing) and molecular methods have proven
challenging over the last century.

From the literature for the diagnosis of MAP, it has been noted that five distinct test types are
frequently available and used. These tests utilise antibodies and antigens against MAP,
detection of specific genes in MAP, bacterial cultivation of faecal samples and visual
inspection of symptoms (Clark, Koziczkowski, Radcliff, Carlson, & Ellingson, 2008). There
can be significant variation for each test which can be dependent on the stage of infection and
the procedure involved in each test. The most well-known test for diagnosing MAP infection
is the use of the enzyme-linked immunoassay (ELISA) to detect an immune response in
MAP. ELISA tests however, have limitations, in particular, reduced sensitivity which may be
as a result of the slow growth rate of MAP. Animals in an early stage of infections with low
faecal shedding may obtain bias results in utilising an ELISA test due to an inadequate
detection capacity (Diéguez et al., 2009). Immunohistochemistry (IHC) is a method similar to
ELISA based on detecting the immune reaction caused by MAP. The advantage of using IHC
is the ability to identify MAP in tissues. The sensitivity of the method in animals with
subclinical MAP infection is relatively good but interaction can occur with other
mycobacterial species and cross reactivity can occur (Moravkova et al., 2008).
Although extremely slow, the use of culturing methods from faecal and tissue samples is the
most traditional method used for detecting MAP infected animals. In conjunction with other
detection methods such as PCR of a region other then IS900, the utilisation of culture
methods can be as accurate as 100% (Ellingson et al., 2016). In determining the infection
status of MAP infected animals’ faecal culture is typically used to estimate the sensitivity of
other diagnostic methods such as ELISA and PCR. Faecal culture also provides confirmation
of MAP positive animals with immunological tests.
Although referred to as the “gold standard” for MAP detection, faecal culture presents
limitations such as a long turnaround time, high cost and high levels of contamination (Donat
et al., 2015). The accuracy of faecal culture may also be affected by the stage of MAP
infection and disease dynamics.
The interest in IS900 PCR for the detection of MAP soon became popular in 1989, although
the utilisation of this specific region in MAP has proven problematic over recent years. The
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insertion element is considered to be “unique” to MAP, although IS900 like sequences have
been found in other mycobacterial species. Considering this statement, various studies have
supported this claim. False positive and false negative results appear when reading studies
documented in the literature which utilise the IS900 gene (Debroy, Tripathi, Sonawane, &
Bind, 2012) (T et al., 2018). Subsequently more established “traditional” methods such as
faecal culture were thought to be more reliable and their utilisation became more common.
This statement does not imply that the application of PCR in detecting MAP is unreliable as
many methods have limitations. PCR of the IS900 gene in the detection of MAP genes has
proven useful over many years for its speed and specificity and low contamination levels, in
which no additional tests are required for confirmation. As mentioned previously the IS900
gene is typically targeted for MAP detection but is subject to false positive results. A
minority of mycobacteria (M. cookii, M. marinum, M. paraffinicum, and M.
scrofulaceum isolates) are found to contain IS900 like elements with 94% identity to the
MAP IS900 gene (Plain et al., 2014). There is a slight possibility that DNA from MAP and
various other microorganisms may also have the potential to produce false positive results.
Additionally the extraction of DNA from complex origins such as milk, faeces and blood has
led to be problematic thereby decreasing the sensitivity of PCR (Acharya, Dhand,
Whittington, & Plain, 2017). In recent years, alternative target sequences for MAP have been
proposed such as the mbtA gene, F57, locus 255, ISMap02 etc. (Mundo, Gilardoni, Hoffman,
& Lopez, 2013) (Qin, 2017) which may have the potential to increase the specificity of PCR
in detecting MAP infected animals. In reviewing publications, it is quite evident that the
choice of primers, PCR format and target sequence directly affect the sensitivity, specificity
and limit of detection of the PCR reaction.
The final method for the detection of MAP is the Johnin Skin Tuberculin Test, which is
commonly used in addition with other tests. The test is based on the visual inspection of the
skin of the neck after a certain time period when injected with Johnin PPD or M.avium PPD.
The interpretation of test results may prove difficult based on observation (Casal et al., 2014).
The test can be utilised by farmers once trained based on test observations.
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The development of a novel mycobacteriophage based diagnostic assays for MAP:
There is a lack of papers in the literature in relation to the development of new phage based
diagnostic assays. The development of a novel phage based diagnostic assay, for the
detection of MAP that incorporates specificity, sensitivity, speed and robustness would be of
high importance. Mycobacteriophage-based assays have been reported as potentially useful
tools for the detection of viable bacilli (mycobacterial species) as well as for antimicrobial
susceptibility testing.
In applying a phage-based detection system, no expensive instruments are required, and a
large majority of the mycobacterial strains utilised are avirulent The use of
mycobacteriophage in a MAP based diagnostic assay would distinguish viable bacterial cells
from non-viable bacterial cells quickly via a surrogate fast growing mycobacterial strain and
a turnaround time of 2 – 4 days compared to 2 months for culturing methods.
In applying mycobacteriophages to this type of assay, data may be obtained within a shorter
time, with increased accuracy as mycobacteriophages are specific to their host strain but also
a reduced cost as propagation is relatively cheap. A variety of attempts were made to mimic
this type of assay in previous years (2003) but it appears that other researchers did not try to
improve on this concept. In 2003, rifampicin resistance was assessed against Mycobacterium
tuberculosis using mycobacteriophage as an indicator of drug resistance and drug sensitivity
(Galí et al., 2003). No specific information in relation to the phage type used or TB strains
used was disclosed; therefore it is difficult to translate this work to other studies. Alternative
areas of mycobacteriophage research in mycobacterial detection have been explored.

Various other attempts were made at developing an assay which has the potential to assess
TB viability. The FASTPlaqueTB assay utilises a similar principle. The assay is mentioned
repeatedly throughout various papers from 2003 to 2005, indicating its wide applicability in
identifying TB from samples (Albay, Kisa, Baylan, & Doganci, 2003). It was developed in
2000 by Biotec Laboratories Ltd. The principle of the FASTPlaque TB assay is the
application of mycobacteriophages (Actiphage™) to detect drug resistant or sensitive TB
isolates and viability of TB in a clinical sample (Phulpoto, Qayyum, Rizvi, & Khuhawar,
2005). The addition of a virucidal solution (Virusol™) has the ability to destroy phages that
have not infected the TB cells and the remaining phage infect a surrogate mycobacterial
strain (M.smegmatis mc2 155) and results are interpreted based on plaque numbers. Since its
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development in 2000, various other researchers have combined this novel phage
amplification assay with other reliable diagnostic technologies.

The utilisation of fluoromycobacteriophages as a novel diagnostic tool in the detection
of MAP infected animals:
The creation of fluoromycobacteriophages in the last 10 years has led to an increase in the
research of Mycobacterium paratuberculosis detection. Fluoromycobacteriophages differ
from luciferase reporter mycobacteriophages in that they are tagged with a green fluorescent
protein as opposed to a lux gene (Piuri, Jacobs, & Hatfull, 2009). A small quantity of
bacterial cells can be identified with no substrate required (<100/ml). In applying
fluoromycobacteriophages to a MAP based detection system, it will be feasible to detect
phage propagation if the mycobacterial host is present in Real-time. This type of assay will
address problems associated with the slow growth rate of MAP and eliminate the need for
plaque assays.
In the development of such an assay, limitations will be addressed. The sensitivity of
mycobacteriophages appears to be varied between assays. When comparing studies, it
emerges that as the fluoromycobacteriophage attaches to the bacterial host, the fluorescence
may suddenly stop (Rondón et al., 2011) (Rondón et al., 2018) (Piuri, Rondón, Urdániz, &
Hatfull, 2013). Additionally, the absorption of mycobacteriophages to the host bacterial strain
is relatively inefficient.

The establishment of a bioluminescence system to detect viable MAP from infected
animals
The investigation of bioluminescence systems can be traced back to 1918 (Harvey, 1918).
The application of bioluminescence systems in microbiology and molecular biology have
increased over the recent number of years with 372 papers published (double check).
Luciferase which is one type of bioluminescence system has played an important role in
disease prevention, detection and treatment. Over the past decade, luciferase reporter
mycobacteriophages (LRPs) have been developed that show great promise for diagnostic
microbiology in research environments (Fu, Ding, Zhang, & Li, 2015b) (Van der Merwe,
Warren, Sampson, & Gey van Pittius, 2014). These mycobacteriophage systems have been
trialed using Mycobacterium paratuberculosis (Mtb) as a host, which is part of the
mycobacteria family.
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As mentioned, previous studies have shown that under research conditions LRP-based assays
can rapidly identify mycobacteria and perform susceptibility tests. It is also possible to
perform a luciferase reporter mycobacteriophage assay in a clinical setting as outlined
elsewhere (Banaiee et al., 2008) and results were comparable to a well-established drug
susceptibility method (BACTEC method). A luciferase reporter phage assay may also have
the ability to increase the speed of disease detection with a lower cost.

The application of qPCR with other diagnostic methods to increase the detection levels
of MAP infected animals
The introduction of qPCR in commercial and research labs over the last two decades has led
to the publication and development of thousands of high impact studies in diagnostics
laboratories worldwide. By combining qPCR and mycobacteriophage technology, detection
accuracy of MAP from various sources such as blood, milk etc. may have the potential to be
increased.

There are two approaches utilised in phage-based assays to detect MAP. These are (i) using
specific sensor cells to detect phages (ii) generation of engineered phages to detect reporter
constructs (for example luciferase reporter phages) (Smartt et al., 2012). It is quite evident
from the literature that many phage-based studies integrate qPCR with more advanced
detection techniques to improve MAP infection. Determining drug susceptibility of MAP to
various drugs utilising qPCR and mycobacteriophages in combination had gained extensive
research in 2012 (Pholwat, Ehdaie, Foongladda, Kelly, & Houpt, 2012) (Marinelli, Hatfull, &
Piuri, 2012). The utilisation of qPCR in combination with mycobacteriophage to determine
drug susceptibilities has been studied extensively by (Pholwat et al., 2011). Applying this
type of assay relies on the change in phage DNA levels which is correlated to a bacterium’s
susceptibility to the drug under investigation.

The search for novel biomarkers in the detection of MAP
Upon entering its host, MAP causes an immune response, which is not completely
understood. Initially upon infection, the host produces a Th1 response which releases
cytokines, in particular IFN- γ which triggers macrophages to kill the MAP cells (Stabel,
2000). In the progression of the disease the Th1 response is switched to a Th2 response. A
minority of animals that produce clinical symptoms may contain both a Th1 and Th2
response caused by IFN- γ whereas the majority of animals lose the Th1 mediated immunity
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(Koets et al., 2015) (Begg et al., 2011). Is it possible to suggest that only the Th1 and Th2
immune responses have the ability to characterise disease progression of MAP? Research is
deficient in how MAP infection progresses in different types of animals. Several studies have
been conducted which provide an account on disease progression in certain animals, while
subclinical infection of MAP persists (Mitchell et al., 2015) (Schukken et al., 2015) (Koets et
al., 2015).

To define disease progression of MAP, biomarkers and antigens have yet to be identified.
Markers that can accurately define disease progression for MAP infection are still to be
identified. Animals excrete low levels of MAP in the subclinical stage of infection therefore
detection is difficult, as a result of this, measureable antibody levels to MAP have not been
identified. Based on the stage of clinical infection different types of assay are used for
detection. IFN-γ assay (Th1 response) is used at subclinical infection and ELISAs (Th2
response) are used at later stages of infection (Scott et al., 2010) (Facciuolo, Kelton, &
Mutharia, 2013) and (Leite, Reinhardt, Bannantine, & Stabel, 2015).

Measuring bacterial shedding from ruminants is an important indicator of disease status in
MAP. No immunological data however, can be obtained from shedding. Evidence suggests
that the propagation of MAP in the intestinal wall corresponds to bacterial shedding in the
faeces of ruminants. Bacterial shedding of MAP is in fact influenced by several factors which
has been implicated in modelling studies (Magombedze, Eda, & Koets, 2016) (Magombedze,
Eda, & Ganusov, 2014). These factors include the replication of MAP within the host, the
lifecycle of macrophages in the host cell, the generation of monocytes in response to MAP,
the condition of the epithelial lining which may alter shedding levels of MAP in the lumen
and the type of immune response (humoral or cell mediated) generated.
In combination with ELISA tests, IFN--γ assays and faecal shedding using statistical analysis
and modelling it may be possible to predict disease diagnosis is MAP (Koets et al., 2015).

Transcriptomics is contributing widely to the identification of novel biomarkers for
mycobacterial species. Additional research is required for MAP to understand the immune
response before novel biomarkers can be discovered. For Mycobacterium bovis (MB) new
biomarkers have been identified and characterised using transcriptomics (MPB70, MPB83,
Rv3615c), however further validation has to be conducted to determine their specificities and
sensitivities (Vordermeier, Gordon, & Hewinson, 2009) and (Sidders et al., 2008).
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SUMMARY:
The diagnosis and treatment of MAP, the causative agent of Johne’s disease, over recent
years has proven challenging. The complexity of diagnosis is subsequently caused by the
slow growth rate of the organism, making detection difficult. Diagnostic assays exist for
MAP which are commonly utilised, and incorporate immune based detection, visual detection
and molecular detection, however these methods are subject to low sensitivity and specificity.
Novel diagnostic assays which have the ability to improve sensitivity and specificity in the
detection of MAP have yet to be developed. The application of mycobacteriophage to such a
diagnostic assay, in the form of luminescent/fluorescent phages, or combination with another
diagnostic method such as qPCR, may have the potential to be highly beneficial in increasing
detection accuracy. These novel areas of diagnostic research have to be further investigated.

REFERENCES:
Acharya, K. R., Dhand, N. K., Whittington, R. J., & Plain, K. M. (2017). PCR inhibition of a
quantitative PCR for detection of Mycobacterium avium subspecies paratuberculosis
DNA in feces: Diagnostic implications and potential solutions. Frontiers in
Microbiology. https://doi.org/10.3389/fmicb.2017.00115
Albay, A., Kisa, O., Baylan, O., & Doganci, L. (2003). The evaluation of FASTPlaqueTBTM
test for the rapid diagnosis of tuberculosis. Diagnostic Microbiology and Infectious
Disease. https://doi.org/10.1016/S0732-8893(03)00048-8
Amin, A. S., Hsu, C. Y., Darwish, S. F., Ghosh, P., Abdel-Fatah, E. M., Behour, T. S., &
Talaat, A. M. (2015). Ecology and genomic features of infection with mycobacterium
avium subspecies paratuberculosis in egypt. Microbiology (United Kingdom).
https://doi.org/10.1099/mic.0.000051
Anany, H. E. M., Basra, S., Khatun, R., Brovko, L., KROPINSKI, A. M., & Griffiths, M. W.
(2014). Isolation and characterization of Mycobacterium avium subspecies
paratuberculosis lytic bacteriophage for the development of phage-based rapid detection
technique in combination with BART-LAMP assay. American Society for Microbiology
114th Annual General Meeting, Boston, MA.
Andrews, J. M. (2002). Determination of minimum inhibitory concentrations. Journal of
41

Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkf083
Arutyunov, D., Singh, U., El-Hawiet, A., Seckler, H. dos S., Nikjah, S., Joe, M., …
Szymanski, C. M. (2014). Mycobacteriophage cell binding proteins for the capture of
mycobacteria. Bacteriophage. https://doi.org/10.4161/21597073.2014.960346
Bannantine, J. P., Radosevich, T. J., Stabel, J. R., Sreevatsan, S., Kapur, V., & Paustian, M.
L. (2007). Development and characterization of monoclonal antibodies and aptamers
against major antigens of Mycobacterium avium subsp. paratuberculosis. Clinical and
Vaccine Immunology. https://doi.org/10.1128/CVI.00022-07
Bastida, F., & Juste, R. A. (2011). Paratuberculosis control: A review with a focus on
vaccination. Journal of Immune Based Therapies and Vaccines.
https://doi.org/10.1186/1476-8518-9-8
Begg, D. J., de Silva, K., Carter, N., Plain, K. M., Purdie, A., & Whittington, R. J. (2011).
Does a th1 over th2 dominancy really exist in the early stages of mycobacterium avium
subspecies paratuberculosis infections? Immunobiology.
https://doi.org/10.1016/j.imbio.2010.12.004
Bengtsson-Palme, J., & Larsson, D. G. J. (2015). Antibiotic resistance genes in the
environment: prioritizing risks. Nature Reviews Microbiology.
https://doi.org/10.1038/nrmicro3399-c1
Beran, V., Havelkova, M., Kaustova, J., Dvorska, L., & Pavlik, I. (2006). Cell wall deficient
forms of mycobacteria: A review. Veterinarni Medicina. https://doi.org/10.17221/5557VETMED
Berkner, Silvia; Konradi, Sabine; Schönfeld, J. (2014). Antibiotic resistance and the
environment-there and back again. EMBO Reports. https://doi.org/10.1038/nbt.2466
Bermudez, L. E., Petrofsky, M., Sommer, S., & Barletta, R. G. (2010). Peyer’s patchdeficient mice demonstrate that Mycobacterium avium subsp. paratuberculosis
translocates across the mucosal barrier via both M cells and enterocytes but has
inefficient dissemination. Infection and Immunity. https://doi.org/10.1128/IAI.01411-09
Bolster, C. H., Cook, K. L., Haznedaroglu, B. Z., & Walker, S. L. (2009). The transport of
Mycobacterium avium subsp. paratuberculosis through saturated aquifer materials.
42

Letters in Applied Microbiology. https://doi.org/10.1111/j.1472-765X.2008.02519.x
Brown-Elliott, B. A., Nash, K. A., & Wallace, R. J. (2012). Antimicrobial susceptibility
testing, drug resistance mechanisms, and therapy of infections with nontuberculous
mycobacteria. Clinical Microbiology Reviews. https://doi.org/10.1128/CMR.05030-11
Cairns, B. J., Timms, A. R., Jansen, V. A. A., Connerton, I. F., & Payne, R. J. H. (2009).
Quantitative models of in vitro bacteriophage-host dynamics and their application to
phage therapy. PLoS Pathogens. https://doi.org/10.1371/journal.ppat.1000253
Carta, T., álvarez, J., Pérez de la Lastra, J. M., & Gortázar, C. (2013). Wildlife and
paratuberculosis: A review. Research in Veterinary Science.
https://doi.org/10.1016/j.rvsc.2012.11.002
Casal, C., Díez-Guerrier, A., Álvarez, J., Rodriguez-Campos, S., Mateos, A., Linscott, R., …
Aranaz, A. (2014). Strategic use of serology for the diagnosis of bovine tuberculosis
after intradermal skin testing. Veterinary Microbiology.
https://doi.org/10.1016/j.vetmic.2014.02.036
Cashman, W., Buckley, J., Quigley, T., Fanning, S., More, S., Egan, J., … O’Farrell, K.
(2008). Risk factors for the introduction and within-herd transmission of Mycobacterium
avium subspecies paratuberculosis (MAP) infection on 59 Irish dairy herds. Irish
Veterinary Journal. https://doi.org/10.1186/2046-0481-61-7-464
Castellanos, E., Juan, L. de, Domínguez, L., & Aranaz, A. (2012). Progress in molecular
typing of Mycobacterium avium subspecies paratuberculosis. Research in Veterinary
Science. https://doi.org/10.1016/j.rvsc.2011.05.017
Clark, D. L., Koziczkowski, J. J., Radcliff, R. P., Carlson, R. A., & Ellingson, J. L. E. (2008).
Detection of Mycobacterium avium Subspecies paratuberculosis: Comparing Fecal
Culture Versus Serum Enzyme-Linked Immunosorbent Assay and Direct Fecal
Polymerase Chain Reaction. Journal of Dairy Science. https://doi.org/10.3168/jds.20070902
Claudia, A., Lurdes Pinto, M. de, Matos, A., Matos, M., & Anjos Pires, M. dos. (2013).
Mycobacterium avium Complex in Domestic and Wild Animals. In Insights from
Veterinary Medicine. https://doi.org/10.5772/54323

43

Collins, M. T. (1996). Diagnosis of paratuberculosis. The Veterinary Clinics of North
America. Food Animal Practice. https://doi.org/10.1016/S0749-0720(15)30411-4
Davis, W. C., Kuenstner, J. T., & Singh, S. V. (2017). Resolution of Crohn’s (Johne’s)
disease with antibiotics: what are the next steps? Expert Review of Gastroenterology and
Hepatology. https://doi.org/10.1080/17474124.2017.1300529
de Kruijf, M., Coffey, A., & O’Mahony, J. (2017). The investigation of the truncated mbtA
gene within the mycobactin cluster of Mycobacterium avium subspecies
paratuberculosis as a novel diagnostic marker for real-time PCR. Journal of
Microbiological Methods. https://doi.org/10.1016/j.mimet.2017.03.005
Debroy, B., Tripathi, B. N., Sonawane, G. G., & Bind, R. B. (2012). Detection of
Mycobacterium avium subspecies paratuberculosis (MAP) in alcohol-fixed tissues of
sheep by ISMav2 gene PCR and its comparison with histopathology, bacterial culture
and IS900 PCR. Small Ruminant Research.
https://doi.org/10.1016/j.smallrumres.2012.02.006
Dedrick, R. M., Mavrich, T. N., Ng, W. L., Cervantes Reyes, J. C., Olm, M. R., Rush, R. E.,
… Hatfull, G. F. (2016). Function, expression, specificity, diversity and incompatibility
of actinobacteriophage parABS systems. Molecular Microbiology.
https://doi.org/10.1111/mmi.13414
Dedrick, R. M., Mavrich, T. N., Ng, W. L., & Hatfull, G. F. (2017a). Expression and
evolutionary patterns of mycobacteriophage D29 and its temperate close relatives. BMC
Microbiology. https://doi.org/10.1186/s12866-017-1131-2
Dedrick, R. M., Mavrich, T. N., Ng, W. L., & Hatfull, G. F. (2017b). Expression and
evolutionary patterns of mycobacteriophage D29 and its temperate close relatives. BMC
Microbiology. https://doi.org/10.1186/s12866-017-1131-2
Diagnosis and Control of Johne’s Disease. (2015). In Diagnosis and Control of Johne’s
Disease. https://doi.org/10.17226/10625
Diéguez, F. J., González, A. M., Menéndez, S., Vilar, M. J., Sanjuán, M. L., Yus, E., &
Arnaiz, I. (2009). Evaluation of four commercial serum ELISAs for detection of
Mycobacterium avium subsp. paratuberculosis infection in dairy cows. Veterinary
Journal. https://doi.org/10.1016/j.tvjl.2007.11.004
44

Donat, K., Kube, J., Dressel, J., Einax, E., Pfeffer, M., & Failing, K. (2015). Detection of
Mycobacterium avium subspecies paratuberculosis in environmental samples by faecal
culture and real-time PCR in relation to apparent within-herd prevalence as determined
by individual faecal culture. Epidemiology and Infection.
https://doi.org/10.1017/S0950268814002465
ELLINGSON, J. L. E., ANDERSON, J. L., KOZICZKOWSKI, J. J., RADCLIFF, R. P.,
SLOAN, S. J., ALLEN, S. E., & SULLIVAN, N. M. (2016). Detection of Viable
Mycobacterium avium subsp. paratuberculosis in Retail Pasteurized Whole Milk by
Two Culture Methods and PCR. Journal of Food Protection.
https://doi.org/10.4315/0362-028x-68.5.966
Emery, D. L., & Whittington, R. J. (2004). An evaluation of mycophage therapy,
chemotherapy and vaccination for control of Mycobacterium avium subsp.
paratuberculosis infection. Veterinary Microbiology.
https://doi.org/10.1016/j.vetmic.2004.08.014
Endersen, L., Coffey, A., Neve, H., McAuliffe, O., Ross, R. P., & O’Mahony, J. M. (2013).
Isolation and characterisation of six novel mycobacteriophages and investigation of their
antimicrobial potential in milk. International Dairy Journal.
https://doi.org/10.1016/j.idairyj.2012.07.010
Espejo, L. A., Godden, S., Hartmann, W. L., & Wells, S. J. (2012). Reduction in incidence of
Johne’s disease associated with implementation of a disease control program in
Minnesota demonstration herds. Journal of Dairy Science.
https://doi.org/10.3168/jds.2011-4550
Facciuolo, A., Kelton, D. F., & Mutharia, L. M. (2013). Novel secreted antigens of
Mycobacterium paratuberculosis as serodiagnostic biomarkers for Johne’s disease in
cattle. Clinical and Vaccine Immunology. https://doi.org/10.1128/CVI.00380-13
Ford, M. E., Stenstrom, C., Hendrix, R. W., & Hatfull, G. F. (1998). Mycobacteriophage
TM4: Genome structure and gene expression. Tubercle and Lung Disease.
https://doi.org/10.1054/tuld.1998.0007
Fortier, L. C., & Sekulovic, O. (2013). Importance of prophages to evolution and virulence of
bacterial pathogens. Virulence. https://doi.org/10.4161/viru.24498
45

Fu, X., Ding, M., Zhang, N., & Li, J. (2015a). Mycobacteriophages: An important tool for the
diagnosis of Mycobacterium tuberculosis (Review). Molecular Medicine Reports.
https://doi.org/10.3892/mmr.2015.3440
Fu, X., Ding, M., Zhang, N., & Li, J. (2015b). Mycobacteriophages: An important tool for the
diagnosis of Mycobacterium tuberculosis (Review). Molecular Medicine Reports.
https://doi.org/10.3892/mmr.2015.3440
Furfaro, L. L., Payne, M. S., & Chang, B. J. (2018). Bacteriophage Therapy: Clinical Trials
and Regulatory Hurdles. Frontiers in Cellular and Infection Microbiology.
https://doi.org/10.3389/fcimb.2018.00376
Galí, N., Domínguez, J., Blanco, S., Prat, C., Quesada, M. D., Matas, L., & Ausina, V.
(2003). Utility of an in-house mycobacteriophage-based assay for rapid detection of
rifampin resistance in Mycobacterium tuberculosis clinical isolates. Journal of Clinical
Microbiology. https://doi.org/10.1128/JCM.41.6.2647-2649.2003
Garcia, A. B., & Shalloo, L. (2015). Invited review: The economic impact and control of
paratuberculosis in cattle. Journal of Dairy Science. https://doi.org/10.3168/jds.20149241
Garvey, M. (2018). Mycobacterium avium subspecies paratuberculosis: A possible causative
agent in human morbidity and risk to public health safety. Open Veterinary Journal.
https://doi.org/10.4314/ovj.v8i2.10
Gerrard, Z. E., Swift, B. M. C., Botsaris, G., Davidson, R. S., Hutchings, M. R., Huxley, J.
N., & Rees, C. E. D. (2018). Survival of Mycobacterium avium subspecies
paratuberculosis in retail pasteurised milk. Food Microbiology.
https://doi.org/10.1016/j.fm.2018.03.004
Golkar, Z., Bagasra, O., & Gene Pace, D. (2014). Bacteriophage therapy: A potential solution
for the antibiotic resistance crisis. Journal of Infection in Developing Countries.
https://doi.org/10.3855/jidc.3573
Gonzalez-y-Merchand, J. A., Zaragoza-Contreras, R., Guadarrama-Medina, R., HelgueraRepetto, A. C., Rivera-Gutierrez, S., Cerna-Cortes, J. F., … Cox, R. A. (2012).
Evaluation of the cell growth of mycobacteria using Mycobacterium smegmatis mc2
155 as a representative species. Journal of Microbiology.
46

https://doi.org/10.1007/s12275-012-1556-0
Good, M., Clegg, T., Sheridan, H., Yearsely, D., O’Brien, T., Egan, J., & Mullowney, P.
(2009). Prevalence and distribution of paratuberculosis (Johne’s disease) in cattle herds
in Ireland. Irish Veterinary Journal. https://doi.org/10.1186/2046-0481-62-9-597
Górski, A., Międzybrodzki, R., Łobocka, M., Głowacka-Rutkowska, A., Bednarek, A.,
Borysowski, J., … Scheres, J. (2018). Phage therapy: What have we learned? Viruses.
https://doi.org/10.3390/v10060288
Górski, A., Miedzybrodzki, R., Weber-Dabrowska, B., Fortuna, W., Letkiewicz, S., Rogóz,
P., … Borysowski, J. (2016). Phage therapy: Combating infections with potential for
evolving from merely a treatment for complications to targeting diseases. Frontiers in
Microbiology. https://doi.org/10.3389/fmicb.2016.01515
Green, E. P., Tizard, M. L. V., Moss, M. T., Thompson, J., Winterbourne, D. J., Mcfadden, J.
J., & Hermon-Taylor, J. (1989). Sequence and characteristics or IS900, an insertion
element identified in a human crohn’s disease isolate or Mycobacterium
paratuberculosis. Nucleic Acids Research. https://doi.org/10.1093/nar/17.22.9063
Halperin, J. J. (2015). Chronic Lyme disease: Misconceptions and challenges for patient
management. Infection and Drug Resistance. https://doi.org/10.2147/IDR.S66739
Harris, N. B., & Barletta, R. G. (2001). Mycobacterium avium subsp. paratuberculosis in
Veterinary Medicine. Clinical Microbiology Reviews.
https://doi.org/10.1128/CMR.14.3.489-512.2001
Harvey, E. N. (1918). STUDIES ON BIOLUMINESCENCE: VII. REVERSIBILITY OF
THE PHOTOGENIC REACTION IN CYPRIDINA. The Journal of General
Physiology. https://doi.org/10.1085/jgp.1.2.133
Hatfull, G F, Barsom, L., Chang, L., Donnelly-Wu, M., Lee, M. H., Levin, M., … Sarkis, G.
J. (1994). Bacteriophages as tools for vaccine development. Dev Biol Stand.
Hatfull, Graham F. (2014). Mycobacteriophages: Windows into Tuberculosis. PLoS
Pathogens. https://doi.org/10.1371/journal.ppat.1003953
Hatfull, Graham F. (2012). Chapter 7 - The Secret Lives of Mycobacteriophages. In
Bacteriophages, Part A. https://doi.org/http://dx.doi.org/10.1016/B978-0-12-39462147

8.00015-7
Hatfult, G. F., & Sarkis, G. J. (1993). DNA sequence, structure and gene expression of
mycobacteriophage L5: a phage system for mycobacterial genetics. Molecular
Microbiology. https://doi.org/10.1111/j.1365-2958.1993.tb01131.x
Jain, S., & Hatfull, G. F. (2000). Transcriptional regulation and immunity in
mycobacteriophage Bxb1. Molecular Microbiology. https://doi.org/10.1046/j.13652958.2000.02184.x
Jesse, F. F. A., Bitrus, A. A., Abba, Y., Sadiq, M. A., Chung, E. L. T., Hambali, I. U., …
Haron, A. W. (2016). Clinical and gross pathological findings of Johne’s disease in a
calf: A case report. Journal of Advanced Veterinary and Animal Research.
https://doi.org/10.5455/javar.2016.c165
Johnston, C., Coffey, A., Mahony, J. O., & Sleator, R. D. (2010). Development of a novel
oral vaccine against Mycobacterium avium paratuberculosis and Johne disease.
Bioengineered Bugs. https://doi.org/10.4161/bbug.1.3.10408
Koets, A. P., Eda, S., & Sreevatsan, S. (2015). The within host dynamics of Mycobacterium
avium ssp. paratuberculosis infection in cattle: where time and place matter. Veterinary
Research. https://doi.org/10.1186/s13567-015-0185-0
Krishnan, M. Y., Manning, E. J. B., & Collins, M. T. (2009a). Comparison of three methods
for susceptibility testing of Mycobacterium avium subsp. paratuberculosis to 11
antimicrobial drugs. Journal of Antimicrobial Chemotherapy.
https://doi.org/10.1093/jac/dkp184
Krishnan, M. Y., Manning, E. J. B., & Collins, M. T. (2009b). Effects of interactions of
antibacterial drugs with each other and with 6-mercaptopurine on in vitro growth of
Mycobacterium avium subspecies paratuberculosis. Journal of Antimicrobial
Chemotherapy. https://doi.org/10.1093/jac/dkp339
Kuenstner, J. T., Naser, S., Chamberlin, W., Borody, T., Graham, D. Y., McNees, A., …
Kuenstner, L. (2017). The consensus from the Mycobacterium avium ssp.
paratuberculosis (MAP) conference 2017. Frontiers in Public Health.
https://doi.org/10.3389/fpubh.2017.00208

48

Lee, H. Y., Biswas, D., & Ahn, J. (2015). In-vitro adhesion and invasion properties of
salmonella typhimurium competing with bacteriophage in epithelial cells and chicken
macrophages. Revista Brasileira de Ciencia Avicola. https://doi.org/10.1590/1516635x1704427-432
Leite, F. L., Reinhardt, T. A., Bannantine, J. P., & Stabel, J. R. (2015). Envelope protein
complexes of Mycobacterium avium subsp. paratuberculosis and their antigenicity.
Veterinary Microbiology. https://doi.org/10.1016/j.vetmic.2014.11.009
Lin, D. M., Koskella, B., & Lin, H. C. (2017). Phage therapy: An alternative to antibiotics in
the age of multi-drug resistance. World Journal of Gastrointestinal Pharmacology and
Therapeutics. https://doi.org/10.4292/wjgpt.v8.i3.162
Lombard, J. E. (2011). Epidemiology and Economics of Paratuberculosis. Veterinary Clinics
of North America: Food Animal Practice. https://doi.org/10.1016/j.cvfa.2011.07.012
Mageeney, C., Pope, W. H., Harrison, M., Moran, D., Cross, T., Jacobs-Sera, D., … Hatfull,
G. F. (2012). Mycobacteriophage Marvin: a New Singleton Phage with an Unusual
Genome Organization. Journal of Virology. https://doi.org/10.1128/JVI.00075-12
Magombedze, G., Eda, S., & Ganusov, V. V. (2014). Competition for Antigen between Th1
and Th2 Responses Determines the Timing of the Immune Response Switch during
Mycobaterium avium Subspecies paratuberulosis Infection in Ruminants. PLoS
Computational Biology. https://doi.org/10.1371/journal.pcbi.1003414
Magombedze, G., Eda, S., & Koets, A. (2016). Can Immune Response Mechanisms Explain
the Fecal Shedding Patterns of Cattle Infected with Mycobacterium avium Subspecies
paratuberculosis? PloS One. https://doi.org/10.1371/journal.pone.0146844
Manson, A. L., Cohen, K. A., Abeel, T., Desjardins, C. A., Armstrong, D. T., Barry, C. E., …
Earl, A. M. (2017). Genomic analysis of globally diverse Mycobacterium tuberculosis
strains provides insights into the emergence and spread of multidrug resistance. Nature
Genetics. https://doi.org/10.1038/ng.3767
Marinelli, L. J., Hatfull, G. F., & Piuri, M. (2012). Recombineering: A powerful tool for
modification of bacteriophage genomes. Bacteriophage.
https://doi.org/10.4161/bact.18778

49

Marston, H. D., Dixon, D. M., Knisely, J. M., Palmore, T. N., & Fauci, A. S. (2016).
Antimicrobial resistance. JAMA - Journal of the American Medical Association.
https://doi.org/10.1001/jama.2016.11764
Martin, M. J., Thottathil, S. E., & Newman, T. B. (2015). Antibiotics Overuse in Animal
Agriculture: A Call to Action for Health Care Providers. American Journal of Public
Health. https://doi.org/10.2105/ajph.2015.302870
Mavrich, T. N., & Hatfull, G. F. (2017). Bacteriophage evolution differs by host, lifestyle and
genome. Nature Microbiology. https://doi.org/10.1038/nmicrobiol.2017.112
Mirzaei, M. K., Haileselassie, Y., Navis, M., Cooper, C., Sverremark-Ekström, E., & Nilsson,
A. S. (2016). Morphologically distinct escherichia coli bacteriophages differ in their
efficacy and ability to stimulate cytokine release in vitro. Frontiers in Microbiology.
https://doi.org/10.3389/fmicb.2016.00437
Mitchell, R. M., Schukken, Y., Koets, A., Weber, M., Bakker, D., Stabel, J., … Louzoun, Y.
(2015). Differences in intermittent and continuous fecal shedding patterns between
natural and experimental Mycobacterium avium subspecies paratuberculosis infections
in cattle. Veterinary Research. https://doi.org/10.1186/s13567-015-0188-x
Moelling, K., Broecker, F., & Willy, C. (2018). A wake-up call: We need phage therapy now.
Viruses. https://doi.org/10.3390/v10120688
Momotani, E., Whipple, D. L., Thiermann, A. B., & Cheville, N. F. (1988). Role of M Cells
and Macrophages in the Entrance of Mycobacterium paratuberculosis into Domes of
Ileal Peyer’s Patches in Calves. Veterinary Pathology.
https://doi.org/10.1177/030098588802500205
Morand, S., McIntyre, K. M., & Baylis, M. (2014). Domesticated animals and human
infectious diseases of zoonotic origins: Domestication time matters. Infection, Genetics
and Evolution. https://doi.org/10.1016/j.meegid.2014.02.013
Moravkova, M., Hlozek, P., Beran, V., Pavlik, I., Preziuso, S., Cuteri, V., & Bartos, M.
(2008). Strategy for the detection and differentiation of Mycobacterium avium species in
isolates and heavily infected tissues. Research in Veterinary Science.
https://doi.org/10.1016/j.rvsc.2007.10.006

50

Mundo, S. L., Gilardoni, L. R., Hoffman, F. J., & Lopez, O. J. (2013). Rapid and sensitive
method to identify Mycobacterium avium subsp. Paratuberculosis in Cow’s milk by
DNA methylase genotyping. Applied and Environmental Microbiology.
https://doi.org/10.1128/AEM.02719-12
Naser, S. A., Ghobrial, G., Romero, C., & Valentine, J. F. (2004). Culture of Mycobacterium
avium subspecies paratuberculosis from the blood of patients with Crohn’s disease.
Lancet. https://doi.org/10.1016/S0140-6736(04)17058-X
Neutra, M. R., Mantis, N. J., & Kraehenbuhl, J. P. (2001). Collaboration of epithelial cells
with organized mucosal lymphoid tissues. Nature Immunology.
https://doi.org/10.1038/ni1101-1004
Norby, B., Fosgate, G. T., Manning, E. J. B., Collins, M. T., & Roussel, A. J. (2007).
Environmental mycobacteria in soil and water on beef ranches: Association between
presence of cultivable mycobacteria and soil and water physicochemical characteristics.
Veterinary Microbiology. https://doi.org/10.1016/j.vetmic.2007.04.015
Ofer, N., Wishkautzan, M., Meijler, M., Wang, Y., Speer, A., Niederweis, M., & Gur, E.
(2012). Ectoine biosynthesis in Mycobacterium smegmatis. Applied and Environmental
Microbiology. https://doi.org/10.1128/AEM.01318-12
Olszak, T., Latka, A., Roszniowski, B., Valvano, M. A., & Drulis-Kawa, Z. (2017). Phage
Life Cycles Behind Bacterial Biodiversity. Current Medicinal Chemistry.
https://doi.org/10.2174/0929867324666170413100136
Ott, S. L., Wells, S. J., & Wagner, B. A. (1999). Herd-level economic losses associated with
Johne’s disease on US dairy operations. Preventive Veterinary Medicine.
https://doi.org/10.1016/S0167-5877(99)00037-9
Over, K., Crandall, P. G., O’Bryan, C. A., & Ricke, S. C. (2011). Current perspectives on
Mycobacterium avium subsp. paratuberculosis, Johne’s disease, and Crohn’âs disease: A
Review. Critical Reviews in Microbiology.
https://doi.org/10.3109/1040841X.2010.532480
Pantziarka, P., Pirmohamed, M., & Mirza, N. (2018). New uses for old drugs. BMJ (Online).
https://doi.org/10.1136/bmj.k2701

51

Parent, K., & Wilson, I. D. (1971). Mycobacteriophage in Crohn’s disease. Gut.
https://doi.org/10.1136/gut.12.12.1019
Pavlik, I., & Falkinham, J. O. (2009). The occurrence of pathogenic and potentially
pathogenic mycobacteria in animals and the role of the environment in the spread of
Infection. In The Ecology of Mycobacteria: Impact on Animal’s and Human’s Health.
https://doi.org/10.1007/978-1-4020-9413-2-6
Payne, K. M., & Hatfull, G. F. (2012). Mycobacteriophage endolysins: Diverse and modular
enzymes with multiple catalytic activities. PLoS ONE.
https://doi.org/10.1371/journal.pone.0034052
Payne, K., Sun, Q., Sacchettini, J., & Hatfull, G. F. (2009). Mycobacteriophage Lysin B is a
novel mycolylarabinogalactan esterase. Molecular Microbiology.
https://doi.org/10.1111/j.1365-2958.2009.06775.x
Pham, T. T., Jacobs-Sera, D., Pedulla, M. L., Hendrix, R. W., & Hatfull, G. F. (2007).
Comparative genomic analysis of mycobacteriophage Tweety: Evolutionary insights and
construction of compatible site-specific integration vectors for mycobacteria.
Microbiology. https://doi.org/10.1099/mic.0.2007/008904-0
Pholwat, S., Ehdaie, B., Foongladda, S., Kelly, K., & Houpt, E. (2012). Real-time PCR using
mycobacteriophage DNA for rapid phenotypic drug susceptibility results for
Mycobacterium tuberculosis. Journal of Clinical Microbiology.
https://doi.org/10.1128/JCM.01315-11
Phulpoto, M. A., Qayyum, S., Rizvi, N., & Khuhawar, S. M. (2005). Diagnostic yield of fast
plaque TBTM test for rapid detection of mycobacterium in tuberculosis suspects. Journal
of the Pakistan Medical Association.
Pickup, R. W., Rhodes, G., Arnott, S., Sidi-Boumedine, K., Bull, T. J., Weightman, A., …
Hermon-Taylor, J. (2005). Mycobacterium avium subsp. paratuberculosis in the
catchment area and water of the river Taff in South Wales, United Kingdom, and its
potential relationship to clustering of Crohn’s disease cases in the city of Cardiff.
Applied and Environmental Microbiology. https://doi.org/10.1128/AEM.71.4.21302139.2005
Pierce, E. S. (2010). Ulcerative colitis and Crohn’s disease: Is Mycobacterium avium
52

subspecies paratuberculosis the common villain? Gut Pathogens.
https://doi.org/10.1186/1757-4749-2-21
Pillars, R. B., Grooms, D. L., Wolf, C. A., & Kaneene, J. B. (2009). Economic evaluation of
Johne’s disease control programs implemented on six Michigan dairy farms. Preventive
Veterinary Medicine. https://doi.org/10.1016/j.prevetmed.2009.04.009
Piuri, M., Jacobs, W. R., & Hatfull, G. F. (2009). Fluoromycobacteriophages for rapid,
specific, and sensitive antibiotic susceptibility testing of Mycobacterium tuberculosis.
PLoS ONE. https://doi.org/10.1371/journal.pone.0004870
Piuri, M., Rondón, L., Urdániz, E., & Hatfull, G. F. (2013). Generation of affinity-tagged
fluoromycobacteriophages by mixed assembly of phage capsids. Applied and
Environmental Microbiology. https://doi.org/10.1128/AEM.01016-13
Plain, K. M., Marsh, I. B., Waldron, A. M., Galea, F., Whittington, A. M., Saunders, V. F.,
… Whittington, R. J. (2014). High-throughput direct fecal PCR assay for detection of
Mycobacterium avium subsp. Paratuberculosis in sheep and cattle. Journal of Clinical
Microbiology. https://doi.org/10.1128/JCM.03233-13
Ponnusamy, D., Periasamy, S., Tripathi, B. N., & Pal, A. (2013). Mycobacterium avium
subsp. paratuberculosis invades through M cells and enterocytes across ileal and jejunal
mucosa of lambs. Research in Veterinary Science.
https://doi.org/10.1016/j.rvsc.2012.09.023
Pope, W. H., Jacobs-Sera, D., Best, A. A., Broussard, G. W., Connerly, P. L., Dedrick, R. M.,
… Hatfull, G. F. (2013). Cluster J Mycobacteriophages: Intron Splicing in Capsid and
Tail Genes. PLoS ONE. https://doi.org/10.1371/journal.pone.0069273
Pribylova, R., Slana, I., Kralik, P., Kralova, A., Babak, V., & Pavlik, I. (2011). Correlation of
Mycobacterium avium subsp. paratuberculosis counts in gastrointestinal tract, muscles
of the diaphragm and the masseter of dairy cattle and potential risk for consumers.
International Journal of Food Microbiology.
https://doi.org/10.1016/j.ijfoodmicro.2011.09.025
Qin, X. (2017). Can Crohn’s Disease Really be Caused by Mycobacterium avium Subspecies
Paratuberculosis?-With My Alternative Theory that Reduction in Commensal Gut
Bacteria and Resultant Impaired Inactivation of Digestive Proteases as the Primary
53

Cause. International Journal of Clinical & Medical Microbiology.
https://doi.org/10.15344/2456-4028/2016/109
Rondón, L., Piuri, M., Jacobs, W. R., De Waard, J., Hatfull, G. F., & Takiff, H. E. (2011).
Evaluation of fluoromycobacteriophages for detecting drug resistance in Mycobacterium
tuberculosis. Journal of Clinical Microbiology. https://doi.org/10.1128/JCM.02476-10
Rondón, L., Urdániz, E., Latini, C., Payaslian, F., Matteo, M., Sosa, E. J., … Piuri, M.
(2018). Fluoromycobacteriophages can detect viable Mycobacterium tuberculosis and
determine phenotypic rifampicin resistance in 3-5 days from sputum collection.
Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2018.01471
Roussel, A. J. (2011). Control of Paratuberculosis in Beef Cattle. Veterinary Clinics of North
America: Food Animal Practice. https://doi.org/10.1016/j.cvfa.2011.07.005
Salgado, M., Alfaro, M., Salazar, F., Badilla, X., Troncoso, E., Zambrano, A., … Collins, M.
T. (2015). Application of cattle slurry containing Mycobacterium avium subsp.
paratuberculosis (MAP) to grassland soil and its effect on the relationship between MAP
and free-living amoeba. Veterinary Microbiology.
https://doi.org/10.1016/j.vetmic.2014.09.022
Savarino, E., Bertani, L., Ceccarelli, L., Bodini, G., Zingone, F., Buda, A., … Blandizzi, C.
(2019). Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for
Mycobacterium avium subspecies paratuberculosis in Crohn’s disease: pharmacological
and clinical implications. Expert Opinion on Biological Therapy.
https://doi.org/10.1080/14712598.2019.1561852
Schukken, Y. H., Whitlock, R. H., Wolfgang, D., Grohn, Y., Beaver, A., VanKessel, J., …
Mitchell, R. (2015). Longitudinal data collection of Mycobacterium avium subspecies
Paratuberculosis infections in dairy herds: the value of precise field data. Veterinary
Research. https://doi.org/10.1186/s13567-015-0187-y
Scott, M. C., Bannantine, J. P., Kaneko, Y., Branscum, A. J., Whitlock, R. H., Mori, Y., …
Eda, S. (2010). Absorbed EVELISA: A diagnostic test with improved specificity for
Johne’s disease in cattle. Foodborne Pathogens and Disease.
https://doi.org/10.1089/fpd.2010.0541
Secott, T. E., Lin, T. L., & Wu, C. C. (2004). Mycobacterium avium subsp. paratuberculosis
54

fibronectin attachment protein facilitates M-cell targeting and invasion through a
fibronectin bridge with host integrins. Infection and Immunity.
https://doi.org/10.1128/IAI.72.7.3724-3732.2004
Seth-Smith, H. M. B., Imkamp, F., Tagini, F., Cuénod, A., Hömke, R., Jahn, K., … Egli, A.
(2019). Discovery and characterization of Mycobacterium basiliensesp. nov., a
nontuberculous mycobacterium isolated from human lungs. Frontiers in Microbiology.
https://doi.org/10.3389/fmicb.2018.03184
Shan, J., Ramachandran, A., Thanki, A. M., Vukusic, F. B. I., Barylski, J., & Clokie, M. R. J.
(2018). Bacteriophages are more virulent to bacteria with human cells than they are in
bacterial culture; Insights from HT-29 cells. Scientific Reports.
https://doi.org/10.1038/s41598-018-23418-y
Shin, A. R., Kim, H. J., Cho, S. N., Collins, M. T., Manning, E. J. B., Naser, S. A., & Shin, S.
J. (2010). Identification of seroreactive proteins in the culture filtrate antigen of
Mycobacterium avium ssp. paratuberculosis human isolates to sera from Crohn’s disease
patients. FEMS Immunology and Medical Microbiology. https://doi.org/10.1111/j.1574695X.2009.00617.x
Sidders, B., Pirson, C., Hogarth, P. J., Hewinson, R. G., Stoker, N. G., Vordermeier, H. M.,
& Ewer, K. (2008). Screening of highly expressed mycobacterial genes identifies
Rv3615c as a useful differential diagnostic antigen for the Mycobacterium tuberculosis
complex. Infection and Immunity. https://doi.org/10.1128/IAI.00150-08
Sigurdardóttir, Ó. G., Bakke-McKellep, A. M., Djønne, B., & Evensen, Ø. (2005).
Mycobacterium avium subsp. paratuberculosis enters the small intestinal mucosa of goat
kids in areas with and without Peyer’s patches as demonstrated with the everted sleeve
method. Comparative Immunology, Microbiology and Infectious Diseases.
https://doi.org/10.1016/j.cimid.2005.01.004
Singer, A. C., Shaw, H., Rhodes, V., & Hart, A. (2016). Review of antimicrobial resistance in
the environment and its relevance to environmental regulators. Frontiers in
Microbiology. https://doi.org/10.3389/fmicb.2016.01728
Smartt, A. E., Xu, T., Jegier, P., Carswell, J. J., Blount, S. A., Sayler, G. S., & Ripp, S.
(2012). Pathogen detection using engineered bacteriophages. Analytical and
55

Bioanalytical Chemistry. https://doi.org/10.1007/s00216-011-5555-5
Stabel, J. R. (2000). Transitions in immune responses to Mycobacterium paratuberculosis.
Veterinary Microbiology. https://doi.org/10.1016/S0378-1135(00)00331-X
Strahl, E. D., Gillaspy, G. E., & Falkinham, J. O. (2001). Fluorescent Acid-Fast Microscopy
for Measuring Phagocytosis of Mycobacterium avium, Mycobacterium intracellulare,
and Mycobacterium scrofulaceum by Tetrahymena pyriformis and Their Intracellular
Growth. Applied and Environmental Microbiology.
https://doi.org/10.1128/AEM.67.10.4432-4439.2001
Suarez, C. A., Franceschelli, J. J., & Morbidoni, H. R. (2019). Mycobacteriophage CRB2
defines a new subcluster in mycobacteriophage classification. PLoS ONE.
https://doi.org/10.1371/journal.pone.0212365
Swift, B. M. C., Denton, E. J., Mahendran, S. A., Huxley, J. N., & Rees, C. E. D. (2013).
Development of a rapid phage-based method for the detection of viable Mycobacterium
avium subsp. paratuberculosis in blood within 48 h. Journal of Microbiological
Methods. https://doi.org/10.1016/j.mimet.2013.06.015
Swift, B. M. C., Gerrard, Z. E., Huxley, J. N., & Rees, C. E. D. (2014). Factors affecting
phage D29 infection: A tool to investigate different growth states of mycobacteria. PLoS
ONE. https://doi.org/10.1371/journal.pone.0106690
T, Y., M, G., T, S., SER, M., S, R., & T, H. (2018). Comparison and Validation of IS900Sequence and Putative Sequences as Specific Target to Detect Mycobacterium avium
subsp. paratuberculosis. Journal of Animal Science and Research.
https://doi.org/10.16966/2576-6457.101
Tasara, T., & Stephan, R. (2005). Development of an F57 sequence-based real-time PCR
assay for detection of Mycobacterium avium subsp. paratuberculosis in milk. Applied
and Environmental Microbiology. https://doi.org/10.1128/AEM.71.10.5957-5968.2005
Van der Merwe, R. G., Warren, R. M., Sampson, S. L., & Gey van Pittius, N. C. (2014).
Phage-based detection of bacterial pathogens. Analyst.
https://doi.org/10.1039/c4an00208c
Verteramo Chiu, L. J., Tauer, L. W., Al-Mamun, M. A., Kaniyamattam, K., Smith, R. L., &
56

Grohn, Y. T. (2018). An agent-based model evaluation of economic control strategies
for paratuberculosis in a dairy herd. Journal of Dairy Science.
https://doi.org/10.3168/jds.2017-13175
Vo, A. T. T., van Duijkeren, E., Fluit, A. C., Hendriks, H. G. C. J. M., Tooten, P. C. J., &
Gaastra, W. (2007). Comparison of the in vitro pathogenicity of two Salmonella
Typhimurium phage types. Comparative Immunology, Microbiology and Infectious
Diseases. https://doi.org/10.1016/j.cimid.2006.09.003
Vordermeier, M., Gordon, S. V., & Hewinson, A. R. G. (2009). Antigen mining to define
Mycobacterium bovis Antigens for the differential diagnosis of vaccinated and infected
animals: A VLA perspective. Transboundary and Emerging Diseases.
https://doi.org/10.1111/j.1865-1682.2009.01070.x
Weber-Dabrowska, B., Jończyk-Matysiak, E., Zaczek, M., Łobocka, M., ŁusiakSzelachowska, M., & Górski, A. (2016). Bacteriophage procurement for therapeutic
purposes. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2016.01177
Whittington, R., Donat, K., Weber, M. F., Kelton, D., Nielsen, S. S., Eisenberg, S., … De
Waard, J. H. (2019). Control of paratuberculosis: Who, why and how. A review of 48
countries. BMC Veterinary Research. https://doi.org/10.1186/s12917-019-1943-4
Whittington, R. J., Begg, D. J., de Silva, K., Purdie, A. C., Dhand, N. K., & Plain, K. M.
(2017). Case definition terminology for paratuberculosis (Johne’s disease). BMC
Veterinary Research. https://doi.org/10.1186/s12917-017-1254-6
Yang, L., & Nolan, J. P. (2007). High-throughput screening and characterization of clones
selected from phage display libraries. Cytometry Part A.
https://doi.org/10.1002/cyto.a.20417

57

CHAPTER 2: A RAPID VIABILITY AND DRUG SUSCEPTIBILITY ASSAY
UTILISING MYCOBACTERIOPHAGE AS AN INDICATOR OF DRUG
SUSCEPTIBILITIES OF ANTI-TB DRUGS AGAINST MYCOBACTERIUM
SMEGMATIS MC2 155
Abstract
A rapid in-house TM4 mycobacteriophage-based assay, to identify multidrug resistance
against various anti-tuberculosis drugs, using the fast-growing Mycobacterium smegmatis
mc2 155 in a microtiter plate format was evaluated, based on phage viability assays. A variety
of parameters were optimised prior to the study including the minimum incubation time for
the drugs, phage and M.smegmatis mc2 155 to be in contact. An increase in phage numbers
over 2 hours was indicative that M.smegmatis mc2 155 is resistant to the drugs under
investigation, however when phage numbers remained static, M.smegmatis mc2 155 found to
be sensitive to the drug. The study confirmed that the data is statistically significant and that
M.smegmatis mc2 155 is in fact sensitive to Isonazid, Rifampicin, Pyranzaimide and
Ethambutol as phage numbers doubled over 2 hours (p-values of 0.015, 0.018, 0.014 and
0.020). The study also confirmed that M.smegmatis mc2 155 is resistant to the drugs
Ampicillin, Erythromycin, Amoxicillin, Streptomycin as phage numbers remain static over
the same 2 hour time period (p-values of 0.028, 0.052, 0.049, 0.04). This drug susceptibility
profiling of eight different drugs against M.smegmatis mc2 155 was detected in as little as 1.5
days with a cost of ~ €1.15 to test four drugs. This test is rapid to perform and will have
widespread applications in drug susceptibility testing of other members of the mycobacterial
genus. Additionally, the platform could also be used as a tool for HTS of novel
antimycobacterial drugs. The main assets of this assay include its relatively cheap cost,
versatility, quick turnaround time and the reproducibility of the method as indicated by
statistical data generated.
Introduction
The emergence of multi-drug resistant (MDR) bacterial species is a major concern in the
modern world. Mycobacterial species in particular have developed resistance to a large array
of antibiotics which disrupt cell wall biosynthesis. Their ability to resist such antibiotics is
caused by the structure of their cell wall, which is composed of approximately 60% lipids
making them notoriously difficult to treat. Most mycobacteria are susceptible to the
antibiotics clarithromycin and rifamycin, but several antibiotic-resistant strains have emerged
(Brown-Elliott, Nash, & Wallace, 2012).
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The delay in identifying drug susceptible isolates is due to the lack of advanced technology
and the time involved in sample preparation. Globally, most susceptible patients are not
diagnosed in time and do not receive appropriate therapy (Manson et al., 2017). They are
clearly at risk of developing even more resistant mycobacterial infections and transmitting
these resistant mycobacterial strains. With today’s knowledge, available diagnostic tools and
epidemiological advances, it cannot be considered acceptable to wait for 16 days to know if a
clinical isolate is drug susceptible or not. Thus, the traditional practices of identification
should be improved upon. From the literature, it has been noted that three established
methods in particular are used to identify drug susceptibilities in mycobacterial species
(MIC’s, BACTEC 460TB method and the mycobacteria Growth Indicator Tube (MGIT) 960
system) (Zhao et al., 2014). The BACTEC and the MGIT methods have been adopted by
many laboratories in the Western world and are based on automated detection of growth in a
liquid medium with anti-tuberculosis drugs. These methods are therefore faster than those
based on visual detection of growth on solid medium. However, one disadvantage of these
systems is the inability to check the colony morphology of the bacterial cultures. Both
invisible contamination and overgrowth with atypical mycobacteria affect the reliability of
the tests. In addition, these methods have disadvantages in that they involve multiple tubes or
bottles and are restricted to discriminating between resistance and susceptibility, rather than
determining the exact MICs of the drugs. The three methods mentioned above are however,
reproducible, accurate and relatively cheap. The materials used in performing each test are
cheap, although the sophisticated equipment required for BACTEC and MGIT is relatively
expensive.
Laboratories in most developing countries lack this sophisticated and costly equipment
required to identify MDR mycobacterial strains. The development of an assay which has the
potential to identify MDR-mycobacterial species at a low cost and rapid time would be highly
beneficial. One potential way to reduce the cost of drug susceptibility testing involves the use
of mycobacteriophages (Sivaramakrishnan.,et al, 2013), which have relatively rapid
replication rates (unlike the slow growth of their hosts), are simple to use, and are relatively
inexpensive to propagate.
Our study set out to prove the concept of this assay using a fast growing surrogate strain
(M.smegmatis mc2 155), which would determine the viability of mycobacteria following
exposure to a range of commonly used drugs. Initially, critical parameters were optimised,
after which the efficacy of the assay was evaluated using a blinded study. The principle is
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based on the fact that the phage will only infect viable cells, and the increase in their numbers
over time is consistent with the host strain demonstrating resistance to the drug under
investigation.
Materials and methods:
Preparation and standardisation of M.smegmatis mc2 155:
Mycobacterium smegmatis mc2 155 (CIT culture collection) was utilised in the study to
optimise the assay as it is a fast-growing strain and non-pathogenic (Ofer et al., 2012).
Cultures of M. smegmatis mc 2 155 (previously stored at -80 °C) were standardised using the
DEN-1 McFarland Densitometer (Grant-bio) to achieve McFarland Standards of 0.5
(approximately 1.5 x 108 cfu/ml) in log phase and suspended in Brain Heart Infusion (BHI)
broth (Sigma Aldrich). The mycobacterial cultures of M. smegmatis mc 2 155 were then
transferred to sterile screw-cap glass tubes containing glass beads (5mm) (Sigma Aldrich) (to
disrupt the cell wall) in 2 ml of Brain Heart Infusion broth. Suspensions were homogenized
with a vortex mixer for 15 to 20 s. Large clumps were allowed to settle by allowing the
suspensions to stand at room temperature for 10 min. The supernatants were transferred to
sterile tubes and adjusted to 101 CFU/ml, 102 CFU/ml, 103 CFU/ml, 104 CFU/ml and
105 CFU/ml with Brain Heart Infusion broth (Sigma Aldrich) and standardised using the
DEN-1 McFarland Densitometer (Grant-bio) to achieve McFarland Standards of 0.5 (1.5 x
108 cfu/ml).
Confirming the phenotype of M.smegmatis mc2 155 through growth profiling, purity
streaks and Ziehl Neelsen staining
A growth curve of M. smegmatis mc 2 155 and Brain Heart Infusion broth (Sigma Aldrich)
was generated to standardise and confirm the purity and identity of M. smegmatis mc 2 155
using established methods (Gonzalez-y-Merchand et al., 2012). Prior to the addition of the
drug and the mycobacteriophage TM4, M. smegmatis mc 2 155 was suspended in 5ml of
Brain Heart Infusion broth (Sigma Aldrich) and 0.05% Tween 80 (Sigma Aldrich) and
incubated at 37 °C for 12 hours. The cell suspensions following 12 hour incubation were
standardised using the DEN-1 McFarland Densitometer (Grant-bio) to achieve a McFarlands
Standard of 1x 108 cfu/ml (McFarlands standard 0.5).

Each cell suspension grown in broth was checked for purity by performing a four-streak
method on BHI agar (Sigma Aldrich) followed by incubation at 37°C for 48 hours.
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Ziehl Neelsen staining was also performed as described previously (Cappuccino and
Sherman 2014), and visualised using the Olympus CH30 light microscope (Olympus). A
2.5µl volume of M. smegmatis mc 2 155 was added to 100µl of fresh media (BHI broth)
(Sigma Aldrich) and 30µl of 0.05% Tween 80 contained in three separate wells of a sterile
microtiter plate (Sarstedt, Germany). The OD of the three wells was read at 600nm using the
Mutiskan FC (Thermo Scientific) for 40 hours at 37°C and average absorbance readings of
the three wells was calculated.
Preparation and standardisation of the mycobacteriophage TM4
To standardise phage propagation, 100µl of a TM4 mycobacteriophage stock (Titer 8 x 108
PFU/ml) (CIT culture collection) was added to 100 μL of early log phase M. smegmatis mc 2
155 cells (log phase was established following repeated standard growth curve analysis) in
5ml of BHI broth (Sigma Aldrich) and incubated at 37°C for 48 hours previously established
from other methods (Endersen et al., 2013). Subsequently after 48 hours, 2 mL of the culture
was removed and placed in a microfuge tube and centrifuged at room temperature at
2000 × g for 5 min to pellet cellular debris. This was then filter-sterilised using a 0.2 μm filter
(Sarstedt, Nümbrecht, Germany).
One hundred microlitres of the filter sterilised supernatant was added to 500 μL of early log
phase M. smegmatis mc2 155 in a microfuge tube and incubated at 37 °C for 30 min. The
suspension was then added to 5 mL of a BHI broth 0.75% overlay agar tube tempered at
50 °C and poured onto the surface of a BHI agar plate. Plates were incubated at 37 °C for
48 h and then examined for plaques.

Phage stocks were generated with the addition of 5ml of phage buffer (50mM TRIS pH 8,
150mM NaCl, 10mM MgCl2, 2mM CaCl2) to the plate described in method 3.2.1. Sterile
hockey sticks were also aseptically run across the surface of the agar plate to physically
recover the phages. The plate was then incubated for 2 h at 37 °C with shaking. The buffer
was subsequently recovered from the plate, centrifuged to pellet debris and filter-sterilised
using a 0.2 μm filter and stored at 4°C until further use.
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Determination of the Minimum Inhibitory Concentrations (MIC’s) of Isonazid,
Rifampicin, Ampicillin, Pyranzamide, Erythromycin, Ethambutol, Amoxicillin and
Streptomycin

The Minimum Inhibitory Concentrations (MIC’s) of each drug under investigation was
performed to establish whether the drug had an antimycobacterial effect and to determine the
drug concentration (if any) required to adequately kill M.smegmatis mc2 155. The MIC’s of
each drug (Isonazid, Pyranzamide, Ethambutol and Rifampicin) (Sigma Aldrich) were
determined as follows. An overnight culture of M. smegmatis mc 2 155 incubated at 37°C
was prepared and standardised using the DEN-1 McFarland Densitometer (Grant-bio) to
reach a McFarland Standard of 0.5. A stock solution of the four drugs was prepared. Some
drugs such as Rifampicin were resuspended in methanol (16mg/ml), Pyranzamide was
resuspended in ethanol (5.7mg/ml) and Ethambutol and Isonazid were resuspended in sterile
distilled water (50mg/ml). Each stock solution was stored at −20°C until needed.
Two fold dilutions of each drug under investigation were prepared using the stock solutions
as outlined above to achieve final assay concentrations of 16µg/ml, 8 µg/ml, 4 µg/ml, 2
µg/ml, 1 µg/ml, 0.5 µg/ml, 0.25 µg/ml and 0 µg/ml. These dilutions were added to an
appropriate volume of log phase M. smegmatis mc 2 155 cells which was previously
established in section 2.2 (contained in BHI broth (Sigma Aldrich), resulting in a cell density
of 5 x 105 cfu/ml. The tubes were incubated at 37°C for 24 hours. The concentration of
antimicrobial in the first clear tube (no growth) after 24 hours was indicative of the Minimum
Inhibitory Concentration (MIC) for each drug (Andrews, 2002).

Determination of the minimum exposure time for M.smegmatis mc2 155 and the drugs
under investigation to be in contact
In order to prove the efficacy of the four drugs that have an effect on M.smegmatis mc2 155
(proven by the MIC values) and the other four drugs that do not have an effect on
M.smegmatis mc2 155, an optimisation assay was conducted to determine the minimum
exposure time for the drug and M.smegmatis mc2 155 to be in contact.
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For Isonazid (0.25µg/ml), 100µl of M. smegmatis mc 2 155 suspension (Neat, 101, 102 , 103,
104 , and 105 CFU/ml) was placed in six allocated wells of 5 sterile microtiter plates
(Sarstedt, Germany) (one for each different temperature was used). The first microtiter plate
was tested directly after the addition of the drug and bacteria (i.e. 0 hours) (2nd plate: 2 hours,
3rd plate: 4 hours, 4th plate: 6 hours and 5th plate: 8 hours).

Each sterile microtiter plate was removed from the 37°C incubator following its allocated
time period. Brain Heart Infusion (Sigma Aldrich) agar plates were seeded with a 0.5
McFarland standard of M.smegmatis mc2 155. A 3µl volume of the drug from the appropriate
microtitre plate was added to the appropriate seeded agar plates. Plates were incubated at 37
°C for 24 hours and plates were subsequently examined for the presence of zones of
inhibition (mm) after each time period according to the CLSI guidelines.
Determination of the minimum exposure time for M.smegmatis mc2 155,
Ampicillin/Rifampicin and TM4 mycobacteriophage to be in contact
The first part of this procedure was conducted using the optimised conditions as outlined in
Section 2.5, utilising an incubation period of 2 hours for M.smegmatis mc2 155 and
Ampicillin and Rifampicin in the microtiter plates.
Following the 2 hour incubation period, 48µl of mycobacteriophage TM4 (Neat, 101, 102,
103, 104, and 105 PFU/ml) was added to the six allocated wells of the sterile microtiter plates
containing Ampicillin (2µg/ml) (Sarstedt, Germany) for a specified time period of 0, 30, 60,
90 and 120 minutes and incubated at 37°C to establish the necessary time period for the drug,
the phage and the bacteria to be in contact. The ten sterile microtiter plates (10 plates for
Rifampicin in duplicate) (plate 1 and 6 were incubated for 0 minutes, plate 2 and 7 were
incubated for 30 minutes, plate 3 and 8 were incubated for 60 minutes, plate 4 and 9 were
incubated for 90 and plate 5 and 10 were incubated for 120 minutes) were removed from the
37°C incubator following their allocated incubation periods and standard plaque assays were
performed to determine the effect on plaque numbers.
For Ampicillin and Rifampicin, phage numbers were determined from the wells by adding
100 μL of the bacterial/drug/phage suspension from separate wells to 100 μL of early log
phase M. smegmatis mc 2 155 cells in a 5 mL Brain Heart Infusion 0.75% w/v overlay agar
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tube which was tempered to 50 °C. The overlay was then poured onto the surface of a Brain
Heart Infusion agar plate (Sigma Aldrich). Plates were incubated at 37 °C overnight and then
examined for phage plaques. The same procedure was performed for Rifampicin.

Application of the optimised mycobacteriophage based microtiter plate assay to identify
drug susceptibilities of six additional drugs
Following the optimisation assays, the efficacy of 6 commonly used drugs was evaluated
(Streptomycin, Erythromycin, Ethambutol, Pyranzaimide, Amoxicillin and Isonazid). The
same procedure was performed as outlined in Section 2.5 and Section 2.6, however the
optimised time periods previously established for the drug, the mycobacteriophage TM4 and
M.smegmatis mc2 155 were utilised (i.e. 2 hours) throughout.

Evaluation of the efficacy of the mycobacteriophage based drug susceptibility assay by
undertaking a blinded study

Following the assay, a blinded study was conducted to ensure that the results obtained were
not affected by bias. For the blinded study the same 8 drugs, Isonazid, Rifampicin,
Ampicillin, Pyranzamide, Erythromycin, Ethambutol, Amoxicillin and Streptomycin (Sigma
Aldrich) were retested. The drugs were randomly coded. The primary objective was to
identify drug susceptibilities of M.smegmatis255 to eight randomised unknown drugs based on
the formation of plaques.
Data analysis
Statistical analysis was performed with IBM SPSS Software v. 24, (Armonk, NY, USA). To
determine if the data was statistically significant, the normality of the data was firstly
assessed with the Shapiro-Wilks test at a significance level of 0.05. A p-value of P < 0.05 was
interpreted as indicating significant correlation at a confidence interval of 95%. Nonparametric tests were chosen for data not normally distributed
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Results:
Phenotype of M.smegmatis mc2 155 by using growth profiling, purity streaks and ziehl
neelsen staining
Following Ziehl Neelson staining, the culture appeared as pink bacilli in clusters under the
100x objective lens as expected as outlined in Figure 3(A). The cultures of the
Mycobacterium smegmatis mc2 155 culture on BHI agar (Sigma Aldrich), appeared as
filamentous, irregulated, undulated margin, flat in shape and cream- white in colour
indicating that pure colonies were obtained when a purity streak was performed as described
previously (Beran et al., 2012) and as outlined in Figure 3(B). The presence of red bacilli
following Ziehl Neelsen staining and the colony morphology described above confirms the
identity of Mycobacterium smegmatis mc2 155. The growth rate of Mycobacterium smegmatis
mc2 155 was measured spectrophotometrically at an OD of 600nm as demonstrated in Figure
3(C). Tween 80 (0.05%) prevented clumping of M. smegmatis mc2 155 throughout its growth
and led to an efficient growth curve. The doubling rate of M. smegmatis mc2 155 is typically
1 to 2 hours, therefore readings were taken every hour to observe this effect. Following 12
hours of incubation M. smegmatis mc2 155 entered its log phage for approximately 12 hours
until it reached stationary phase at 24 hours.
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(B)
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Figure 2 - Growth curve of Mycobacterium smegmatis mc2
155 at an OD @ 600nm in triplicate
0.5

OD600nm

0.4
0.3
0.2

OD @ 600nm

0.1
0
0 2 4 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40
-0.1

(C)
Time (Hours)

Figure 3: (A) Ziehl Neelsen staining of M.smegmatis mc2 155 as described previously (Cappucino
and Sherman, 2014) (B) Purity streak of M.smegmatis mc2 155 on BHI agar (Sigma Aldrich) after
incubation for 48 hours at 37°C (C) Growth curve of Mycobacterium smegmatis mc2 155 at OD600nm
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Determination of the Minimum Inhibitory Concentrations (MIC’s) and Minimum
Contact time (Zones of inhibition (cm) for M.smegmatis mc2 155 and the four drugs
under investigation to be in contact

Drug

MIC
(ug/ml)

Zones of
inhibition (cm)
after 2 hours

Zones of
inhibition (cm)
after 4 hours

Zones of
inhibition (cm)
after 6 hours

Zones of
inhibition (cm)
after 8 hours

Isoniazid
Rifampicin
Pyranzaimide
Ethambutol

0.25
2
0.5
5

1.3
2.6
1.6
2.9

1.1
2.4
1
2.7

1
1.9
0.9
2.3

0.7
1.9
0.9
2.2

Table 4: Minimum Inhibitory Concentrations (MIC’s) and Zones of inhibition (cm) of
four drugs used to determine the minimum contact time for Mycobacterium smegmatis
mc2 155 and the drug under investigation to be in contact

The MIC of each drug under investigation was determined using M. smegmatis mc 2 155 in
order to record the concentration required to kill viable M.smegmatis mc2 155 cells and to
establish an effective drug concentration for the assay. The four drugs in Table 4 exhibited
growth-inhibitory effects against Mycobacterium smegmatis mc2 155, although some drugs
had a better inhibitory effect than others. The MIC’s of each drug varied as outlined in Table
4. The highest MIC obtained was for Ethambutol at 5 ug/ml whereas the lowest MIC value
obtained was for Isonazid at 0.25µg/ml. The highest MIC values (zones of inhibition cm) for
each drug were obtained after 2 hours. From 4 hours to 8 hours the zones of inhibition began
to decrease.

Optimisation assays were conducted to determine the minimum contact period for M.
smegmatis mc 2 155, and the drug under investigation. All eight drugs were analysed for this
optimisation assay.
The optimisation assay was undertaken to determine the minimum contact time period for M.
smegmatis mc 2 155, and the drug of choice (in this case the eight drugs were utilised). The
determination of the minimum contact time was based on MIC values as outlined in Table 4.
Comparison of contact periods was determined over an 8 hour time frame.
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Table 4 provides an accurate determination of the contact time required. It is evident that a
contact time of 2 hours is sufficient in order to achieve an efficient response.
Determination of the minimum exposure time of M.smegmatis mc2 155,
Ampicillin/Rifampicin and TM4 mycobacteriophage to be in contact

Optimisation assays were conducted to determine the optimum contact period for M.
smegmatis mc 2 155, the drug and the mycobacteriophage TM4. Ampicillin (2µg/ml) (Sigma
Aldrich) and Rifampicin (4µg/ml) (Sigma Aldrich) were used for the purpose of the
optimisation assays.

The optimisation assay was undertaken at time intervals of 30 minutes in duplicate and was
based on the changes in plaque numbers (pfu/ml) as outlined in Figure 4. An increase in
phage numbers was seen to be indicative of drug resistance as TM4 can lyse viable
mycobacterial cells which have not been inactivated by the drug.

For Ampicillin (2µg/ml) (Sigma Aldrich), at time 0, the average plaque numbers obtained
were 46 pfu/ml and after 120 minutes the average plaque numbers obtained were 152 pfu/ml.
For Rifampicin (4µg/ml) (Sigma Aldrich) the plaque numbers (pfu/ml) obtained at at 0
minutes were 76 pfu/ml and following 120 minutes the plaque numbers obtained were 76
pfu/ml.
M.smegmatis mc2155 is resistant to Ampicillin as outlined in Figure 4 given the large
increase in plaque numbers (pfu/ml) from time 0 minutes to time 120 minutes. Phage
numbers (pfu/ml) that remain static from time 0 to time 120 minutes suggest that
M.smegmatis mc2155 is sensitive to the drug as the drug has inactivated viable cells.
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Figure 4 - Optimum time required for drugs under investigation to
be in contact with M.smegmatis mc2 155 based on PFU/ml for
mycobacteriophage TM4
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Figure 4- Optimum time (minutes) required for Ampicillin and Rifampicin under
investigation to be in contact with M.smegmatis mc2 155 based on the change/no change
in PFU/ml for the mycobacteriophage TM4

A graphical representation of the optimum time period for the mycobacteriophage TM4,
M.smegmatis mc2 155 and the drug to be in contact was constructed. As outlined in Figure 4
the average pfu/ml either increased with respect to time (minutes) or remained static
throughout the indicated time periods for ampicillin and rifampicin according to their efficacy
against the host. A time period of 2 hours was chosen based on Figure 4.

Application of the optimised mycobacteriophage based microtiter plate assay to identify
drug susceptibilities of six drugs

In order to ensure consistency of results and to test the efficacy of the optimised assay,
various other drugs were used to indicate drug susceptibilities. Each assay was performed in
triplicate.

The drugs Ampicillin (4µg/ml) (Sigma Aldrich) and Rifampicin (2µg/ml) (Sigma Aldrich)
were tested for drug susceptibilities as outlined in Figure 5. To allow for comparison in
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identifying drug susceptibilities two time points (t = 0 and t = 2 hours) were utilised based on
the experiment above. As already discussed, an increase in phage numbers is indicative of
drug resistance. From Figure 5 it can be said that M.smegmatis mc2155 is resistant to
Ampicillin (p-value of 0.028) as a result of the large increase in plaque numbers (pfu/ml)
from time 0 minutes to time 120 minutes. M.smegmatis mc2155 appears to be sensitive to
Rifampicin (Sigma Aldrich) (p-value of 0.018) as phage numbers (pfu/ml) remain static from
time 0 to time 4 hours.
The drugs Streptomycin (2.5µg/ml) (Sigma Aldrich) and Isonazid (0.25µg/ml) (Sigma
Aldrich) were also tested against M.smegmatis mc2 155 as outlined in Figure 5. Likewise two
time points (t = 0 hours and t = 4 hours) were utilised to contrast the difference in plaque
numbers between the two points. As already discussed, an increase in phage numbers is
indicative of drug resistance. From Figure 5, it can be said that M.smegmatis mc2155 is
resistant to Streptomycin (p-value 0.049) as a result of the large increase in plaque numbers
(pfu/ml) from time 0 minutes to time 120 minutes. M.smegmatis mc2155 appears to be
sensitive to Isonazid (p-value 0.015) as phage numbers (pfu/ml) remain static from time 0 to
time 120 minutes.
Pyranzamide (0.5µg/ml) (Sigma Aldrich), Erythromycin (0.15µg/ml) (Sigma Aldrich),
Ethambutol (5µg/ml) (Sigma Aldrich) and Amoxicillin (4µg/ml) (Sigma Aldrich) were also
used in this assay to demonstrate drug susceptibilities based on differences in plaque numbers
(pfu/ml) as outlined in Figure 6. M.smegmatis mc2 155 appears to be resistant to
Erythromycin (Sigma Aldrich) (p-value of 0.048) and Amoxicillin (Sigma Aldrich) (p-value
of 0.049) as plaque numbers (pfu/ml) obtained in Figure 6 increase from time 0 to time 4
hours indicating that M.smegmatis mc2 155 is resistant to the three drugs. M.smegmatis mc2
155 is sensitive to the drugs Pyranzamide (Sigma Aldrich) (p-value of 0.014) and Ethambutol
(Sigma Aldrich) (p-value of 0.02) as indicated in Figure 6. The plaque numbers (pfu/ml) from
time 0 to time 4 hours remain relatively static indicating that the cells are still viable.
The data obtained in relation to the drug susceptibilities appears to be statistically significant
as p-values of less than 0.05 at a confidence interval of 95% were obtained as outlined above.
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Figure 5: Drug susceptibility profiles of Ampicillin and Rifampicin
using the change in average pfu/ml of mycobacteriophage TM4
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Figure 5: Drug susceptibility profiles of four drugs (streptomycin, isoniazid, rifampicin
and ampicillin) based on changes in average pfu/ml of the mycobacteriophage TM4
versus time (hours T0-T2)

Two-time points (T0 and T4 hours) were utilised to assess the drug susceptibility of four
drugs (in this case streptomycin, isonazid, rifampicin and ampicillin) as before. The average
pfu/ml versus time (hours) was measured in this assay. An increase in phage numbers from
time point 0 to time point 4 hours indicates that M.smegmatis mc2 155 is resistant to the drug.
If the phage numbers (pfu/ml) remain static then M.smegmatis mc2 155 is sensitive to the
drug under investigation.
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Figure 6: Drug susceptibility profiles of four drugs using the change
in average pfu/ml of mycobacteriophage TM4
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Figure 6: Drug susceptibility profiles of four drugs (erythromycin, amoxicillin,
pyranzaimide and ethambutol) using changes in average pfu/ml of the
mycobacteriophage TM4 versus time (hours T0-T2), utilising optimised conditions
established previously

Evaluation of the efficacy of the mycobacteriophage based drug susceptibility assay by
undertaking a blinded study
To rule out the chance of bias, a blinded study was conducted. At the end of the blinded study
the identity of each drug was confirmed. The bars indicate drugs to which M. smegmatis mc 2
155 is sensitive as phage numbers remain static from time 0 to time 4 hours. The bars which
increase significantly from time 0 hours to time 4 hours are drugs to which M. smegmatis mc
2

155 are resistant to. The identity of the A was confirmed as Isonazid (p-value of 0.016), B

was confirmed as Rifampicin (p-value of 0.012), C was confirmed as Pyranzaimide (p-value
of 0.019) and D was confirmed as Ethambutol (p-value of 0.011). M. smegmatis mc 2 155 is
in fact sensitive to these four drugs as outlined in the literature [10] [11] thereby validating this
method. The identity of E was confirmed as Ampicillin (p-value of 0.049), F was confirmed
as Erythromycin (p-value of 0.041), G was confirmed as Amoxicillin (p-value of 0.044) and
H was confirmed as Streptomycin (p-value of 0.047). Various studies have outlined that M.
smegmatis mc 2 155 is resistant to these four drugs [12] [13].
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Universally the data obtained in relation to the drug susceptibilities is statistically significant
as p-values of less than 0.05 at a confidence interval of 95% were obtained as outlined above.

Figure 7: Blinded study to determine the resistance profiles of eight
drugs using mycobacteriophage TM4 to determine the change in
PFU/ml
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A: Isonazid, B: Rifampicin, C: Pyranzaimide, D: Ethambutol, E: Ampicillin, F:
Erythromycin, G: Amoxicillin and H: Streptomycin
Figure 7: Blinded study to determine the resistance profiles of eight drugs utilised above
using the mycobacteriophage TM4 based on the changes in average PFU/ml versus time
(hours T0-T4), utilising the optimised conditions established previously
Discussion:
Over the past years, the use and misuse of antimicrobials has increased the numbers and types
of resistant organisms including mycobacterial species. As a large majority of mycobacterial
species have relatively slow growth rates, it would be of importance to detect these resistant
strains within an adequate period of time to provide appropriate treatment options. Advanced
drug susceptibility assays have been developed within recent years such as the BACTEC
TB480 method and the MGIT method particularly in hospital settings, however these assays
can take days or weeks to generate results (Grigoriu et al., 2014) (Bustin and Huggett, 2017).
Based on this knowledge it would be of interest to be able to construct an assay which has the
ability to identify drug susceptibilities within a shorter period, in order to expedite clinical
treatment. The major applications of such a rapid viability assay would include (1)
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determining drug sensitivities of clinical mycobacterial isolates and (2) identifying novel
antimycobacterial drugs using High-Throughput Screening (HTS).
The assay was a preliminary study in order to provide proof of concept that
mycobacteriophages can be used to detect drug resistance or sensitivity using a fast growing
mycobacterial strain, before the assay can be translated to more complex mycobacterial
species. For this purpose, M.smegmatis mc2 155 was employed in this study as it is a very
useful surrogate for the research of other species in the genus mycobacteria (slow growers) in
laboratories, due to its rapid replication (reaches stationary phase within 48 hours) and its
non-pathogenic nature (i.e. model organism). The rationale for utilising mycobacteriophages
in this study is that they are widely applicable, cheap to propagate and have a rapid
replication rate.
In order to assess drug susceptibilities of M.smegmatis mc2 155, eight drugs typically used to
treat mycobacterial infections were chosen, four drugs in which M.smegmatis mc2 155 has
been shown to be resistant and four drugs in which M.smegmatis mc2 155 has exhibited
sensitivity. Prior to conducting the assay, optimisation steps had to be performed. The length
of time the drug, bacteria and mycobacteriophage were in contact was an important
optimisation step, as the less time required for contact implied that the drug susceptibility
results could be obtained rapidly, which was a main focus of the study.
Following completion of the optimisation steps and the assay, a blinded study was conducted,
to authenticate that the results generated were not affected by bias. The blinded study was
another crucial part of the assay in order to provide proof of concept that the assay has the
ability to work efficiently. The blinded study had the ability to validate that the utilisation of
mycobacteriophage has the potential to identify drug susceptible isolates within a shorter
period of time compared to the BACTEC and MGIT methods. In comparison to the cost of
the BACTEC 460TB method (1.3 US dollars) and MGIT method (1.2 US dollars), drug
susceptibilities can be detected within 1.5 days (albeit for a rapid mycobacterial host) with an
average cost of approximately €1.15 (Traore et al., 2007) (Laverdiere et al., 2000).
Although initially promising, there is uncertainty in relation to the applicability of this assay
to other mycobacterial species. Incubation periods for slowing growing mycobacterial species
are approximately 4 to 16 weeks, in comparison to a fast growing mycobacterial host (in this
case M.smegmatis mc2 155) which requires an incubation period of 24 to 48 hours. Future
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work will focus on developing this assay to generate rapid results with slow growing
pathogenic mycobacterial strains.
As the assay has demonstrated the ability of one mycobacteriophage strain to identify drug
susceptible/resistant isolates against M.smegmatis mc2 155 it may be possible to utilise this
assay as a HTS tool for novel anti-mycobacterial drugs based plaque numbers. The assay
would also increase the speed in which novel drugs or compounds are detected. As antibiotic
resistance is becoming a major global threat the development of novel drug compounds is of
major importance.
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CHAPTER 3: APPLICATION OF A MYCOBACTERIOPHAGE BASED ASSAY TO
ASSESS DRUG SUSCEPTIBILITIES AND VIABILITIES OF MAP FIELD
ISOLATES FROM IRISH FARMS
Abstract:
A significant problem hindering antimicrobial profiling studies of Mycobacterium avium
paratuberculosis is the long generation time of the organism. In this study, we describe the
development of a rapid mycobacteriophage based assay to detect drug resistance profiles of
six Irish MAP field isolates against fourteen drugs. If the drug is not effective against MAP,
the cells would remain viable and mycobacteriophage would infect causing an increase in
plaque forming units (pfu) over a four hour time period. Alternatively, if the drug is effective,
then MAP wouldn’t be viable, leaving no cells to infect and the pfu count will remain static
over time. The assay was successfully optimised and performed with 100% correlation
demonstrated between previously determined MIC assays. All six MAP strains tested were
resistant to four commonly used drugs (Ampicillin, Streptomycin, Erythromycin and
Amakacin). The study also confirmed that the same six MAP strains were sensitive to
Rifampicin, Isoniazid and Clindamycin as indicated by no change in plaque numbers. Varied
drug susceptibility profiles were obtained for the six MAP strains against the remaining seven
drugs. Resistance levels for 3 MAP strains against Vancomycin, Ciproflaxin, Clofazimine
and Cefdinir were moderate, and for the remaining MAP strains drug sensitivity was high
against Trimethoprim, Tetracycline and Doxycycline. The assay was further enhanced by the
incorporation of a 6 phage cocktail with no adverse effects to pfu/ml counts. Potential
applications of this assay include high throughput screening for novel anti-mycobacterial
drugs and identification of drug resistant isolates during epidemiological studies.
Introduction:
Mycobacterium avium subspecies paratuberculosis (MAP) is the etiological agent of
granulomatous enteritis in ruminants, known as paratuberculosis (Johne’s disease). This
infection is characterized by chronic granulomatous enteritis, persistent diarrhea, progressive
wasting, and finally death (Lombard, 2011). Treatment of Johne’s disease is complicated as
the infection develops as asymptomatically until the latter stages of the disease in which
treatment is no longer effective. Therefore, MAP infection results in significant economic
losses to the dairy and cattle industries (Roussel, 2011). Since MAP can be shed into milk,
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soil and water environments from infected cows, contamination of the environment by MAP
is a major problem in the spread of the disease.
Currently, treatment of paratuberculosis in cattle is limited to the extra label use of
therapeutic agents. Even with a prolonged drug regimen, paratuberculosis in cattle is
invariably fatal. Better diagnostic and therapeutic options are badly needed.
A significant problem hindering antimicrobial profiling studies of this organism is the long
generation time of M. paratuberculosis and the tendency of certain antibiotics to degrade
during the evaluation period. MAP has also been shown to be resistant to a large array of
highly used agricultural antimicrobial agents in recent years, mainly due to its thick, waxy
cell wall and the acquisition of antibiotic resistance genes (Beran et al., 2006).
Current drug susceptibility testing for MAP such as the BACTEC, MGIT and MIC based
methods can take 12 to 15 weeks to generate data (Krishnan, Manning, & Collins, 2009a),
thereby it is quite evident that faster methods are required.
The main objective of the assay described here was to develop a rapid approach to
antimicrobial drug testing for MAP utilising mycobacteriophages as indirect measures of
drug susceptibilities based on monitoring the change of plaque forming units (pfu/ml) over
time. The premise of this assay has already been proven using fast growing mycobacteria
(Crowley et al, 2019) and the purpose of this study is to evaluate its efficacy with clinically
relevant mycobacterial strains. A secondary objective was to determine the AB profiles of 6
field isolates of MAP.
Similarly to the FASTPlaqueTBTM assay for TB (Albay et al., 2003) which also utilises
bacteriophage, the strategy involved is as follows: if the drug was not effective at killing
MAP, the cells would remain viable and subsequent addition of mycobacteriophage would
infect these cells cause an increase in plaque forming units over time. If the drug was
effective against MAP, then the MAP cells would no longer be viable, and the added phage
would remain static.

The future applications of this assay could include High Throughput screening to identify
novel drugs for the treatment of Johne’s disease and the identification of drug resistance
profiles in epidemiological studies.
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Materials and methods:
Preparation and standardisation of MAP strains:
Six Irish Mycobacterium avium paratuberculosis (MAP) field isolates were utilised during
evaluation. Drug susceptibilities of these six strains was not determined prior to the study.
The mycobacterial strains utilised are listed in Table 5 and were obtained from the School of
Veterinary Medicine, Veterinary Sciences Centre, University College Dublin. M.
avium subsp. paratuberculosis was cultured in Middlebrook 7H9 broth (Sigma Aldrich)
supplemented with Mycobactin J (2 mg/L, Serosep Limited) and with 10% (vol/vol) oleic
acid-albumin-dextrose-catalase (OADC) (Sigma Aldrich) for up to 16 weeks. Following 16
weeks, cultures of MAP were standardised using the DEN-1 McFarland Densitometer (Grantbio) to achieve McFarlands Standards of 0.5 (approximately 1.5 x 108 cfu/ml).

Table 5: Mycobacterial strains utilised in the study
Bacterial strain

Strain ID

Source

Mycobacterium avium

TB14-6416

University College Dublin

TB14-6278

University College Dublin

TB14-9294

University College Dublin

TB14-7535

University College Dublin

TB14-9252

University College Dublin

TB14-6196

University College Dublin

paratuberculosis (MAP)
Mycobacterium avium
paratuberculosis (MAP)
Mycobacterium avium
paratuberculosis (MAP)
Mycobacterium avium
paratuberculosis (MAP)
Mycobacterium avium
paratuberculosis (MAP)
Mycobacterium avium
paratuberculosis (MAP)

Confirming the phenotype of MAP strains through molecular analysis
Molecular analysis was also carried out. DNA extraction was performed with the GenElute™
Bacterial Genomic DNA Kit Protocol Part B (Sigma Aldrich) as per manufacturer's protocol.
The cells were initially sheared using the MagNA lyser system (Roche Diagnostics,
Germany) at 6500 rpm for 2 min which was carried out three times per MAP strain. The
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DNA quantity and purity was analysed on a Nanodrop 1000 spectrophotometer (NanoDrop
Technologies).

IS900 specific primers (as per Miller et al. [25]) were used and the PCR reaction undertaken
as outlined previously. A 1KB DNA marker was utilised as a molecular weight marker. Gels
were visualized using the MiniBis Pro Bioimaging System (DNR Bioimaging Systems,
Biosciences). Secondary PCR based confirmation was performed using primers specific for
the mbtA-MAP2179 gene based on a previous study (de Kruijf, Coffey, & O’Mahony, 2017).

Following confirmation of their phenotype, the MIC of fourteen drugs was evaluated as
follows:
Determination of the Minimum Inhibitory Concentrations (MIC’s) of Ampicillin,
Rifampicin, Streptomycin, Erythromycin, Isonazid, Vancomycin, Ciproflaxin,
Amakacin, Clofazamine, Azithromycin, Clindamycin, Doxycycline, Trimethroprim and
Cefdinir
A series of assays was carried out to determine antibiotic resistance profiles of the strains
under investigation. The Minimum Inhibitory Concentrations (MIC’s) of fourteen drugs
which are commonly used in agricultural environments to treat animal diseases was
evaluated. All MAP strains were propagated for up to 12-16 weeks in 20mls of Middlebrook
7H9 broth (Sigma Aldrich) and supplemented with Mycobactin J (2 mg/L, Serosep Limited),
with 10% (vol/vol) oleic acid-albumin-dextrose-catalase (OADC) (Sigma Aldrich) and 0.05%
Tween 80 (Sigma Aldrich) and the tubes were incubated at 37°C in sterile 50ml conical tubes
(Sarstedt, Germany). 10ml volumes from each individual conical tube containing six
individual MAP strains was aliquoted into six sterile test tubes and the McFarland standard
number of each tube was read using the DEN-1 McFarland Densitometer (Grant-bio). This
serial dilution was adjusted to 5 x 105 CFU/ml in the microtiter plate as outlined below.
Stock solutions of the fourteen drugs under investigation were prepared and diluted in the
appropriate solvent in 1.5ml sterile eppendorf tubes (Sigma Aldrich) as outlined in a previous
study (Andrews, 2002). Some drugs were stored at −20°C for up to one month (Rifampicin,
Isonazid, Vancomycin, Ciproflaxin, Amikacin, Clofazamine, Trimethoprim and Cefdinir) and
the remaining stock solutions (Ampicillin, Streptomycin, Erythromycin, Azithromycin,
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Clindamycin and Doxycycline) were prepared on the day of the assay due to their instability
in storage.

Two fold dilutions of each drug under investigation were prepared in sterile 96 well
microtiter plates (18 microtiter plates in total, one for each of the six MAP strains and the
fourteen drugs in duplicate) (Sarstedt, Germany) using the stock solutions to achieve final
assay concentrations of 124 µg/ml, 64 µg/ml, 32 µg/ml, 16 µg/ml, 8 µg/ml, 4 µg/ml, 2 µg/ml
and 1 µg/ml, 0.5 µg/ml, 0.25µg/ml and 0µg/ml (negative control). These dilutions were added
to 5 x 105 CFU/ml contained in Middlebrook 7H9 broth (Sigma Aldrich) with 10% (vol/vol)
oleic acid-albumin-dextrose-catalase (OADC) (Sigma Aldrich) enrichment and Mycobactin J
(2 mg/L, Serosep Limited). The 18 microtiter plates (each containing one MAP strain) were
incubated at 37°C for 6 to 12 weeks. The lowest concentration at which each MAP strain was
completely inhibited (as evidenced by the absence of visible bacterial growth) was recorded
as the minimal inhibitory concentration or MIC for each MAP strain as outlined in Table 2.
Tubes that appeared turbid suggested bacterial resistance while tubes that remain clear
demonstrated bacterial sensitivity.
The MIC assay is one of the gold standard methods for identifying drug sensitive or resistant
isolates, however for slow growing MAP strains, results can take between 6 to 12 weeks.
There is a requirement for reducing the time involved in drug susceptibility testing for
Mycobacterium avium paratuberculosis (MAP) which may be solved by the development of
more rapid assays such as those outlined above and in Figure 8.
Preparation and standardisation of the mycobacteriophage TM4
Generation of a high titre preparation and stocks of the mycobacteriophage TM4:
To standardise phage propagation, 100µl of seven individual mycobacteriophage stocks
(TM4, LE1, LE2, LE3, LE4, LE5, and LE6) (Titer 109 PFU/ml) (CIT culture collection) were
added individually to 100 μL of early log phase M.smegmatis mc2 155 cells (log phase was
established following repeated standard growth curve analysis) in 5ml of Middlebrook 7H9
broth (Sigma Aldrich) and incubated at 37°C for 48 hours previously established from other
methods (Endersen et al., 2013). Following 48 hours, 2 mL of each broth containing separate
mycobacteriophages (LE1 to LE6 and TM4) and M.smegmatis mc2 155 were removed and
placed in separate microfuge tubes (1 tube for each individual mycobacteriphage) and each
tube was centrifuged at room temperature at 2000 × g for 5 min to pellet cellular debris.
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These individual mycobacteriophages were then filter-sterilised using a 0.2 μm filter
(Sarstedt, Nümbrecht, Germany). One hundred microlitres of each individual filter sterilised
supernatant was added to 500 μL of early log phase M.smegmatis mc2 155 in seperate
microfuge tube and incubated at 37 °C for 30 min. The individual mycobacteriophage
suspensions were then added to 5 mL of a Middlebrook broth 7H10 0.75% overlay agar tube
tempered at 50 °C and poured onto the surface of a Middlebrook 7H10 agar plate. Plates were
incubated at 37 °C for 48 h and then examined for plaques.

Phage stocks were generated with the addition of 5ml of phage buffer (50mM TRIS pH 8,
150mM NaCl, 10mM MgCl2, 2mM CaCl2) to the individual plates. Sterile hockey sticks were
also aseptically run across the surface of the agar plates to physically recover the phages. The
individual plates were then incubated for 2 h at 37 °C with shaking. The buffer was
subsequently recovered from each of the plates, centrifuged to pellet debris and filtersterilised seperately using a 0.2 μm filter. Each individual mycobacteriophage stock was
stored at 4°C until further use.

Preparation of a high titre phage cocktail
Mycobacteriophage cocktails were prepared by combining 1 mL of each individual purified
phage solution (LE1 to LE6) at high titres at or in excess of 109 pfu mL−1 into a sterile 10ml
conical tube (Sarstedt, Germany), to give a final volume of 6 mL. After a brief vortex, 1ml
volumes were removed aseptically and aliquoted into separate sterile 1.5 ml eppendorf tubes
(Sigma Aldrich). Each individual phage (LE1 to LE6) was aliquoted from high titre broth
preparations and stored at 4 °C for the study until required.

Determination of the minimum exposure time for MAP, Ampicillin/Rifampicin and
TM4 mycobacteriophage to be in contact

Initially, it was important to determine the minimum time for MAP, the drug under
investigation and mycobacteriophage TM4 to be in contact. Two hour time intervals were
chosen initially as mycobacteriophages replicate rapidly. Ampicillin was employed to
determine this stage of the study. 100µl of MAP strain TB14-6416 was added to fifteen
allocated wells (in triplicate – 15 wells in total) of a sterile 96 well microtiter plate (Sarstedt,
Germany) containing 2µg/ml of Ampicillin and incubated at 37°C for a two hour time period
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(Step 1. and Step 2. in Figure 8). This two hour incubation period remained fixed throughout
the duration of the assay. Subsequently, 100µl of mycobacteriophage TM4 was aliquoted into
the fifteen wells of the sterile 96 well microtiter plate (Step 3 from Figure 8). 100µl of the
mycobacteriophage/drug/bacterial suspension was removed from the microtiter plate (T0,
Step 3 in Figure 8) and added to 100 μL of early log phase M. smegmatis mc 2 155 cells (as a
surrogate strain) in a 5 mL Middlebrook 7H10 0.4% w/v overlay agar tube which was
tempered to 50 °C. The purpose of this step was to determine initial phage numbers at T0.
The overlay was then poured onto the surface of a Middlebrook 1.5% w/v 7H10 agar plate
supplemented with OADC (Sigma Aldrich) and incubated at 37°C.

The microtiter plate was then incubated at 37°C for two hour time periods (2, 4, 6 and 8
hours) to generate a substantial increase in phage numbers beyond T0. Following each two
hour phage incubation period (Step 4. in Figure 8), phage numbers were determined by
adding 100 μL of the bacterial/drug/phage suspension from separate wells to 100 μL of
early log phase M. smegmatis mc 2 155 cells (as a surrogate strain) in a 5 mL Middlebrook
7H10 0.4% w/v overlay agar tube which was tempered to 50 °C (Step 4. from Figure 8). The
overlay was then poured onto the surface of a Middlebrook 1.5% w/v 7H10 agar plate
supplemented with OADC (Sigma Aldrich). Plates were incubated at 37 °C overnight and
then examined for plaque numbers (Step 5. and Step 6. in Figure 8)

The exact procedure was then repeated for a drug that mycobacteria are traditionally sensitive
to (in this case Rifampicin at a concentration of 4µg/ml).
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Figure 8: The procedure involved in the development of a mycobacteriophage based drug
susceptibility assay by incubating six MAP strains, a drug under investigation and the
mycobacteriophage TM4 to identify drug susceptibilities through plaque assays

Application of the mycobacteriophage based microtiter plate assay to identify drug
susceptibilities of fourteen drugs
Following optimisation, the drug susceptibility profiles of fourteen commonly used drugs
including Rifampicin and Ampicillin) was evaluated (Ampicillin, Rifampicin, Streptomycin,
Erythromycin, Isonazid, Vancomycin, Ciproflaxin, Amakacin, Clofazamine, Azithromycin,
Clindamycin, Doxycycline, Trimethroprim and Cefdinir) against the six MAP strains as
referenced in Table 5. The same procedure was performed as outlined in the previous section,
with a 2 hour incubation step which was fixed throughout the duration of the assay for Step 2
and a subsequent 4 hour step for step 4 which was decided based on the data obtained from
the previous section.

Evaluation of the efficacy of the mycobacteriophage based drug susceptibility assay by
undertaking a blinded study

In order to reduce any chance of bias, a related blinded study was conducted. For this study,
two unknown drugs were retested against the six MAP strains. The drugs were randomly
85

coded by a second operator. The procedure carried out in Section 3.7 was identical to that
outlined in Section 3.6 using the optimised assay described above.

Application of a cocktail of mycobacteriophages to drug susceptibility assay
The applications for this potential assay are varied. Were it to be used for HTS of new antimycobacterial drugs, the use of a single phage which had previously shown efficacy against
the host strain under investigation would be sufficient. However if the assay were to be used
as part of determining the drug susceptibility profile of an unknown isolate, it would be
important to ensure that a range of phages would be used in order to maximise the chances of
the phage(s) infecting and reducing the potential for false negative results. To that end, a
cocktail of previously characterised phages would enhance the applicability of this assay, by
increasing the host range of the phages used in this assay. However, it would be important to
show that the use of additional phages did not interfere with the performance of this assay
and it was therefore repeated with the cocktail of phages described earlier.
The procedure carried out is identical to that outlined in Figure 8 except for, a combination
of individual mycobacteriophages (LE1 to LE6 at high titre (109 pfu/ml for each individual
mycobacteriophage).
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Results:
Confirming the phenotype of MAP strains through molecular analysis
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MAP
strains
and
positive
control

(b)

Blue: TB14-6416, Orange: TB14-6278, Pink: TB14-9294, Red: TB14-7535, Yellow:
TB14: 9252, Green: TB14-9252 and Purple: Positive Control (MAP K10 strain)

Figure 9: (a): Mycobacterium avium subsp. paratuberculosis specific amplicons (413 bp) by
PCR using IS900 specific primers. Lane 1: 1KB DNA ladder, Lane 2: Positive control;
Lane 3: TB14-7535, Lane 4: TB14-6416, Lane 5: TB14-9252, Lane 6: TB14-6278, Lane
7: TB14-6196 and Lane 8: TB14-9294; (b): Melting curve of six MAP isolates utilising a
primer specific mbtA-MAP2179 gene analysed by Real Time PCR. The mbtA-MAP2179
target qPCR generated a melting curve proﬁle containing two peaks at 87 °C and 93 °C.
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It was important to confirm each MAP strain by performing molecular testing (in this case
PCR of the IS900 region and Real Time PCR of the mbtA-MAP2179 gene. A product size of
413bp was obtained for all 6 MAP strains based on the agarose gel which can be seen in
Figure 9(a). 1KB DNA marker was utilised as the molecular weight marker.
Real time PCR analysis was also performed to provide further identification of the six MAP
strains. The mbtA gene utilised provides additional specificity in tandem with IS900 specific
primers. Figure 9(b) provides further confirmation of the presence of MAP DNA due to the
melting curve curve profile obtained for the six MAP strains using the mbtA target. The
mbtA target should produce two peaks with melting temperatures of 87 °C and 93 °C which
is consist with Figure 9(b).

Determination of the Minimum Inhibitory Concentrations (MIC’s) of Ampicillin,
Rifampicin, Streptomycin, Erythromycin, Isonazid, Vancomycin, Ciproflaxin,
Amakacin, Clofazamine, Azithromycin, Clindamycin, Doxycycline, Trimethroprim and
Cefdinir
Table 6: Minimum Inhibitory Concentrations (MIC’s) (µg/ml) of fourteen commonly
used drugs against the six MAP strains under investigation

AMP: Ampicillin, RIF: Rifampicin, STR: Streptomycin, ERY: Erythromycin, IZD:
Isonazid, VAN: Vancomycin, CIP: Ciproflaxin, AMK: Amakican, CLF: Clofazamine,
AZM: Azithromycin, CLI: Clindamycin, DOX: Doxycycline, TMP: Trimethoprim, CDR:
Cefdinir
The MIC of each drug under investigation was determined using six MAP strains. Ten drugs
in Table 6 exhibited growth-inhibitory effects against the six MAP strains, although some
drugs had a better inhibitory effect than others. Each strain under investigation had a novel
profile based on their MIC results. Four drugs in Table 6 (Ampicillin, Streptomycin,
Erythromycin and Amikacin) generated no MIC value (µg/ml) indicating that the six MAP
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strains were resistant. The data also produced interesting and novel results relating to the
antibiotic resistance properties of these six MAP field isolates. This variation can be observed
in particular for Ciproflaxin in which five MAP strains appeared resistant to this antibiotic
and one MAP strain appeared sensitive whereas five MAP strains were sensitive to
doxycycline with one MAP strain resistant. Two MAP strains were resistant to Trimethoprim
and the remaining four MAP strains were sensitive. Similarly two MAP strains were resistant
to Cefdinir and the remaining four strains were sensitive to the drug. Even with limited data it
is quite evident that field isolates have varied drug resistance profiles.

Determination of the optimum exposure time for MAP, Ampicillin/Rifampicin and TM4
mycobacteriophage to be in contact based on Figure 8 (Step 4, Step 5 and Step 6)

Figure 10: Assay to determine the contact period for drug, TM4 and MAP
to be in contact using Ampicillin performed in triplicate
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The MAP strain used was incubated with Ampicillin for 2 hours initially and the influence of
time was then evaluated in terms of how it affected the number of phage that accumulated at
each time point. The objective was to identify a time point where the number of phage that
accrued were notably higher than the initial T0 reading.
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Figure 11: Assay to determine the contact period for drug, TM4 and
MAP to be in contact using Rifampicin performed in triplicate
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A suitable exposure time for the drug, TM4 and a typical MAP strain (TB14-6416) was
determined, as the main purpose of the assay was to reduce the time involved in drug
susceptibility testing for MAP. Two hour time intervals of 0, 2, 4, 6 and 8 hours were chosen
as shown in Figure 10. Two drugs were utilised (Ampicillin and Rifampicin) in which their
drug susceptibilities had been established (one sensitive and one resistant). At the various
time points (2, 4, 6 and 8 hours) plaque assays were conducted and plaque numbers were
compared to T0.

Plaque numbers increase for ampicillin three fold when compared to T0 and T8 suggesting
TB14-6416 is resistant to the drug. In contrast there are minor fluctuations in plaque numbers
at time 2, 4, 6 and 8 hours for Rifampicin compared to T0 indicating sensitivity to the drug as
illustrated in step 6 of Figure 8. A minimum time period of 4 hours is adequate to achieve the
desired effect based on the data above (T0 versus T4). The preliminary data at this point
would suggest that the assay is functional but requires further validation with additional
drugs.

The MAP strain used was incubated with Rifampicin for 2 hours initially and the influence of
time was then evaluated in terms of how it affected the number of phage that accumulated at
each time point. The objective was to identify a time point where the number of phage that
accrued were notably higher than the initial T0 reading.
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Application of the optimised mycobacteriophage based microtiter plate assay to identify
drug susceptibilities of fourteen drugs
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Figure 12: Drug susceptibility profile of six MAP strains against four drugs
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Figure 13: Drug susceptibility profile of six MAP strains against four drugs
utilising mycobacteriophage as indicators of drug susceptibility based on Δ
PFU/ml
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Figure 14: Drug susceptibility profile of six MAP strains against four drugs utilising
mycobacteriophage as indicators of drug susceptibility based on Δ PFU/ml
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Figure 15: Drug susceptibility profile of six MAP strains against two drugs
utilising mycobacteriophage as indicators of drug susceptibility based on Δ
PFU/ml
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Following drug susceptibility testing, drug susceptibility profiles were obtained for fourteen
drugs in total. The drug susceptibility profile of each drug against MAP was unknown. In
particular, MAP strains TB14-6416, TB14-9294 and TB14-6196 generated varied drug
susceptibility profiles in comparison to the other strains. These three strains presented high
levels of resistance to common drugs after only a four hour assay period whereas the other
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three MAP strains demonstrated sensitivity to a large majority of these drugs. Based on their
MIC values, plaque numbers for the six strains against ampicillin, streptomycin,
erythromycin and amakacin increased suggesting that all six MAP strains were resistant to
these drugs. The six MAP strains demonstrated sensitivity to Rifampicin and Clindamycin as
plaque numbers remained static. Plaque numbers for each of the remaining eight drugs had
varied drug resistance and sensitivity profiles to certain MAP strains.
Comparison of the MIC values and the plaque numbers obtained for this assay are listed in
Table 7. Based on this data it is evident that the resistance profiles obtained for this assay
show 100% correlation to the MIC values obtained.
Table 7 – MIC (µg/ml) values and mycobacteriophage drug susceptibility resistance or
sensitivity profiles for six different MAP strains against fourteen commonly used drugs

AMP: Ampicillin, RIF: Rifampicin, STR: Streptomycin, ERY: Erythromycin, IZD:
Isonazid, VAN: Vancomycin, CIP: Ciproflaxin, AMK: Amakacin, CLO: Clofazamine,
AZM: Azithromycin, CLI: Clindamycin, DOX: Doxycycline, TMP: Trimethoprim, CDR:
Cefdinir
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Evaluation of the efficacy of the mycobacteriophage based drug susceptibility assay by
undertaking a blinded study
Figure 16: Blinded study to determine the resistance profiles of drug 2 using
mycobacteriophage TM4 to determine the change in PFU/ml
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Drug X: Erythromycin and Drug Y: Ciproflaxin

A blinded-experiment was conducted following the application of the assay in which the
identity of the drug was masked, to reduce or eliminate bias. The mini blinded study
generated results that were identical to the previous assay. Drug X was identified as
Erythromycin and Drug Y was identified as Ciproflaxin as expected. Plaque numbers for
Erythromycin increased over 4 hours as all six MAP strains were resistant. Plaque numbers
for Ciproflaxin varied. For TB14-6416, TB14-6278, TB14-9294, TB14-7535, TB14-9252
plaque numbers increased indicating resistance whereas TB14-6196, plaque numbers
remained static indicating sensitivity as shown in Figure 15.
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Application of a cocktail of mycobacteriophages to drug susceptibility assay:
Figure 17: Application of a phage cocktail to the drug susceptibility assay
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A combination of mycobacteriophages (phage cocktail) was applied, to ensure that the
addition of extra phage didn’t interfere with the fidelity of the assay. Based on the data in
Figure 16, the addition of a phage cocktail did not impair the assay and is identical to the
plaque numbers obtained for one mycobacteriophage type.
Discussion:
The proportion of antibiotics effective against Johne’s disease in cattle is very limited and
there are no antibiotics currently approved for its treatment. In instances where antibiotics
have been used to prolong the life of a valuable animal, the disease remains virtually fatal as
drug susceptibility profiles are unknown (Davis, Kuenstner, & Singh, 2017). The use of
chemotherapy for animals as an alternative to antibiotic treatment is further confounded by
the lack of a standardized susceptibility method and the empirical use of antituberculous
agents without in vitro susceptibility testing, which is hampered by the slow growth of the
organism and its fastidious nutritional requirements.
Antimicrobial regimens for treatment of MAP based diseases have included antibiotics such
as rifampicin (RIF), isonazid (IZD), and cefdinir (CEF) given separately or in combination
for a period of one to several months. Other trials have used clarithromycin, clofazimine or
azithromycin (Savarino et al., 2019). Efficacy is variable and relapse is a common occurrence
once therapy is stopped. Prior to administration, drug susceptibility data should be obtained
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to prevent the occurrence of relapse and variable efficacy. As mentioned previously however,
the slow growth of the organism prevents the development of rapid drug susceptibility
methods.
Currently to identify drug susceptibilities of MAP, the BACTEC, MGIT and MIC method are
used which have their limitations (Krishnan et al., 2009a). The MIC is considered the gold
standard for drug susceptibility testing of a large array of fast and slow growing
microorganisms. For fast growing microorganisms drug susceptibility results can take 24
hours, but is not feasible for slow growers such as MAP which can take 6 to 12 weeks to
generate (Krishnan et al., 2009a).
Faster assays are essential in the treatment of MAP based diseases and our objective was to
develop a rapid assay for MAP utilising mycobacteriophage as an indirect measure of drug
susceptibilities based on plaque forming units (pfu/ml). The FASTPlaqueTBTM assay is a
similar assay which also utilises actiphage to identify drug susceptibilities of Mycobacterium
tuberculosis. The principle of each assay is very similar.
The premise of utilising mycobacteriophage in this assay is based on the following principle:
If the drug is not effective against killing MAP, MAP cells would remain viable and
mycobacteriophage would infect these cells causing an increase in plaque forming units. If
the drug is effective against MAP, then the MAP cells would no longer be viable, therefore
the mycobacteriophage have no cells to infect and plaque forming units will remain
equivalent over time.
To ensure functionality of the assay, initial studies were conducted utilising the
mycobacteriophage TM4, the drug under investigation and a single MAP strain. It was
important to be able to test a wide variety of common agricultural drugs using the same
platform, therefore a microtiter plate format was chosen for the assay. Two drugs were
selected in which the drug susceptibility profiles were known (MAP is resistant to Ampicillin
and MAP is sensitive to Rifampicin). After an initial 2 hour period whereby the drug and the
MAP strain are in contact, a subsequent 4 hour incubation interval (established during step 4
Figure 6) was chosen based on the notable differences in plaque numbers between T0 and T4.
For the phage based assay, differences in plaque numbers were obtained for certain MAP
strains indicating resistance or sensitivity. The excessive usage of antibiotics in agriculture,
aquaculture and livestock may select for resistant MAP isolates as large amount of antibiotics
may find their way into natural habitats particularly spreading to cattle (Martin, Thottathil, &
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Newman, 2015). In particular, strains TB14-6416 and TB14-9292 isolated from cattle had
high levels of resistance for both the MIC and phage based assay. TB14-6416 was resistant to
eight drugs using both assays and was sensitive to the remaining six drugs. TB14-9292 also
demonstrated high levels of resistance and was resistant to seven drugs in both assays and
sensitive to the remaining seven drugs. The presence of such high levels of resistance against
a high number of drugs would indeed be a concern for the presence of antibiotic resistance
genes in these two field isolates. The two strains were isolated from beef cattle in the
southern region of Ireland.
The remaining MAP strains TB14-9252, TB14-7535, TB14-6278 and TB14-6278
comparatively had lower levels of resistance in comparison, however this increase in
resistance of field isolates may be as a consequence of overuse of these antibiotics in
agriculture given that these strains were isolated from farm environments. Another possibility
is the generation of antibiotic resistance genes through manure. Manure is a natural reservoir
for the transfer of antibiotic resistance genes in the environment which has been outlined in
many studies (Marston, Dixon, Knisely, Palmore, & Fauci, 2016) (Berkner, Silvia; Konradi,
Sabine; Schönfeld, 2014) (Singer, Shaw, Rhodes, & Hart, 2016).
The remaining four strains were also isolated from dairy cattle in Southern Ireland. This is the
first study to show the prevalence of MAP resistance genes in Ireland. However, the
correlation between antibiotic resistance and geographical location of MAP residence in
cattle in Ireland may have an impact on the emerging levels of antibiotic resistance which has
been suggested in other geographical locations outside of Ireland (Bengtsson-Palme &
Larsson, 2015).
Evidence suggests that human activities, such as wastewater treatment plants, animal feedlots
and pharmaceutical factories are significant point sources of Antibiotic Resistance Genes
(ARG’s) into the receiving environmental bodies (Graham et al., 2010; LaPara et al., 2011; Li
et al., 2012), which may also explain the reason why high contaminations of ARGs were
observed in the Munster region due to the presence of large numbers of pharmaceutical
factories in which some antibiotics are produced such as GlaxoSmithKline (GSK), Pfizer and
MSD (Merck Sharp & Dohme).
In order to ensure the competence of this phage based assay, the MIC’s of the six MAP
strains against fourteen commonly used agricultural drugs were compared. For the MIC assay
ten drugs exhibited growth-inhibitory effects against six MAP field isolates (refer to Table 7),
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although some drugs had more of an increased inhibitory effect than others. The presence of
antibiotic resistance genes in the six field isolates may have contributed to this variation.
According to the Department of Agriculture (Health.gov.ie, 2019), tetracyclines (39%),
sulphonamides (20%), penicillin’s (20.8%) and macrolides (7%) were utilised the most in
Ireland in 2018. This statement is certainly true for penicillins in accordance with the data
from this study as all six MAP strains were resistant to ampicillin. Erythromycin and
azithromycin are members of the macrolide antibiotic group in which six MAP strains from
this study had varied drug susceptibility results. All six MAP strains were resistant to
Erythromycin whereas only three MAP strains were resistant to Azithromycin. This result is
not unexpected however, as Erythromycin is commonly prescribed as a “general” antibiotic
whereas Azithromycin is typically given for more specialised infections such as intestinal
infections and pneumonia.
As tetracyclines are the highest used antibiotics in Ireland in 2018 we would expect our data
to correlate with this finding. One MAP strain was in fact resistant to tetracycline and the
remaining MAP strains were sensitive to the drug. Tetracyclines are commonly given in
combination with another antibiotic to kill hardy bacterial infections such as Lyme’s disease,
Malaria and anthrax. As the incidence of Lyme’s disease in cattle, sheep, deer etc. in Ireland
has increased over the last few years then this would likely cause an increase in the
percentage of Tetracyclines being administered and cause ARG’s in these species of bacteria
(Halperin, 2015). Two MAP strains were resistant to trimethoprim which is a sulphonamide
typically used to treat Pseudomonas, Staphylococcal and Salmonella infections (Pantziarka,
Pirmohamed, & Mirza, 2018). Based on this data, the high levels of use of these drugs in the
environment/agriculture in 2018 may have led to the presence of antibiotic resistance in these
field strains.
As the development of antibiotic resistance for MAP is increasing as outlined in this study, it
was necessary to perform a blinded study to confirm the efficacy of the phage based assay in
determining drug sensitivity and resistance. The efficacy and reproducibility of the assay was
confirmed based on the plaque numbers obtained and the identity of each drug. Similarly to
the blinded study, the application of a mycobacteriophage cocktail to the assay had the ability
to validate the assay in comparison to utilising one mycobacteriophage type.
As the assay has only been applied to six field MAP isolates, the applicability of the assay to
lab adapted MAP strains is unknown and other field MAP isolates from a wider region. The
98

assay has only been performed utilising fourteen common drugs utilised in agriculture and
may not work as efficiently for other antibiotic classes. It is also not possible to consider the
dissemination of antibiotic resistance genes in each of the six field MAP isolates until
bioinformatics analysis has been undertaken.
Comparable plaque forming units and drug susceptibility profiles were obtained for the six
MAP field isolates for both the MIC and phage based assay. This assay may also have the
potential to be used as a High Throughput Screening method (HTS) for other agricultural
drugs.
In summary the addition of mycobacteriophage to the study has a significant reduction in the
time required to obtain drug susceptibility results for six field isolates of Mycobacterium
avium paratuberculosis. This reduction in time and the assay format will be useful for HTS
screening of novel anti-mycobacterial drugs. In comparing this assay to the MIC method
(gold standard for drug susceptibility), the drug susceptibility profiles are in fact identical
with results generated within an adequate time period.

This assay therefore has multiple applications such as its use in High Throughput screening to
identify novel compounds and drugs for the treatment of Johne’s disease, identification of
drug resistant isolates in general, in a more time efficient manner.
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CONCLUSION:
As already discussed, the treatment and diagnosis of Johne’s disease caused by MAP is
extremely subjective and time consuming. Current diagnostic methods which are based on
immune-mediated reactions and targeting genes of interest are adequate but are subject to
bias. The development of an assay which has the ability to incorporate efficacy, sensitivity
and specificity is required for the control of Johne’s disease.
Though this research only reflects a very small aspect of drug susceptibility testing of
mycobacteria utilising mycobacteriophage, the potential of this assay is a considerable
contribution to Johne’s disease research. The assay has the ability to determine viability of
mycobacteria as well as a drug susceptibility profiles of MAP strains, therefore it may be
useful in detecting the presence of viable MAP cells in Johne’s disease affected animals, to
ensure the administration of adequate treatment. Future studies could be undertaken in
broadening the host range of the assay to determine if it is effective against other
mycobacterial types. Additionally, the application of different phage types and cocktails
could be attempted for use in the assay to determine the effect of the cocktail and various
other drug susceptibility profiles. As the assay is carried out in a microtiter plate format and
has the ability to reduce the time involved in drug susceptibility testing, the assay may have
the potential to be used for High Throughput Screening (HTS) of novel anti-mycobacterial
drugs.
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APPENDICES:
Throughout the duration of the research masters I examined 200 different environmental
samples for the presence of novel mycobacteriophages. No mycobacteriophages were found.
Spiking experiments were performed to ensure that I could recover phage from a sample
aswell as the use of a positive control.

Table 8: Environmental samples tested for the presence of novel mycobacteriophages
utilising plaque assays from various locations in Ireland.
No.
Analysed

4
5

Location
Ryans Farm, Cobh,
Cork
Ryans Farm, Cobh,
Cork
Ryans Farm, Cobh,
Cork
Lehane Farm,
Glanmire, Cork
Farm Leamlara, Cork

6

Murphys Farm
Carrigtwohill, Cork

1
2
3

7
8
9
10
11
12
13
14
15
16
17

Murphys Farm,
Carrigtwohill, Cork
Glouthaune Farm 1,
Cork
Glouthaune Farm 2,
Cork
Glouthaune Farm 3,
Cork
Cotter Farm,
Blackwater, Kerry
Cotter Farm,
Blackwater, Kerry
Cotter Farm,
Blackwater, Kerry
Watergrasshill Farm,
Cork
Buttimer Farm,
Clonakilty, Cork
Chicken Farm,
Midleton, Cork
WWTP Riverstick,
Cork

Environmental
Source

Date Collected

Phages
Found

Soil

01/09/2017

Absent

Soil

01/09/2017

Absent

Soil

01/09/2017

Absent

Soil
Soil

01/09/2017
01/09/2017

Absent
Absent

Soil

01/09/2017

Absent

Soil

01/09/2017

Absent

Soil

08/09/2017

Absent

Soil

08/09/2017

Absent

Soil

08/09/2017

Absent

Soil

11/09/2017

Absent

Soil

11/09/2017

Absent

Soil

11/09/2017

Absent

Soil

13/09/2017

Absent

Manure

13/09/2017

Absent

Manure

17/09/2017

Absent

Activated Sludge

06/10/2017

Absent
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30

WWTP - Riverstick,
Cork
Charles Fort, Kinsale,
Cork
Charles Fort, Kinsale,
Cork
Old Head of Kinsale,
Cork
Garrettstown Beach,
Cork
Garrettstown Beach,
Cork
Farm Garrettstown,
Cork
Maynooth wood,
Kildare
Maynooth wood,
Kildare
Maynooth wood,
Kildare
Maynooth wood,
Kildare
Maynooth wood,
Kildare
Maynooth wood,
Kildare

31

Kielys Farm,
Donoughmore, Cork

Manure

13/11/2017

Absent

32

Kielys Farm,
Donoughmore, Cork

Soil

14/11/2017

Absent

Manure

15/11/2017

Absent

Fast flowing Water

20/01/2018

Absent

Slow flowing Water

21/01/2018

Absent

Soil
Soil

22/01/2018
23/01/2018

Absent
Absent

18
19
20
21
22
23
24
25
26
27
28
29

Effluent

06/10/2017

Absent

Mulch

15/10/2017

Absent

Soil

15/10/2017

Absent

Soil

15/10/2017

Absent

Sea water

15/10/2017

Absent

Sand

15/10/2017

Absent

Soil

15/10/2017

Absent

Soil

26/10/2017

Absent

Soil

26/10/2017

Absent

Fast flowing Water

26/10/2017

Absent

Slow flowing Water

26/10/2017

Absent

Stagnant Water

26/10/2017

Absent

Mulch

26/10/2017

Absent

36
37

Kielys Farm,
Donoughmore, Cork
Curragh woods,
Midleton, Cork
Curragh woods,
Midleton, Cork
Curragh woods,
Midleton, Cork
Fota soil, Cork

38

Rossacroo na Loo
wood, Kenmare, Kerry

Water

28/01/2018

Absent

39

Rossacroo na Loo
wood, Kenmare, Kerry

Soil

28/01/2018

Absent

40

Tracton woods,
Carrigaline, Cork

Stream water

04/02/2018

Absent

41

Tracton woods,
Carrigaline, Cork

Pond water

04/02/2018

Absent

33
34
35
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42
43

Lough beg (water),
Antrim
Blackwater river, Kerry

Lake water
River water

16/02/2018
16/02/2018

Absent
Absent

44

Tracton woods,
Carrigaline, Cork

Stream water

25/02/2018

Absent

45

Tracton woods,
Carrigaline, Cork

Stream water

26/02/2018

Absent

46

Tracton woods,
Carrigaline, Cork

Soil

27/02/2018

Absent

47

Tracton woods,
Carrigaline, Cork

Soil

28/02/2018

Absent

48
49
50
51

Tracton woods,
Carrigaline, Cork
Glanmire, Cork
Gurteen, Sligo
Gurteen, Sligo

Soil
Soil
Soil
Soil

01/03/2018
12/03/2018
25/03/2018
26/03/2018

Absent
Absent
Absent
Absent

52

Desmonds Farm
Ovens, Co.Cork

Soil

17/04/2018

Absent

53

Desmonds Farm
Ovens, Co.Cork

Soil

17/04/2018

Absent

54

Desmonds Farm
Ovens, Co.Cork

Soil

17/04/2018

Absent

55

Desmonds Farm
Ovens, Co.Cork

Stagnant water

17/04/2018

Absent

56

Desmonds Farm
Ovens, Co.Cork

Faeces

17/04/2018

Absent

57

Desmonds Farm
Ovens, Co.Cork

Faeces

17/04/2018

Absent

58

Desmonds Farm
Ovens, Co.Cork

Faeces

17/04/2018

Absent

59

Kilmichael, Twohig
farm, Cork

Soil

21/04/2018

Absent

60

Kilmichael, Twohig
farm, Cork

Soil

21/04/2018

Absent

61

Kilmichael, Twohig
farm, Cork

Soil

21/04/2018

Absent

Soil

21/04/2018

Absent

Soil

21/04/2018

Absent

Soil
Faeces

21/04/2018
21/04/2018

Absent
Absent

63

Kilmichael, Twohig
farm, Cork
Kilmichael, Twohig
farm, Cork

64
65

Kilmichael, Twohig
farm, Cork
Kilmichael, Twohig

62
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66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91

farm, Cork
Kilmichael, Twohig
farm, Cork
Crosshaven, Cork
Crosshaven, Cork
Crosshaven, Cork
Donegal - Soil
Donegal - Soil - woods
Donegal - Stagnant
water - A1
Donegal - Stagnant
water - A2
Donegal - fast flowing
water - waterfall
Donegal - soil - malin
head - A1
Donegal - soil - malin
head A2
Donegal - soil - malin
head A3
Fermanagh - soil/water
- culcaigh
Fermanagh - soil culcaigh
Fermanagh - soil culcaigh
Fermanagh - soil culcaigh
Fermanagh - stagnant
water - culcaigh
Fermanagh - hay culcaigh
Fermanagh - hay culcaigh
Teagasc - Fermoy,
Cork
Teagasc - Fermoy,
Cork
Teagasc - Fermoy,
Cork
Teagasc - Fermoy,
Cork
Teagasc - Fermoy,
Cork
Teagasc - Fermoy,
Cork
Teagasc - Fermoy,

Faeces
Compost Pit Soil
Compost Pit Soil
Compost Pit Soil
Soil
Soil

21/04/2018
05/05/2018
05/05/2018
05/05/2018
19/05/2018
19/05/2018

Absent
Absent
Absent
Absent
Absent
Absent

Stagnant water

19/05/2018

Absent

Stagnant water

19/05/2018

Absent

Water

19/05/2018

Absent

Soil

19/05/2018

Absent

Soil

19/05/2018

Absent

Soil

19/05/2018

Absent

Soil/Water

19/05/2018

Absent

Soil

19/05/2018

Absent

Soil

19/05/2018

Absent

Soil

19/05/2018

Absent

Stagnant water

19/05/2018

Absent

Hay

19/05/2018

Absent

Hay

19/05/2018

Absent

Faeces

23/05/2018

Absent

Faeces

23/05/2018

Absent

Faeces

23/05/2018

Absent

Faeces

23/05/2018

Absent

Faeces

23/05/2018

Absent

Faeces
Faeces

23/05/2018
23/05/2018

Absent
Absent
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Cork
Teagasc - Fermoy,
Cork
Teagasc - Fermoy,
Cork
Teagasc - Fermoy,
Cork
Teagasc - Fermoy,
Cork
Ardmore, Co
Waterford
Ardmore, Co
Waterford
Ardmore, Co
Waterford
Ardmore, Co
Waterford
Ardmore, Co
Waterford
Ardmore, Co
Waterford
Ardmore, Co
Waterford
Ardmore, Co
Waterford

104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123

Ardmore, Co
Waterford
Salt Hill - Galway
Salt Hill - Galway
Salt Hill - Galway
Galway - Woods
Galway - Woods
Galway - Woods
Galway - Woods
Galway - Woods
Galway - Woods
Dingle, Kerry
Dingle, Kerry
Dingle, Kerry
Dingle, Kerry
Dingle, Kerry
Dingle, Kerry
Dingle, Kerry
Trim, Co Meath
Trim, Co Meath
Trim, Co Meath

92
93
94
95
96
97
98
99
100
101
102

Faeces

23/05/2018

Absent

Faeces

23/05/2018

Absent

Faeces

23/05/2018

Absent

Faeces

23/05/2018

Absent

Soil

09/06/2018

Absent

Soil

10/06/2018

Absent

Soil

11/06/2018

Absent

Sea water

12/06/2018

Absent

Sea water

13/06/2018

Absent

Sea water

14/06/2018

Absent

Mulch

15/06/2018

Absent

Mulch

16/06/2018

Absent

Mulch
Sea water
Seaweed
Seaweed
Soil
Stagnant water
Hay
Hay
Faeces
Faeces
Hay
Hay
Hay
Soil
Soil
Soil
Soil
Mulch
Mulch
Soil

17/06/2018
30/06/2018
30/06/2018
30/06/2018
30/06/2018
30/06/2018
30/06/2018
30/06/2018
30/06/2018
30/06/2018
14/07/2018
14/07/2018
14/07/2018
14/07/2018
14/07/2018
14/07/2018
14/07/2018
28/07/2018
28/07/2018
28/07/2018

Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
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124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139

143

Trim, Co Meath
Trim, Co Meath
Trim, Co Meath
Dungarvan
Dungarvan
Dungarvan
Dungarvan
Dungarvan
Dungarvan
Portumna, Galway
Portumna, Galway
Portumna, Galway
Portumna, Galway
Portumna, Galway
Portumna, Galway
Portumna, Galway
Wicklow Mountains,
Wicklow
Wicklow Mountains,
Wicklow
Wicklow Mountains,
Wicklow
Wicklow Mountains,
Wicklow

144

Comeragh mountains,
Waterford

Soil

06/10/2018

Absent

145

Comeragh mountains,
Waterford

Soil

06/10/2018

Absent

Soil
Soil
Soil
Leaves
Leaves
Leaves

06/10/2018
30/10/2018
30/10/2018
12/11/2018
12/11/2018
12/11/2018

Absent
Absent
Absent
Absent
Absent
Absent

Soil

28/11/2018

Absent

Soil

28/11/2018

Absent

Soil

28/11/2018

Absent

Stagnant water

13/12/2018

Absent

140
141
142

154

Comeragh mountains,
Waterford
The Lough, Cork
The Lough, Cork
Garryduff woods, Cork
Garryduff woods, Cork
Garryduff woods, Cork
Currabinny woods,
Cork
Currabinny woods,
Cork
Currabinny woods,
Cork

155

Marlagoe Woods, East
Ferry, Cork

146
147
148
149
150
151
152
153

Soil
Stagnant water
Stagnant water
Soil
Soil
Soil
Faeces
Faeces
Faeces
River Shannon water
River Shannon water
River Shannon water
Lough Derg water
Lough Derg water
Lough Derg water
Lough Derg water

28/07/2018
28/07/2018
28/07/2018
06/08/2018
06/08/2018
06/08/2018
06/08/2018
06/08/2018
06/08/2018
25/08/2018
25/08/2018
25/08/2018
25/08/2018
25/08/2018
25/08/2018
25/08/2018

Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent

Soil

11/09/2018

Absent

Soil

11/09/2018

Absent

Mulch

11/09/2018

Absent

Soil

11/09/2018

Absent
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156

Marlagoe Woods, East
Ferry, Cork

Stagnant water

13/12/2018

Absent

157

Marlagoe Woods, East
Ferry, Cork

Mulch

13/12/2018

Absent

158

Marlagoe Woods, East
Ferry, Cork

Mulch

13/12/2018

Absent

159

Lisheen woods,
Ballincollig, Cork

Soil

10/01/2019

Absent

160

Lisheen woods,
Ballincollig, Cork

Soil

10/01/2019

Absent

161

Lisheen woods,
Ballincollig, Cork

Soil

10/01/2019

Absent

Soil

10/01/2019

Absent

Fast flowing water

14/02/2019

Absent

Slow flowing water

14/02/2019

Absent

Hay

14/02/2019

Absent

Hay

14/02/2019

Absent

Seaweed

23/02/2019

Absent

Seaweed

23/02/2019

Absent

Sand

23/02/2019

Absent

Sand

23/02/2019

Absent

Soil

10/03/2019

Absent

Soil

10/03/2019

Absent

Soil

10/03/2019

Absent

Soil

10/03/2019

Absent

Soil

17/03/2019

Absent

Soil

17/03/2019

Absent

Soil

17/03/2019

Absent

Soil
Septic Tank Run Off

17/03/2019
24/03/2019

Absent
Absent

162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179

Lisheen woods,
Ballincollig, Cork
Kilbritains Woods,
Cork
Kilbritains Woods,
Cork
Kilbritains Woods,
Cork
Kilbritains Woods,
Cork
Inch Beach, Midleton,
Cork
Inch Beach, Midleton,
Cork
Inch Beach, Midleton,
Cork
Inch Beach, Midleton,
Cork
Nagles Woods,
Mallow, Cork
Nagles Woods,
Mallow, Cork
Nagles Woods,
Mallow, Cork
Nagles Woods,
Mallow, Cork
Ballincollig Regional
Park, Cork
Ballincollig Regional
Park, Cork
Ballincollig Regional
Park, Cork
Ballincollig Regional
Park, Cork
Glounthaune, Cork
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180
181
182
183
184
185
186
187
188
189
190
191
192
193
194

Glounthaune, Cork
Glounthaune, Cork
Glounthaune, Cork
Glounthaune, Cork
Glounthaune, Cork
Glounthaune, Cork
Hungry Hill, Cork
Hungry Hill, Cork
Hungry Hill, Cork
Hungry Hill, Cork
Hungry Hill, Cork
Waterfall A1, Cork
Waterfall A2, Cork
Waterfall A3, Cork
Waterfall A4, Cork

Mulch
Soil
Faeces
Soil
Soil
Sludge
Soil
Soil
Soil
Soil
Soil
Fast flowing water
Fast flowing water
Slow flowing water
Slow flowing water

24/03/2019
24/03/2019
24/03/2019
24/03/2019
24/03/2019
24/03/2019
01/05/2019
01/05/2019
01/05/2019
01/05/2019
01/05/2019
28/05/2019
28/05/2019
28/05/2019
28/05/2019

Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent
Absent

195

Farran woods A1 (refer
to MAP), Cork

Mulch

04/06/2019

Absent

196

Farran woods A2 (refer
to MAP), Cork

Mulch

04/06/2019

Absent

197

Farran woods A3 (refer
to MAP), Cork

Mulch

04/06/2019

Absent

198

Farran woods A4 (refer
to MAP), Cork

Mulch

04/06/2019

Absent

199

Farran woods A5 (refer
to MAP), Cork

Mulch

04/06/2019

Absent

200

Farran woods A6 (refer
to MAP), Cork

Stagnant water

04/06/2019

Absent

201

Farran woods A7 (refer
to MAP), Cork

Stagnant water

04/06/2019

Absent

202

Farran woods A8 (refer
to MAP), Cork

Stagnant water

04/06/2019

Absent

203

Farran woods A9 (refer
to MAP), Cork

Soil

04/06/2019

Absent

204

Farran woods A10
(refer to MAP), Cork

Soil

04/06/2019

Absent

205

Farran woods A11
(refer to MAP), Cork

Soil

04/06/2019

Absent

206

Farran woods A12
(refer to MAP), Cork

Soil

04/06/2019

Absent

Soil

04/06/2019

Absent

Sand

21/06/2019

Absent

207
208

Farran woods A13
(refer to MAP), Cork
Inchydoney Beach A1,
Cork
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209
210
211
212
213
214
215
216

Inchydoney Beach A2,
Cork
Inchydoney Beach A3,
Cork
Inchydoney Beach A4,
Cork
Inchydoney Beach A5,
Cork
Inchydoney Beach A6,
Cork
Inchydoney Beach A7,
Cork
Inchydoney Beach A8,
Cork
Inchydoney Beach A9,
Cork

Sand

21/06/2019

Absent

Sand

21/06/2019

Absent

Seaweed

21/06/2019

Absent

Seaweed

21/06/2019

Absent

Seaweed

21/06/2019

Absent

Seaweed

21/06/2019

Absent

Sea water

21/06/2019

Absent

Sea water

21/06/2019

Absent

Table 9: Comparative analysis of 230 mycobacteriophage genomes based on cluster
designation and morphotype

Mycobacteriophage
name
Mycobacteriophage
Wheeler
Mycobacteriophage
Nhonho

Length
(bp)
53,588
51,355

Morphotype
Siphoviridae
Siphoviridae

GC
Content
(%)

Sequencing
complete

Cluster

Subcluster

Genbank
Accession
number

63.30%

Yes

A

A1

KF416340

63.80%

Yes

A

A1

KR997934

63.40%

Yes

A

A1

KR997929

Mycobacteriophage
Barriga

52,643

Mycobacteriophage
Edtherson

51492

Siphoviridae

64%

Yes

A

A1

KP027196

Mycobacteriophage
Alvin

49577

Siphoviridae

63.50%

Yes

A

A1

KP027205

Mycobacteriophage
Pinto

50610

Siphoviridae

63.50%

Yes

A

A1

KJ690250

Siphoviridae

63.70%

Yes

A

A1

Mycobacteriophage
Seabiscuit

51781

Siphoviridae

KJ194585

Mycobacteriophage
SarFire

53701

Siphoviridae

63.80%

Yes

A

A1

KF024726

Mycobacteriophage
Graduation

52823

Siphoviridae

63.50%

Yes

A

A1

KF560331

Mycobacteriophage
Aeneas

53684

Siphoviridae

63.60%

Yes

A

A1

JQ809703

125

Mycobacteriophage
Turj99

51161

Siphoviridae

63.70%

Yes

A

A1

KT388014

Mycobacteriophage
Nerujay

53455

Siphoviridae

63.70%

Yes

A

A1

KR080201

Mycobacteriophage
Abrogate

52530

Siphoviridae

63.80%

Yes

A

A1

KM597531

Mycobacteriophage
Pari

50614

Siphoviridae

63.50%

Yes

A

A1

KT438500

Mycobacteriophage
TheloniousMonk

52055

Siphoviridae

63.60%

Yes

A

A1

KT363731

Mycobacteriophage
Rufus

52357

Siphoviridae

63.90%

Yes

A

A1

KT259047

Mycobacteriophage
Tasp14

51409

Siphoviridae

63.90%

Yes

A

A1

KT326768

Mycobacteriophage
Pepe

50515

Siphoviridae

64%

Yes

A

A1

KT818595

Mycobacterium
phage Lamina13

53255

Siphoviridae

63.70%

Yes

A

A1

KJ409696

Mycobacteriophage
Alsfro

52136

Siphoviridae

63.60%

Yes

A

A1

KJ174156

Mycobacteriophage
Doom

51421

Siphoviridae

63.80%

Yes

A

A1

JN153085

Mycobacteriophage
Trouble

52102

Siphoviridae

63.60%

Yes

A

A1

KF024724

Mycobacteriophage
PattyP

52057

Siphoviridae

63.60%

Yes

A

A1

KC661273

52250

Siphoviridae

63.20%

Yes

A

A1

AY500153

51277

Siphoviridae

63.70%

Yes

A

A1

AY500152

Mycobacteriophage
Makemake

52496

Siphoviridae

63.80%

Yes

A

A1

KX369584

Mycobacteriophage
Papez

52501

Siphoviridae

63.80%

Yes

A

A1

KX369586

Mycobacteriophage
Trike

44716

Siphoviridae

64.50%

Yes

A

A10

KM101120

Mycobacteriophage
RhynO

46739

Siphoviridae

65.30%

Yes

A

A10

KJ156985

Mycobacteriophage
Severus

49894

Siphoviridae

64.40%

Yes

A

A10

KC661279

Mycobacteriophage
Mulciber

52428

Siphoviridae

63.70%

Yes

A

A11

KU695581

Mycobacteriophage
Bethlehem
Mycobacteriophage
U2
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Mycobacteriophage
Phlei

50418

Siphoviridae

60.10%

Yes

A

A13

KT206225

Mycobacteriophage
Luchador

53387

Siphoviridae

62.10%

Yes

A

A14

KR080193

Mycobacteriophage
Adzzy

52,519

Siphoviridae

62.60%

Yes

A

A2

KF416344

Mycobacteriophage
D29

49136

Siphoviridae

63.50%

Yes

A

A2

AF022214

Mycobacteriophage
Che12

52047

Siphoviridae

62.90%

Yes

A

A2

DQ398043

Mycobacteriophage
SweetiePie

53184

Siphoviridae

63.50%

Yes

A

A2

KM591906

Mycobacteriophage
ArcherNM

52561

Siphoviridae

64.20%

Yes

A

A2

KU761559

Mycobacteriophage
loser

53486

Siphoviridae

64.50%

Yes

A

A2

KU761558

Mycobacteriophage
Serenity

52088

Siphoviridae

62.60%

Yes

A

A2

KT381276

Mycobacteriophage
Larenn

52967

Siphoviridae

63.50%

Yes

A

A2

KM677210

Mycobacterium
phage Equemioh13

53042

Siphoviridae

63.50%

Yes

A

A2

KJ959632

Mycobacteriophage
Piro94

52647

Siphoviridae

63.40%

Yes

A

A2

KM197169

Mycobacteriophage
LadyBird

53141

Siphoviridae

63.50%

Yes

A

A2

KT588442

Mycobacteriophage
RedRock

53332

Siphoviridae

64.50%

Yes

A

A2

GU339467

Mycobacteriophage
Echild

53159

Siphoviridae

63.70%

Yes

A

A2

KF981601

52892

Siphoviridae

63.30%

Yes

A

A2

EU744250

52297

Siphoviridae

62.30%

Yes

A

A2

Z18946

64.20%

Yes

A

A3

AY129332

Mycobacteriophage
Pukovnik
Mycobacteriophage
L5
Mycobacteriophage
Bxz2

50,913

Mycobacteriophage
MarQuardt

50882

Siphoviridae

64%

Yes

A

A3

KM233454

Mycobacteriophage
Tiffany

50768

Siphoviridae

64%

Yes

A

A3

KM101119

Mycobacteriophage
Phantastic

50101

Siphoviridae

63.80%

Yes

A

A3

KJ510415

Mycobacteriophage
Jobu08

50679

Siphoviridae

64%

Yes

A

A3

KC661281

Siphoviridae
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Mycobacteriophage
Iracema64

51637

Siphoviridae

64%

Yes

A

A4

KU055616

Mycobacteriophage
Kampy

51378

Siphoviridae

63.90%

Yes

A

A4

KJ510414

Mycobacteriophage
Obama12

51797

Siphoviridae

64%

Yes

A

A4

KF959563

Mycobacteriophage
Nyxis

51250

Siphoviridae

63.90%

Yes

A

A4

KF954506

Mycobacteriophage
BellusTerra

51236

Siphoviridae

63.90%

Yes

A

A4

KF841475

Mycobacteriophage
Peaches

51376

Siphoviridae

63.90%

Yes

A

A4

GQ303263

Mycobacteriophage
Theia

51543

Siphoviridae

60.80%

Yes

A

A5

KT438501

Mycobacteriophage
Swirley

49717

Siphoviridae

61%

Yes

A

A5

KM101118

Mycobacteriophage
Chadwick

49421

Siphoviridae

59.80%

Yes

A

A5

KT246486

Mycobacteriophage
Conspiracy

50755

Siphoviridae

60.60%

Yes

A

A5

KF560330

Mycobacteriophage
Little Cherry

50690

Siphoviridae

60.90%

Yes

A

A5

KF017001

Mycobacteriophage
UnionJack

49158

Siphoviridae

60.00%

Yes

A

A5

KT004677

Mycobacteriophage
Zaka

52122

Siphoviridae

61.50%

Yes

A

A6

KF560334

Mycobacteriophage
Artemis2UCLA

52344

Siphoviridae

61.40%

Yes

A

A6

KF560333

Mycobacteriophage
CloudWang3

52873

Siphoviridae

61.40%

Yes

A

A6

KF560332

Mycobacteriophage
Sheen

52,927

63.40%

Yes

A

A7

KP273225

Mycobacteriophage
HINdeR

52617

Siphoviridae

62.80%

Yes

A

A7

KC661275

Mycobacteriophage
Smeadley

52392

Siphoviridae

61.40%

Yes

A

A8

KT184694

Mycobacteriophage
Catalina

53411

Siphoviridae

62.60%

Yes

A

A9

KU613353

Mycobacteriophage
Pops

68,367

66.60%

Yes

B

B1

KR997967

Mycobacteriophage
Osmaximus

69,118

66.30%

Yes

B

B1

JN006064

Siphoviridae

Siphoviridae
Siphoviridae
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Mycobacteriophage
Swish

68735

Siphoviridae

66.50%

Yes

B

B1

KJ194579

Mycobacteriophage
Badfish

69030

Siphoviridae

66.50%

Yes

B

B1

KJ194580

Mycobacteriophage
Orion

68427

Siphoviridae

66.50%

Yes

B

B1

DQ398046

Mycobacteriophage
Phipps

68293

Siphoviridae

66.50%

Yes

B

B1

JF704102

Mycobacteriophage
Apizium

68227

Siphoviridae

66.40%

Yes

B

B1

KR781349

Mycobacteriophage
Eremos

68472

Siphoviridae

66.50%

Yes

B

B1

KM236502

Mycobacteriophage
ShiVal

68355

Siphoviridae

66.5

Yes

B

B1

KC576784

Siphoviridae

66.40%

Yes

B

B1

KJ595576

Mycobacterium
phage Manad

68807

Mycobacteriophage
Suffolk

68262

Siphoviridae

66.60%

Yes

B

B1

KF713485

Mycobacteriophage
Newman

68598

Siphoviridae

66.50%

Yes

B

B1

KC691258

Mycobacteriophage
Rosebush

67,480

68.90%

Yes

B

B2

AY129334

Mycobacteriophage
Qyrzula

67188

Siphoviridae

68.80%

Yes

B

B2

DQ398048

Mycobacteriophage
Pipefish

69059

Siphoviridae

67.30%

Yes

B

B3

DQ398049

Mycobacteriophage
Phlyer

69378

Siphoviridae

67.50%

Yes

B

B3

FJ641182

Mycobacteriophage
Cooper

70654

Siphoviridae

69.10%

Yes

B

B4

DQ398044

Mycobacteriophage
BrownCNA

71214

Siphoviridae

68.90%

Yes

B

B4

KT270441

Mycobacteriophage
Vincenzo

72139

Siphoviridae

68.90%

Yes

B

B4

KR080194

Mycobacteriophage
Nigel

69904

Siphoviridae

68.30%

Yes

B

B4

EU770221

Mycobacteriophage
Phelemich

70,115

Siphoviridae

68.30%

Yes

B

B5

KF416341

Mycobacteriophage
Baee

70270

Siphoviridae

67.60%

Yes

B

B5

KR080199

Mycobacteriophage
KayaCho

70838

Siphoviridae

70%

Yes

B

B6

KF024729

Siphoviridae

129

Mycobacteriophage
Bxz1

156,102

Mycobacteriophage
Pleione

155,586

Mycobacteriophage
MoMoMixon

154,573

Mycobacteriophage
Nappy

156,646

Mycobacteriophage
Catera

153766

Mycobacteriophage
Tonenili

Myoviridae

64.80%

Yes

C

C1

AY129337

64.70%

Yes

C

C1

JN624850

64.80%

Yes

C

C1

JN699626

64.70%

Yes

C

C1

JN699627

Myoviridae

64.70%

Yes

C

C1

DQ398053

160985

Myoviridae

64.10%

Yes

C

C1

KX752698

Mycobacteriophage
HyRo

153714

Myoviridae

64.70%

Yes

C

C1

KT281790

Mycobacteriophage
Breeniome

154434

Myoviridae

64.80%

Yes

C

C1

KF006817

Mycobacteriophage
Astraea

154872

Myoviridae

64.70%

Yes

C

C1

KC691257

Mycobacteriophage
ArcherS7

156558

Myoviridae

64.70%

Yes

C

C1

KC748970

Mycobacteriophage
Gizmo

157482

Myoviridae

64.60%

Yes

C

C1

KC748968

Mycobacteriophage
Cali

155372

Myoviridae

64.70%

Yes

C

C1

EU826471

Mycobacteriophage
Spud

154906

Myoviridae

64.80%

Yes

C

C1

EU826468

Mycobacteriophage
Rizal

153894

Myoviridae

64.70%

Yes

C

C1

EU826467

Mycobacteriophage
Myrna

164602

Myoviridae

65.40%

Yes

C

C2

EU826466

Siphoviridae

59.80%

Yes

D

D1

Siphoviridae

59.80%

Yes

D

D1

DQ398051

Mycobacteriophage
PBI1

64494

Mycobacteriophage
Plot

64787

Myoviridae
Myoviridae
Myoviridae

DQ398047

Mycobacteriophage
Troll4

64618

Siphoviridae

59.60%

Yes

D

D1

FJ168662

Mycobacteriophage
Gumball

64807

Siphoviridae

59.60%

Yes

D

D1

FJ168661

Mycobacteriophage
Hawkeye

67383

Siphoviridae

57%

Yes

D

D2

Mycobacteriophage
Estave 1

60,727

61.30%

Yes

F

F1

Siphoviridae

KJ194582

KM279937
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Mycobacteriophage
Daenerys

58,043

Mycobacteriophage
Velveteen

54,314

Mycobacteriophage
Florinda

59,416

Mycobacteriophage
Quico

58,671

Mycobacteriophage
Che8

59,471

Mycobacteriophage
Hades

54,986

Mycobacteriophage
Bobi

59,179

Mycobacteriophage
Wee

59,230

Mycobacteriophage
Tweety
Mycobacteriophage
Cabrinians

Siphoviridae

61.60%

Yes

F

F1

KF017005

61.50%

Yes

F

F1

KF017004

61.70%

Yes

F

F1

KR997930

61.70%

Yes

F

F1

KR997968

61.30%

Yes

F

F1

AY129330

61.40%

Yes

F

F1

KM101122

61.70%

Yes

F

F1

KF114874

Siphoviridae

61.80%

Yes

F

F1

HQ728524

58692

Siphoviridae

61.70%

Yes

F

F1

EF536069

56669

Siphoviridae

61.20%

Yes

F

F1

KT895281

56692

Siphoviridae

61.40%

Yes

F

F1

DQ398050

56852

Siphoviridae

61.50%

Yes

F

F1

DQ398045

Mycobacteriophage
PopTart

55094

Siphoviridae

61.60%

Yes

F

F1

KT281792

Mycobacteriophage
Dante

59652

Siphoviridae

61.80%

Yes

F

F1

KT309034

Mycobacteriophage
Ovechkin

58338

Siphoviridae

62%

Yes

F

F1

KR824843

Mycobacteriophage
Llama

58472

Siphoviridae

61.10%

Yes

F

F1

KM402757

Mycobacteriophage
Xfactor

55617

Siphoviridae

61.70%

Yes

F

F1

KT281795

Mycobacteriophage
Phatniss

57293

Siphoviridae

61.30%

Yes

F

F1

KT279576

Mycobacteriophage
CaptainTrips

57328

Siphoviridae

61.50%

Yes

F

F1

KM652553

Mycobacteriophage
Bipolar

58985

Siphoviridae

61.40%

Yes

F

F1

KM597530

Mycobacteriophage
Seagreen

57766

Siphoviridae

61.80%

Yes

F

F1

KT281793

Mycobacteriophage
PMC
Mycobacteriophage
Llij

Siphoviridae
Siphoviridae
Siphoviridae
Siphoviridae
Siphoviridae
Siphoviridae
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Mycobacteriophage
Kimberlium

56826

Siphoviridae

61.40%

Yes

F

F1

KR935214

Mycobacteriophage
Sparkdehlily

56275

Siphoviridae

61.20%

Yes

F

F1

KT895280

Mycobacteriophage
Cerasum

53636

Siphoviridae

61.50%

Yes

F

F1

KM215148

Mycobacteriophage
Inventum

57052

Siphoviridae

61.40%

Yes

F

F1

KM066034

Mycobacteriophage
Hades

54986

Siphoviridae

61.40%

Yes

F

F1

KM101122

Mycobacteriophage
BuzzLyseyear

59419

Siphoviridae

61.10%

Yes

F

F1

KM347889

Mycobacteriophage
Saal

57775

Siphoviridae

61.30%

Yes

F

F1

KJ025956

Mycobacteriophage
Hamulus

57155

Siphoviridae

61.80%

Yes

F

F1

KF024723

Mycobacteriophage
Job42

59626

Siphoviridae

61.20%

Yes

F

F1

KC661280

Mycobacteriophage
SiSi

56279

Siphoviridae

61.50%

Yes

F

F1

KC661278

Mycobacteriophage
Ramsey

58578

Siphoviridae

61.20%

Yes

F

F1

FJ174693

Mycobacteriophage
Pacc40

58554

Siphoviridae

61.30%

Yes

F

F1

FJ174692

Mycobacteriophage
Fruitloop

58471

Siphoviridae

61.80%

Yes

F

F1

FJ174690

52141

Siphoviridae

61.50%

Yes

F

F1

GU060500

56,275

Siphoviridae

60.90%

Yes

F

F2

AY129336

62.40%

Yes

F

F3

KM101124

Mycobacteriophage
Ardmore
Mycobacteriophage
Che9d
Mycobacteriophage
Squirty

60,285

Mycobacteriophage
Halo

42,289

Siphoviridae

66.70%

Yes

G

G1

DQ398042

Mycobacteriophage
Sneeze

42429

Siphoviridae

66.50%

Yes

G

G1

KX534004

Mycobacteriophage
Cambiare

45161

Siphoviridae

68.80%

Yes

G

G2

KR080198

Mycobacteriophage
FlagStaff

44576

Siphoviridae

68.50%

Yes

G

G2

KR080197

Mycobacteriophage
MOOREtheMARYer

44492

Siphoviridae

68.60%

Yes

G

G3

KR080202

Siphoviridae
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Mycobacteriophage
Damien

68386

Siphoviridae

57.60%

Yes

H

H1

KJ567046

Mycobacteriophage
Oaker

69099

Siphoviridae

57.50%

Yes

H

H1

KF986247

Mycobacteriophage
Konstantine

68952

Siphoviridae

57.40%

Yes

H

H1

FJ174691

Mycobacteriophage
Barnyard

70,797

57.50%

Yes

H

H2

AY129339

Mycobacteriophage
Brujita

47057

66.80%

Yes

I

I1

FJ168659

Mycobacteriophage
Che9c

57,050

65.40%

Yes

I

I2

AY129333

Mycobacteriophage
Sbash

55,832

65.60%

Yes

I

I2

KP027201

Mycobacteriophage
CrimD

59798

Siphoviridae

66.90%

Yes

K

K1

HM152767

Mycobacteriophage
Murucutumbu

60609

Siphoviridae

66.70%

Yes

K

K1

KM677211

Mycobacteriophage
Enkosi

59052

Siphoviridae

67.20%

Yes

K

K1

KT281789

Mycobacteriophage
Validus

62466

Siphoviridae

68.40%

Yes

K

K1

KF713486

Mycobacteriophage
ZoeJ

57,315

68.50%

Yes

K

K2

KJ510412

Mycobacteriophage
TM4

52797

Siphoviridae

68.10%

Yes

K

K2

AF068845

Mycobacteriophage
Mufasa

58065

Siphoviridae

68.20%

Yes

K

K2

KT591490

Mycobacteriophage
Milly

58211

Siphoviridae

68.30%

Yes

K

K2

KP027206

Mycobacteriophage
Keshu

61,251

67.30%

Yes

K

K3

KP027199

Mycobacteriophage
ShedlockHolmes

61081

Siphoviridae

67.30%

Yes

K

K3

KR080206

Mycobacteriophage
Cheetobro

57253

Myoviridae

68%

Yes

K

K4

KJ944841

Mycobacteriophage
Omnicron

61,511

64%

Yes

K

K5

KM363596

Mycobacteriophage
Kratio

62738

Siphoviridae

65.70%

Yes

K

K5

KM923971

Mycobacteriophage
OkiRoe

62661

Siphoviridae

64.90%

Yes

K

K5

KJ567042

Siphoviridae

Siphoviridae
Siphoviridae
Siphoviridae

Siphoviridae

Siphoviridae

Siphoviridae
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Mycobacteriophage
Faith 1

75,960

Siphoviridae

58.90%

Yes

L

L2

JF744988

Mycobacteriophage
Archie

76271

Siphoviridae

58.70%

Yes

L

L2

KT591489

Mycobacteriophage
Crossroads

76129

Siphoviridae

58.90%

Yes

L

L2

KF024731

Mycobacteriophage
Lolly9

75816

Siphoviridae

59.30%

Yes

L

L3

KT281791

Mycobacteriophage
Snenia

75626

Siphoviridae

59.20%

Yes

L

L3

KT281794

Mycobacteriophage
Whirlwind

76050

Siphoviridae

59.30%

Yes

L

L3

KF024725

Mycobacteriophage
PegLeg

80955

Siphoviridae

61.50%

Yes

M

M1

KC900379

Mycobacteriophage
Wildcat

78,296

57.20%

Yes

V

n/a

DQ398052

n/a

No

Singleto
n

n/a

NC_02359
1.1 (Refseq
number)

61.40%

Yes

J

n/a

AY129338

65.40%

Yes

O

n/a

AY129335

63.70%

Yes

E

n/a

AY129331

66.20%

Yes

T

n/a

KJ510413

60.90%

Yes

J

n/a

KF114875

63.00%

Yes

E

n/a

KF306380

63.00%

Yes

E

n/a

JN006061

Siphoviridae

Siphoviridae

Mycobacteriophage
Adler

95,705

Mycobacteriophage
Omega

110,865

Mycobacteriophage
Corndog

69,777

Mycobacteriophage
Cjw1

75,931

Mycobacteriophage
Bernal13

42,392

Mycobacteriophage
Redno2

108297

Mycobacteriophage
DrDrey

77,367

Mycobacteriophage
Toto

75,933

Mycobacteriophage
Goku

76,483

Siphoviridae

62.80%

Yes

E

n/a

KF416343

Mycobacteriophage
Papyrus

70,657

Siphoviridae

56%

Yes

R

n/a

KF416342

Mycobacteriophage
Mindy

75796

Siphoviridae

63%

Yes

E

n/a

KR080204

Mycobacteriophage
244

74483

Siphoviridae

63.40%

Yes

E

n/a

DQ398041

Mycobacteriophage
Ariel

109801

Siphoviridae

61.00%

Yes

J

n/a

KM400683

Siphoviridae
Siphoviridae
Siphoviridae
Siphoviridae
Siphoviridae
Siphoviridae
Siphoviridae
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Mycobacteriophage
Dumbo

75736

Siphoviridae

63%

Yes

E

n/a

KC691255

Mycobacteriophage
Bruin

74210

Siphoviridae

63%

Yes

E

n/a

KF562099

Mycobacteriophage
Nala

75894

Siphoviridae

63.10%

Yes

E

n/a

KF562101

Mycobacteriophage
PhatBacter

76217

Siphoviridae

63%

Yes

E

n/a

KF562102

Mycobacteriophage
Phrann

44872

Siphoviridae

66.30%

Yes

N

n/a

KU935731

Mycobacteriophage
Xeno

42395

Siphoviridae

66.80%

Yes

N

n/a

KU935728

Mycobacteriophage
Panchino

43516

Siphoviridae

65.90%

Yes

N

n/a

KU935727

Mycobacteriophage
Dusk

75339

Siphoviridae

63%

Yes

E

n/a

KT222942

Mycobacteriophage
MiaZeal

110764

Siphoviridae

61.20%

Yes

J

n/a

KM925136

Mycobacteriophage
NelitzaMV

72790

Siphoviridae

63.10%

Yes

E

n/a

KT222941

Mycobacteriophage
Carcharodon

43680

Siphoviridae

66.20%

Yes

N

n/a

KM588359

Mycobacteriophage
Gaia

90460

Siphoviridae

56.80%

Yes

X

n/a

KJ567043

Mycobacteriophage
Wanda

109960

Siphoviridae

60.80%

Yes

J

n/a

KF006818

Mycobacteriophage
MosMoris

65243

Siphoviridae

63.40%

Yes

S

n/a

KJ538721

Mycobacteriophage
Redi

42594

Siphoviridae

66.10%

Yes

N

n/a

JN624851

Mycobacteriophge
Charlie

43036

Siphoviridae

66.30%

Yes

N

n/a

JN256079

Mycobacteriophage
MichelleMyBell

42240

Siphoviridae

66%

Yes

N

n/a

KF986246

Mycobacteriophage
Dylan

69815

Siphoviridae

65.40%

Yes

O

n/a

KF024730

Mycobacteriophage
Catdawg

72108

Siphoviridae

65.40%

Yes

O

n/a

KF017002

Mycobacteriophage
Muddy

48228

Siphoviridae

58.80%

Yes

AB

n/a

KF024728

Mycobacteriophage
Phrux

74711

Siphoviridae

63.10%

Yes

E

n/a

KC661277
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Mycobacteriophage
Murphy

76179

Siphoviridae

62.90%

Yes

E

n/a

KC748971

Mycobacteriophage
Butters

41491

Siphoviridae

65.80%

Yes

N

n/a

KC576783

Mycobacteriophage
Sparky

63334

Siphoviridae

65.20%

Yes

Singleto
n

n/a

KM083128

Mycobacteriophage
Contagion

74533

Siphoviridae

63.10%

Yes

E

N/a

KF024732

Mycobacteriophage
Phayonce

49,203

66.70%

Yes

P

P1

KR080195

Mycobacteriophage
Malithi

46,869

67.10%

Yes

P

P1

KP027200

Mycobacteriophage
Brusacoram

47618

Siphoviridae

67%

Yes

P

P1

KT347313

Mycobacteriophage
Donovan

47162

Siphoviridae

67.20%

Yes

P

P1

KF841477

Mycobacteriophage
Fishburne

47109

Siphoviridae

67.30%

Yes

P

P1

KC691256

Siphoviridae
Siphoviridae

To examine mycobacteriophage diversity, I decided to conduct a small scale study and collect
data for different mycobacteriophage genomes, using programs such as Genbank,
phagesdb.org and phamerator. Based on this data table 9 was generated. This data was then
analysed using Phandango and Phisigns to create phylogeny trees for each
mycobacteriophage cluster.
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